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ABSTRACT 
The employment of HIV-1 protease (PR) inhibitors (PIs) in antiviral therapy has been successful 
in reducing mortality of HIV/AIDS patients.  However, the long-term efficacy of PIs is challenged by the 
rapid emergence of drug-resistant mutants of PR. To understand the underlying mechanism of drug re-
sistance, structures and activities of HIV-1 PR and its drug resistant mutants have been extensively stud-
ied. Here, PR mutants PRR8Q, PRD30N, PRI47V, PRI50V, PRI54M, PRV82A, and PRN88D/S bearing single substitu-
tions have been investigated by crystallography and kinetics.  
GRL-0519 is a potent new antiviral inhibitor of HIV-1 PR that possesses tris-tetrahydrofuran 
(tris-THF) as the P2 ligand. The crystal structures of GRL-0519 were determined at resolutions of 1.06-
1.49 Å in complex with the mutants PRR8Q, PRD30N, PRI50V, PRI54M, and PRV82A. I50V lost its interaction 
with inhibitor while V82A
 
and I54M compensated for the mutation through the main chain shift and flex-
ibility of 80’s loop (residues 78-82), respectively. The structural changes may account for the worst inhi-
bition of GRL-0519 for PRI50V (60-fold decrease relative to wild-type enzyme) and moderate inhibition for 
  
PRI54M and PRV82A (6-7-fold decrease). The large tris-THF group at P2 provides a good fit in the S2 subsite 
and may be effective against resistant virus with mutations of residues in this subsite.  
SQV and DRV are two clinical inhibitors that were designed to target the wild type PR and its 
drug resistant mutants, respectively. The crystal structures of PR mutants PRI47V, PRN88D/s in complex 
with DRV and mutants PRI47V and PRN88D in complex with SQV with resolutions of 1.13-1.72 Å were also 
analyzed. Mutation I47V gained more hydrophobic interactions with DRV and SQV. Interestingly, the 
structural changes did not affect the inhibition of both inhibitors for PRI47V (relative Ki is 0.7 and 1 for 
DRV and SQV, respectively)
. 
DRV and SQV showed 8-fold increase in Ki for PRN88D and only very sub-
tle local changes have been observed on the structures. DRV induced 0.3 fold reduction in Ki for PRN88S 
and the distal structural changes have been transferred to the active site. This study provided fundamental 
information for understanding drug resistance and future design of potential antiviral drugs. 
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1 INTRODUCTION  
 
1.1 General Introduction of HIV/ AIDS 
1.1.1 Current status of disease 
Acquired immunodeficiency syndrome (AIDS) is a life-threatening disease that interferes with 
the immune system. There are approximately 70 million people have been infected with the HIV virus 
since the first case was reported in the United States in 1981.  At the end of 2012, approximately 35 mil-
lion people were globally living with HIV/AIDS and about 69% of them from Sub-Saharan Africa 
(Maghina, Govind et al. 1998, UNAIDS, 2013). Although there is no effective vaccine available (Girard 
and Bansal 2008), highly active antiretroviral therapy (HAART) has greatly improved the lives of AIDS 
patients(Brenner, Turner et al. 2002). HAART employs a combination of different antiretroviral drugs to 
strengthen the immune system and maximally suppress the HIV virus. The AIDS related mortality has 
declined in recent years due to the scaling up of effective antiretroviral therapy and the reduction of HIV 
incidence. It has been reported that there were 1.7 million people who died of AIDS-related illnesses in 
2011, down 24% from 2.3 million in 2005. However, HIV disease is the top 6th cause of death and con-
tinues to be a major health problem in the world, especially in Africa. Therefore, intensified efforts are 
needed to develop more effective and low-cost drugs to combat HIV/AIDS. 
1.1.2  HIV-1 life cycle 
AIDS is a severe immunological disease caused by human immunodeficiency virus (HIV), a 
member of the retroviruses that are characterized by RNA genomes. Although HIV comprises two major 
subtypes HIV-1 and HIV-2, HIV-1 is the virus that was originally discovered and is more infective 
(Gilbert, McKeague et al. 2003). In addition, HIV-1 infections predominate globally whereas HIV-2 is 
largely found in West Africa (Reeves and Doms 2002). The features of HIV virus are indicated in Figure 
1.1. The conical capsid of HIV virus contains two copies of the single-stranded viral RNA genome with 
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genes encoding for the three large polyprotein precursors Gag, Gag-Pol, and Env and several small acces-
sory proteins Nef, Ref, Tat, Vif, Vpr and Vpu. It also has three essential viral enzymes: protease (PR), 
reverse transcriptase (RT) and integrase (IN) in its capsid. The capsid of the viron particle is surrounded 
by a matrix, which is further surrounded by a lipid bilayer embedded by envelope proteins from the host 
cell. The virus enters the host cell and replicates itself through several stages (Figure 1.2). It begins infec-
tion by recognizing and binding to host cell receptor CD4 through its docking glycoprotein gp120. This 
process is accomplished under the help of co-receptor CCR5 and CXCR4 from the host cell. The virus 
then fuses with host cell membrane and enters the cell (Maddon, Dalgleish et al. 1986; Deng, Liu et al. 
1996; Doranz, Rucker et al. 1996). Following cell fusion and entry, the viral RNA is released to the host 
cell and reverse transcribed into viral DNA by the HIV RT in cytoplasm. The viral DNA is then trans-
ported across the nucleus and integrated into host cell genome by another HIV enzyme IN. Therefore, 
HIV viral DNA will be transcribed and translated using the host machinery. New viral RNA is produced 
and transported to the cytoplasm to be used as genomic RNA to synthesize polyproteins Gag, Gag-pol, 
Env and other accessory proteins.  Gag is a polyprotein which can be cleaved to produce structural com-
ponents of the virus; for example, matrix and capsid proteins. Pol contains three important viral enzymes 
that are essential for replication of infectious virus: RT, IN and PR. The exterior proteins SU (surface unit 
glycoprotein) and TM (transmembrane envelope) that recognize and bind to the host receptors are from 
polyprotein Env. These two proteins will be produced by cleavage of Env by cellular protease. However, 
Gag and Gag-Pol polyprotein precursors as well as viral RNA migrate to the cell membrane, where they 
assemble to form immature viral particles that are released from the infected cells. Viruses have no infec-
tious ability until their polyproteins are cleaved into functional proteins, such as the MA, CA and NC by 
PR (Figure 1.3). Taken together, a mature HIV virus is produced by several steps including fusion and 
entry, reverse transcription, integration, translation, assembly and budding as shown in Figure 1.2 These 
steps could be drug targets for treatment of HIV due to their critical role in HIV life cycle.  
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1.1.3 HIV-1 protease is essential for viral maturation 
HIV-1 PR is catalytically active as a homodimer. The two monomers form an active site that sub-
strate or inhibitor can bind to and be processed. It is critical for viral particle maturation since it cleaves 
the viral precursor polypeptides Gag and Gag-Pol into the mature structural and enzymatic proteins 
(Darke, Nutt et al. 1988; Oroszlan and Luftig 1990). Inactivation of PR will interrupt the cleavage of its 
substrate, therefore, preventing the formation of mature and infectious virus (Kohl, Emini et al. 1988; 
Seelmeier, Schmidt et al. 1988). PR is regarded as an effective target for antiviral drugs due to its essen-
tial function in virus replication. The availability of PR inhibitors as clinical drugs in antiretroviral thera-
py dramatically improved the life quality of HIV/AIDS patients (Brenner, Turner et al. 2002).  
The compositions of the Gag and Gag-Pol polyproteins are shown in Figure 1.3. Cleavage of Gag 
by PR produces structural proteins MA, CA, p2, NC, p1 and p6 (Henderson, Bowers et al. 1992) 
(Wondrak, Louis et al. 1993). In addition to the first five structural proteins from Gag, Gag-Pol also pro-
duces several viral enzymes, including RT, IN and PR (Louis, Weber et al. 2000). PR itself is released 
from the precursor Gag-Pol as an active dimer by autoprocessing (Louis, Nashed et al. 1994; Louis, 
Wondrak et al. 1999). Both in vitro and in vivo studies have shown that PR cleaves the Gag-Pol precursor 
at specific sites and in a specific order (Pettit, Moody et al. 1994; Wiegers, Rutter et al. 1998; Pettit, 
Henderson et al. 2002). Figure 1.3 lists the cleavage sites in Gag and Gag-Pol and the sequential order of 
cleavage. The p2/NC site is cleaved first, followed by MA/CA. Cleavage of the sites on either side of PR 
was the last two steps. It has been reported that correct order of processing is also essential for proper as-
sembly and viral maturation (Oroszlan and Luftig 1990; Rose, Craik et al. 1998). 
1.2 The structural properties of HIV-1 PR  
Great efforts have been made to determine the three dimensional structures of PR in order to 
serve as guides for design of antiviral protease inhibitors (PIs). The first X-ray crystal structures of PR 
were determined with resolution of approximately 3 Å in 1989 (Lapatto, Blundell et al. 1989; Miller, 
Schneider et al. 1989; Navia, Fitzgerald et al. 1989; Wlodawer, Miller et al. 1989). Higher resolution 
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structures have been obtained with the technical advances in X-ray detectors and availability of high in-
tensity synchrotron sources for X-rays (Tie, Boross et al. 2004; Liu, Boross et al. 2005; Tie, Kovalevsky 
et al. 2007). In 2006, the X-ray crystal structure of PR mutant bearing single substitutions of V32I was 
solved at ultra-high resolution of 0.84 Å (Kovalevsky, Liu et al. 2006). Up to date, there are more than 
400 HIV-1 PR structures unliganded or complexed with various inhibitors or substrates have been depos-
ited in the Protein Data Bank (Berman, Westbrook et al. 2000). 
HIV-1 PR is enzymatically active as a dimer of two 99-residue subunits. It belongs to the aspartic 
protease family which is characterized by the conserved catalytic triplet sequence of Asp-Thr/Ser-Gly 
(Darke, Nutt et al. 1988). The structure of PR is predominantly composed of β-sheet with a very short α-
helix near the C terminus (residues 86–94) as shown in Figure1.4 (A). Inhibitors or substrates bind the 
active site between two subunits through hydrogen bonds and van der Waals interactions. Two aspartic 
acids at residue 25 from two subunits form the central active site and are essential for enzyme activity. 
The mutation of Asp25 leads to complete loss of the enzyme’s ability to hydrolyze the substrate peptide 
bonds (Kohl, Emini et al. 1988; Seelmeier, Schmidt et al. 1988).  
Another important region in the PR structure is the flexible flaps. HIV-1 PR possesses two flap 
regions, one from each subunit comprising residues 45 to 56. The flaps are very flexible and were ob-
served in different conformations depending on whether the substrate or inhibitor is bound. This flexibil-
ity is very important to the catalytic activity of PR. The closed conformation ensures the tight binding of 
the substrate or inhibitor. The closed conformation with the inhibitor also blocks the processing of its sub-
strate once the competitive PI is bound to the catalytic site (Darke, Nutt et al. 1988; Mahalingam, Louis et 
al. 1999; Scott and Schiffer 2000; Weber and Agniswamy 2009). The state of the flap can also be affected 
by the mutation in the flap regions, thus mutation of the flap residues has great impact on the PR activity 
and substrate or inhibitor binding affinity as shown in Figure 1.4B (Liu, Kovalevsky et al. 2006). It has 
been shown that the Gly-rich region (Gly48, Gly49, Gly51, Gly52) in the flap is more sensitive to substi-
tution (Shao, Everitt et al. 1997). However, flap residues (Ile47, Ile50, Ile54 and Val56) whose side 
chains are directed inward and may interact directly or indirectly with the substrate and inhibitor could 
13 
 
tolerate a few mutations (Shao, Everitt et al. 1997). Molecular dynamic simulations and NMR experi-
ments also demonstrated that the flap is in the dynamic equilibrium of open, partially open and closed 
conformation (Tozser, Blaha et al. 1991; Coffin, Hughes et al. 1997; Bagossi, Sperka et al. 2005). Indeed, 
our most recent study of a clinically derived extreme HIV-1 PR mutant (PR20) bearing 20 mutations re-
vealed three distinct conformations of the flexible flaps from structures of free PR20, peptide bond and 
inhibitor bound PR20 (Agniswamy, Shen et al. 2012). The remarkable variety of flap conformations may 
influence the catalytic activity and stability of PR and contribute to resistance mechanisms (Liu, 
Kovalevsky et al. 2006; Agniswamy, Shen et al. 2012).   
The catalytic Asp25 from each subunit and the flap regions play important roles in enzyme activi-
ty and stability. In addition, the ionic interactions of Arg 8 with Asp 29’ and Arg 87’, the N- terminus 
(residues 1-4) and C-terminus (residues 96-99) form the dimer interface and also influence the dimeriza-
tion significantly (Louis, Ishima et al. 2003). Substitution of Arg by Gln at residue 8 resulted in the loss 
of ionic interaction with Asp29 and thus decreased stability and catalytic activity (Weber 1990; 
Mahalingam, Louis et al. 1999).  Finally, Gly86-Arg87-Asn88 is the second conserved triad in retroviral 
proteases (Pearl and Taylor 1987; Louis, Weber et al. 2000). Although residues Gly86-Arg87-Asn88 that 
are located in the α-helix do not directly interact with the substrate or inhibitor, they are close (with indi-
rect interactions) to the active site loop and may contribute to dimer formation (Schechter and Berger 
1967; Louis, Smith et al. 1989; Ishima, Gong et al. 2010) .  
1.3 The catalytic mechanisms of HIV-1 PR 
In order to facilitate the design of novel antiviral inhibitors, intensive efforts have been put into 
study of the catalytic mechanism of HIV-1 PR. In fact, a general acid-base mechanism has been proposed 
for aspartic PR by kinetic study of pepsin-like aspartic PR (Suguna, Bott et al. 1987; Ji and Loeb 1992). 
In 1991, Hyland proposed the reaction mechanism specifically for HIV-1 PR based on the 18O exchange 
mass spectrometry experiments and structure data (Hyland, Tomaszek et al. 1991; Brik and Wong 2003; 
Yu, Wild et al. 2005). Similar to the general acid-base model proposed by Suguna (Suguna, Bott et al. 
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1987), the catalytic Asp25 residue from subunit is un-protonated and acts as base, whereas the other 
Asp25 is protonated and acts as acid. An H2O attacks and transfers a proton to the basic Asp25 while the 
acidic Asp25 attacks and protonates the substrate (Figure 1.5). There is a reversible tetrahedral intermedi-
ate formed before the peptide is hydrolyzed.  
An H2O molecule is involved in catalytic mechanism proposed for both pepsin-like protease and 
HIV-1 PR. However, the quaternary structure of HIV-1 PR is different from that of pepsin-like protease. 
HIV-1PR is enzymatically active as a dimer and the two catalytic Asp25 are from two subunits while  
pepsin-like PR is active as a monomer and the two catalytic Asp25 involved in the reaction are from two 
domains of the monomer. Therefore, the H2O in the active site of the pepsin-like protease may not be pre-
sent for HIV-1 PR since there is no space for such an H2O in the active site as shown in crystal structures 
of HIV-1 PR with inhibitors. Another possibility could be the conserved water that is consistently ob-
served between the NH groups of the main chain of flap residues Ile50 / Ile50’ and two C=O groups of 
the substrate/inhibitors (Coffin 1995). However, this conserved H2O molecule is not close to the active 
catalytic Asp25 and has less chance to attack the scissile bond that is located on the opposite side of sub-
strate to the way proposed in the model. The later study by Baca showed that this water does not directly 
interact with the catalytic Asps and substrate, which is further supported by the molecular dynamics simu-
lation studies performed by the Chatfield group (Baca and Kent 1993; Chatfield and Brooks 1995). In 
1994, Harrison proposed another model to explain how this H2O molecule possibly contributes the cata-
lytic reaction by the molecular dynamic simulations of HIV PR (Harrison and Weber 1994). In his model, 
the H2O molecule attacks scissile bond from opposite side to form the transition-state intermediate. 
In addition to the enzyme kinetics and theoretical models, X-ray crystallographic analysis is also 
a powerful tool to illustrate different states in catalytic mechanisms (Kuwata, Miyazaki et al. 1997). The 
tetrahedral reaction intermediates proposed in the model have been observed in several structures as illus-
trated in Figure 1.5 (Shafer 2002; Wu, Schiffer et al. 2003; Torbeev, Mandal et al. 2008). In our most re-
cent crystallographic study, three consecutive stages in the proteolytic reaction were captured in near-
atomic-resolution in HIV-1 PR and its mutants (Shen, Tie et al. 2012). 
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Recently, neutron crystallography, which is able to provide the critical information about the lo-
cation of hydrogen atoms, has been exploited in the study of reaction intermediate. Single protonated 
Asp25 was observed in the structure of PR with the inhibitor KNI-272 (Adachi, Ohhara et al. 2009). The 
most recent joint x-ray/neutron crystallographic study of HIV-1 PR with amprenavi suggested different 
location of hydrogen atoms on the protonated Asp (Weber, Waltman et al. 2013). Taken together, differ-
ent catalytic mechanisms have been proposed for HIV-1 PR and involvements of the nucleophilic water 
and the function of the two aspartic residues are commonly accepted; however, the debate continues on 
the detailed reaction mechanism. Neutron crystallography may shed light on reveal of the catalytic mech-
anisms of HIV-1 PR. 
1.4 The substrate specificity of HIV-1 PR 
HIV-1 PR exhibits very high specificity for the viral precursor Gag and Gag-Pol polyproteins and 
other peptides with the natural cleavage site sequences (Darke, Nutt et al. 1988). The substrate has a min-
imum of seven residues (P4-P3’) for optimal catalysis (Darke, Nutt et al. 1988; Tozser, Blaha et al. 1991; 
Tomasselli and Heinrikson 1994; Coffin, Hughes et al. 1997). HIV-1 PR cleaves the substrate at the scis-
sile bond, which has four residues located on its N terminus defined as P1, P2, P3 and P4 and three resi-
dues on its C terminus defined as  P1’, P2’ and P3’ as shown in Figure1.6 (Schechter and Berger 1967; 
Shen, Tie et al. 2012).  The corresponding binding sites on PR that accommodate P4-P3’ residues are de-
fined as subsites S4 to S3’. Residues that are involved in binding the substrate in the subsites are also il-
lustrated in Figure1.6. The specificity has been investigated by incorporating different residues at each 
position (Beck, Morris et al. 2002). These studies showed that the size and chemical property of the side 
chain on the substrate affects the binding specificity with the PR. There are preferences for P1/P1’ and 
P2/P2’. P1 and P1’ favor residues with large hydrophobic and aromatic side chains whereas P2 and P2’ 
can be hydrophobic and small polar residues (Bagossi, Sperka et al. 2005). Understanding the polyprotein 
cleavage sites and the substrate specificity provides very valuable information that can be incorporated in 
the design of antiviral inhibitors. 
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1.5 Structure guided design of PIs  
1.5.1 The  first generation of antiviral PIs 
Over the past decades, extraordinary efforts have been made in order to develop effective antivi-
ral therapy and overcome HIV drug resistance. Up to date, there are about 25 antiretroviral drugs ap-
proved by the FDA (Food and Drugs Administration) and used to treat HIV/AIDS patients. Currently, 
nine of the drugs in HAART are designed to target HIV PR, including amprenavir, indinavir, lopinavir, 
nelfinavir, ritonavir, saquinavir, atazanavir, tipranavir and darunavir (Figure 1.7).  HAART therapy that 
uses a cocktail of different drugs has greatly improved the life quality of HIV/AIDS patients, especially 
after the introduction of the first PI, saquinavir, in the market (Wlodawer and Vondrasek 1998).  
The information for the design of antiviral PIs was deduced from the first X-ray crystal structures 
of wild type HIV-1 PR complexed with non-hydrolysable peptide analogs (Miller, Schneider et al. 1989). 
Hydrogen bonds and hydrophobic interactions were observed between the PR and the peptide analogs. It 
has been shown that the main chain atoms of the peptide analogs interact with active site residues 25-29 
on one side and flap residues 48-50 on the other side by conserved hydrogen bonds (Gustchina and Weber 
1990; Gustchina, Sansom et al. 1994). These observations have been confirmed in the more recent high 
resolution structures of HIV-1 PR with substrate analogs as shown in Figure1.8 (Tie, Boross et al. 2005). 
Most of the residues in the active site can form hydrophobic interactions with the peptidic inhibitor. There 
are several obstacles to overcome for the peptide inhibitors, however. For example, these inhibitors are 
usually very large and could not easily penetrate into the cells. In addition, some peptide-like compounds 
are very unstable and could be digested by the cellular enzymes. Therefore, the design of new inhibitors 
that are relatively smaller and less peptidic is necessary. The first generation of clinical inhibitors, such as 
saquinavir (SQV, Figure1.7&1.9A) was designed primarily based on the crystal structures of HIV-1 PR 
with peptidic inhibitors. They were designed to bind tightly in the active site cavity of the wild type PR 
by mimicking the interactions between HIV-1 PR and peptidic inhibitors. The first generation of PIs con-
tains polar groups that resemble the peptide-like amides and carbonyl groups, and therefore maintains its 
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hydrogen bonds with the main chain of the PR. It also possesses large hydrophobic groups that mimic the 
peptide side chains and bind in hydrophobic subsites (Figure 1.6). It has been proved that the use of these 
early PIs in combination with reverse transcriptase inhibitors successfully suppressed viral maturations.  
1.5.2 Structure guided design of PIs targeting drug resistant HIV-1 PR. 
Even though HAART therapy with incorporation of PIs has made tremendous progress in de-
creasing the mortality for HIV/AIDS patients; there are several obstacles for PIs in its long term effec-
tiveness, including the emergence of drug resistant viral strains (Wensing, van Maarseveen et al. 2010). 
The presence of these mutations on PR could readily reduce its binding affinity with the earlier PIs. For 
drug resistance to occur, these mutations should maintain viral fitness while diminishing drug binding. 
Comparison of the X-ray structures of HIV-1 PR and its variants demonstrated that the main chain atoms 
of residues cannot easily be altered by mutation. In addition, some residues are conserved since their mu-
tations may result in the loss of PR catalytic activity. Therefore, the strategy for design of the next genera-
tion of inhibitor is to maximize inhibitor interactions with PR backbone atoms and conserved residues 
that are required to maintain the critical PR function in viral replication (Ghosh, Chapsal et al. 2008). The 
early structure-based efforts also include reducing the peptide-like features of PIs in order to improve bio-
availability. 
According to the backbone-binding strategies, the active site residues become an ideal target re-
gion for inhibitor binding, thus maximizing the hydrogen-bonding interactions between the inhibitor and  
the protein backbone atoms in the S2–S2’ subsites becomes the focus of drug design (Ghosh, Anderson et 
al. 2012). Pursuit of this strategy led to the discovery of a variety of potent antiviral inhibitors including 
darunavir (DRV, Figure1.7&1.9B), which has been proved to be a successful for AIDS salvage therapy 
(Koh, Nakata et al. 2003; King, Prabu-Jeyabalan et al. 2004; Tie, Boross et al. 2004). DRV exhibits 
stronger binding affinity (5pM affinity) partly due to the many hydrogen bond interactions with PR (King, 
Prabu-Jeyabalan et al. 2004). It not only blocks the processing of the substrate but also inhibits the dimer-
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ization of PR (Koh, Matsumi et al. 2007), thus acting as dual inhibitor and demonstrated high potency and 
clinical efficacy on resistant viral infections (Tozser, Blaha et al. 1991; Ghosh, Kincaid et al. 1998; Tie, 
Boross et al. 2004; Surleraux, Tahri et al. 2005). It incorporates bis-tetrahydrofuran (THF) in the P2 group, 
thus introducing more hydrogen bond interactions with PR main chain atoms and conserved residues 
(Ghosh, Xu et al. 2010). Comparison of the crystal structures of DRV with PR and resistant PR mutants 
have shown that the majority of the strong hydrogen bond interactions observed between DRV and PR 
were maintained in its interaction with drug resistant variants (Tie, Boross et al. 2004; Kovalevsky, Liu et 
al. 2006; Kozisek, Bray et al. 2007; Liu, Kovalevsky et al. 2008). The X-ray structures suggested that 
DRV may have a second binding site on the flap region of PR (Kovalevsky, Tie et al. 2006). This is fur-
ther confirmed by its kinetic study, which suggested a “mixed-type competitive–uncompetitive inhibition 
model” (Kovalevsky, Ghosh et al. 2008). In summary, design of DRV was a milestone in the combating 
AIDS disease and HIV resistance. 
1.5.3  Development of the next generation of PIs 
Based on the backbone scaffold of DRV, a wild range of new inhibitors have been developed. 
These new inhibitors employed a variety of chemical groups at P2, P1’ and P2’. The chemical structures 
of some new inhibitors that have been developed by the Ghosh group in recent several years are illustrat-
ed in Figure1.10. Most of them showed picomolar inhibition of PR and nanomolar range of antiviral IC50 
values. In addition, they exhibit high potency on cells infected by resistant virus. Inhibitors including 
GRL-0519A, GRL-04410, GRL-0249 and GRL-0489 have P2 groups different from DRV (Ghosh, 
Leshchenko-Yashchuk et al. 2009; Ghosh, Xu et al. 2010; Ghosh, Chapsal et al. 2012). X-ray crystallog-
raphy study showed that the newly incorporated THF ring in GRL-0519A had enhanced interaction with 
conserved residues and filled the hydrophobic S2 subsite. This is consistent with the tenfold increase in its 
antiviral activity against multidrug-resistant strains relative to DRV (Ghosh, Xu et al. 2010). GRL-0249 is 
another antiviral inhibitor with modified P2 group. Structural analysis showed that it formed new hydro-
gen bond interactions with Gly48 in flap of PR (Ghosh, Chapsal et al. 2012). Antiviral inhibitor GRL-
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02031 was developed by varying the P1’ group of DRV. It has been reported that GRL-02031 exhibited 
full potency against a variety of multidrug-resistant HIV-1 strains (Ghosh, Leshchenko-Yashchuk et al. 
2009). In summary, these newly developed antiviral PIs with various P2 and P1’ groups showed enhanced 
interaction with the conserved residues and proved to be potent antiviral inhibitors. However, design of 
next generation of inhibitor with an improved strategy is still necessary due to the persistent emergence of 
drug resistance.    
1.6 Molecular mechanisms of drug resistance of HIV-1 PR  
1.6.1 HIV-1 PR mutations 
HIV-1 PR is critical for viral particle maturation since it cleaves the viral precursor polypeptides 
Gag and Gag-Pol into the mature structural and enzymatic proteins (Darke, Nutt et al. 1988; Oroszlan and 
Luftig 1990). Thus PR is an effective target for antiviral drugs, however, the most severe challenge to the 
long-term efficacy of PIs in HAART is the emergence of drug-resistant mutants of PR(Richman, Morton 
et al. 2004). In fact, HIV-1 PR is naturally polymorphic and the polymorphisms exist in approximately 
half of the residues (Velazquez-Campoy, Todd et al. 2001). Regardless of the natural polymorphisms, the 
development of mutations is very rapid and it results in very severe problems in AIDS treatment. It has 
been reported that drug resistant viruses are harbored by over 70% of HIV-1 infected individuals and ap-
proximately 5-10% of them are resistant to all of the current PR inhibitors used in the clinic (Yu, Wild et 
al. 2005). The major causes leading to the rapid emergence of mutations are the lack of 3’-5’exonuclease 
proofreading function of HIV-1 RT and rapid replication of virus particles (Ji and Loeb 1992).  In an 
HIV-1 infected patient, there are over 109 new cells infected and 10 billion new virus particles produced 
every day if no treatment is received (Coffin 1995; Ho, Neumann et al. 1995; Wei, Ghosh et al. 1995). In 
addition, simultaneous infection by more than one virus with different sequences may increase the genetic 
diversity through recombination (Robertson, Sharp et al. 1995; Kuwata, Miyazaki et al. 1997). The pres-
ence of resistant virus could also come from the drug selection during antiviral therapy. The drug resistant 
mutants become dominant when the wild type virus has been killed in the presence of antiviral drugs 
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(Jacobsen, Yasargil et al. 1995; Wei, Ghosh et al. 1995). The drug resistant mutations on PR also affect 
their abilities to process the substrates, thus additional mutations emerge in order to restore their catalytic 
efficiency (Condra, Schleif et al. 1995). For the drug resistant HIV strains, mutations may occur on both 
the substrate Gag and Gag-Pol and PR in order to maintain the enzyme’s ability to normally process its 
substrate in the presence of the drug (Mammano, Petit et al. 1998; Tamiya, Mardy et al. 2004). The rapid 
emergence of the resistant mutants becomes the key challenge of antiviral therapy because these mutants 
still retain their protease function while reducing or eliminating susceptibility to the PIs so HIV can repli-
cate during drug therapy (Miller 2001).   
1.6.2 Molecular mechanisms of drug resistance 
Mutations in up to 36 of 99 residues in HIV-1 PR are related to drug resistance for the current PIs 
(Wu, Schiffer et al. 2003; Johnson, Calvez et al. 2013). The positions of these mutations are mapped on 
Figure1.11. These mutations are classified as major or minor mutations in terms of their effects on antivi-
ral therapy. Major mutations usually exhibit higher levels of resistance and are able to cause drug re-
sistance to one or more PIs themselves. On the other hand, the minor mutations show relatively lower re-
sistance to the PIs and are likely to appear with other mutations (Shafer 2002). There are 15 major muta-
tions and 21 minor mutations as shown in Figure 1.11. In fact, the same mutation may have different lev-
els of resistance to different drugs. In this case, it will be regarded as major mutation on Figure 1.11. The 
mutation could also be classified into active site, flap region, dimer interface and distal region mutations 
based on their locations on HIV-1 PR.  
The structures and activities of HIV-1 PR mutants have been extensively studied in order to re-
veal the molecular mechanisms of drug resistance. Several different mechanisms have been discovered by 
comparison of wild type PR and its single mutants (Weber and Agniswamy 2009).  Generally, the muta-
tions located in the inhibitor binding site lead to the decreased interaction with the drugs. These include 
mutations of residues Leu23, Asp30, Val32, Met46, Ile47, Gly48, Ile50, Val82, and Ile84 that interact 
with substrate or inhibitor as indicated in Figure 1.6. The mutations in the dimer interface primarily influ-
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ence the protein stability. The classification of mutations based on the location is not absolute. For exam-
ple, some mutations on the flap region residue not only affect direct interaction with the inhibitor, but also 
alter the interation between two subunits and thus contribute to the reduction of PR dimer stability. This 
has been clearly illustrated in mutation I50V. The loss of the interaction between two subunits and the 
lower PR stability are also observed in other mutations such as L24I and F53L (Darke, Nutt et al. 1988; 
Liu, Kovalevsky et al. 2006). Thus, the reduced PR dimer stability is regarded as a widely used mecha-
nism to produce resistance to PIs. A distinctive mechanism has been observed in active site mutation 
V82A, which exhibits a main chain shift to accommodate the inhibitor. However, the main chain shift 
will not always compensate for the loss of interaction with inhibitor caused by mutation (Tie, Boross et al. 
2004; Tie, Boross et al. 2005; Tie, Kovalevsky et al. 2007). Different from the mutations stated above, the 
mutations located in the distal region usually have subtle and variable effects (Mahalingam, Louis et al. 
2001; Mahalingam, Wang et al. 2004; Kozisek, Bray et al. 2007).  The structural changes caused by these 
mutations, such as L90M and G73S, are transmitted to the active site, thus having an indirect impact on 
the interaction with inhibitors (Darke, Nutt et al. 1988; Tozser, Blaha et al. 1991; Mahalingam, Louis et 
al. 1999; Liu, Kovalevsky et al. 2006).  Even though some mechanisms of drug resistance have been iden-
tified, drug resistance in clinical isolates may result from the combination of different subtle changes and 
can be much more complicated. However, the discovered underlying molecular mechanisms for drug re-
sistance can always be incorporated into the strategies of structure guided design of antiviral PIs targeting 
drug resistant HIV strains. 
1.7 Rationale for this study 
The long-term effectiveness of antiviral therapy is severely challenged by the drug resistance and 
its underlying molecular machenisms are still elusive. Up to date, hundreds of crystal structures have been 
determined in order to guide the design of more effective PIs to combat drug resistance. The antiviral PIs 
SQV and DRV were designed to target the wild type PR and its drug resistant mutants, respectively.  Se-
lective drug resistance of I47V was found to most FDA approved drugs including DRV, with SQV being 
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the only exception. Therefore, it would be interesting to investigate how I47V mutation exhibits different 
effects on DRV and SQV. The effects of a distal region mutation N88D/S on these two PIs were also 
studied.   
The bis-THF of DRV introduces more hydrogen bonds with PR main chain atoms (Ghosh, 
Kincaid et al. 1998; Surleraux, Tahri et al. 2005). Recently, a third THF ring was added to enlarge P2 and 
fit better in the S2 binding pocket of PR, leading to the novel PI called GRL-0519. The incorporation of 
the third ring endows GRL-0519 with excellent antiviral activity on drug resistant virus (Ghosh, Xu et al. 
2010). In order to study the molecular basis for the potency of GRL-0519 against drug resistant viral 
strains, the structural and kinetic effects of mutations from different regions including active site (PRD30N, 
PRI50V, PRV82A), flap region (PRI50V, PRI54M) and dimer interface (PRR8Q, PRI50V) were analyzed with 
GRL-0519. These mutations, with the exception of R8Q, are common in drug resistant clinical isolates 
(Johnson, Calvez et al. 2013). These studies will help improve our knowledge of the molecular basis of 
drug resistance and guide the design of more potent anti-viral inhibitors. 
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Figure 1.1 The schematic picture of the HIV virus particle shows its major components. 
From the website: http://www.eenzyme.com/hivresearchtools.aspx.
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Figure1.2 The life cycle of HIV.  
From the website: http://cnx.org/content/m44599/latest/?collection=col11448/latest. 
 Figure 1.3 Gag and Gag-Pol polyproteins and HIV
HIV-1 PR cleavage sites are indicated by orange arrows. The number represents the order of cleavage of 
the polyproteins by HIV-1 PR with 1 for the first and 5 for the last
 
 
 
 
 
 
-1 PR cleavage sites.  
 (Wiegers, Rutter et al. 1998
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). 
 Figure 1.4 The overall structure of HIV
(A) The active site Asp25 is indicated by red sticks. The flap regions and the termini (N and
at the dimer interface are represented in magenta and cyan, respectively. The inhibitor (here DRV) is 
shown in green lines. (B) Different conformations of flaps are showed in superposition of unliganded pr
tease (PRWT in green, PDB ID: 1HHP) 
(PRF53L in red, PDB ID: 2G69) (Liu, Kovalevsky et al. 2006
PDB ID: 2IEN, inhibitor is removed for clarity) 
 
 
-1 PR/inhibitor (DRV) complex. 
(Spinelli, Liu et al. 1991), unliganded protease with F
) and protease complex with darunavir (blue, 
(Tie, Boross et al. 2004).  
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Figure 1.5 The scheme for a catalytic mechanism of HIV-1 PR. 
 
 
 
 
 
 
 
 
 Figure 1.6 Diagram of a substrate (P4
The scissile peptide bond is indicated by a red star. PR residues contributing to the binding site are l
beled (Shen, Tie et al. 2012).  
 
 
 
-P3’) with its binding sites (S4-S3’) on HIV-1 PR.
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Figure 1.7 Currently approved FDA drugs for HIV
 
 
 
-1 PR with date of approval.  
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 Figure 1.8 Hydrogen bond interactions between PR and substrate analogs p2/NC.
Hydrogen bond interactions between PR and inhibitor in high resolution structure of HIV
strate analogs p2/NC at 1.4Å. Carbon atoms are colored gray for PR
ter molecules are indicated by red spheres. The conserved and nonconserved hydrogen bond interactions 
between the PR and inhibitor are shown as green and black dashed lines, respectively 
2005). 
 
 
 
 
 
 
 
and yellow for peptide inhibitor. W
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-1 PR with sub-
a-
(Tie, Boross et al. 
  
Figure 1.9 Hydrogen bond interactions between PR and inhibitors
Carbon atoms are colored gray for PR
spheres. The hydrogen bond interactions between the PR and inhibitor are shown as black dotted lines. 
(A) Hydrogen bond interactions between PR and Saquinavir. (B) Hydrogen bond interactions betw
and Darunavir (Koh, Nakata et al. 2003
 
 
. 
 
and cyan for inhibitor. Water molecules are indicated by red 
; Tie, Boross et al. 2004; Tie, Kovalevsky et al. 2007
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een PR 
). 
  
Figure 1.10 The chemical structures of new antiviral inhibitors
(Ghosh, Leshchenko-Yashchuk et al. 2009; Ghosh, Xu et al. 2010; Ghosh, Chapsal et al. 2012).
 
 
 
 
.  
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 Figure 1.11 Mutations in the PR gene associated with resistance to 
Major mutations and minor mutations are indicated by red and blue 
the PR are also labeled (Johnson, Calvez 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PIs. 
sphere, respectively. The positions on 
et al. 2013). 
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2 1NOVEL P2 TRIS-TETRAHYDROFURAN GROUP IN ANTIVIRAL COMPOUND 1 
(GRL-0519) FILLS THE S2 BINDING POCKET OF SELECTED MUTANTS OF HIV‑1 
PROTEASE 
2.1 Abstract    
GRL-0519 (1) is a potent antiviral inhibitor of HIV-1 protease (PR) possessing tris-
tetrahydrofuran (tris-THF) at P2. The high resolution X-ray crystal structures of inhibitor 1 in complexes 
with single substitution mutants PRR8Q, PRD30N, PRI50V, PRI54M, and PRV82A were analyzed in relation to 
kinetic data. The smaller valine side chain in PRI50V eliminated hydrophobic interactions with inhibitor 
and the other subunit consistent with 60-fold worse inhibition. Asn30 in PRD30N showed altered interac-
tions with neighboring residues and 18-fold worse inhibition. Mutations V82A and I54M showed com-
pensating structural changes consistent with 6−7-fold lower inhibition. Gln8 in PRR8Q replaced the ionic 
interactions of wild type Arg8 with hydrogen bond interactions without changing the inhibition signifi-
cantly. The carbonyl oxygen of Gly48 showed two alternative conformations in all structures likely due to 
the snug fit of the large tris-THF group in the S2 subsite in agreement with high antiviral efficacy of 1 on 
resistant virus.   
2.2  Introduction 
HIV/AIDS is a life-threatening disease that interferes with the immune system, and approximate-
ly 1.8 million people died of AIDS-related illnesses in 2010 (Maghina, Govind et al. 1998). Although 
there is no effective vaccine available(Girard and Bansal 2008), highly active antiretroviral therapy 
(HAART), which employs a combination of different antiretroviral drugs, improves the lives of AIDS 
patients(Brenner, Turner et al. 2002). HIV-1 protease (PR) is critical for viral particle maturation since it 
                                                     
 
1
 This chapter was published: Zhang, H.; Wang, Y. F.; Shen, C. H.; Agniswamy, J.; Rao, K. V.; Xu, C. X.; Ghosh, 
A. K.; Harrison, R. W.; Weber, I. T. J Med Chem 2013, 56, 1074-83. 
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cleaves the viral precursor polypeptides Gag and Gag-Pol into the mature structural and enzymatic pro-
teins (Darke, Nutt et al. 1988; Oroszlan and Luftig 1990). Thus PR is an effective target for antiviral 
drugs, however, the most severe challenge to the long-term efficacy of protease inhibitors (PIs) in 
HAART is the emergence of drug-resistant mutants of PR(Richman, Morton et al. 2004).  
HIV-1 PR is catalytically active as a homodimer. Structural regions critical for PR activity and 
stability are the dimer interface including the catalytic Asp25 from each subunit and the flexible flaps 
comprising residues 45 to 55 (Mahalingam, Louis et al. 1999; Weber and Agniswamy 2009) To date, 
there are nine approved clinical PIs. The first clinical inhibitors, such as saquinavir (SQV), were designed 
to bind tightly in the active site cavity of the wild type enzyme; however, their binding affinity can be 
readily lowered by mutations. Analysis of the structural and biochemical properties of PR mutants sug-
gests that resistant mutations act by multiple mechanisms, including mutations in the binding site that di-
rectly lower inhibitor affinity, mutations at the dimer interface that destabilize the catalytically active di-
mer, and flap mutations that alter the conformational flexibility (Weber and Agniswamy 2009). Drug re-
sistant PR mutants exhibit decreased binding affinity for inhibitors while maintaining the critical PR func-
tion in viral replication (Miller 2001). Two clinical PIs, darunavir (DRV) and amprenavir (APV), contain 
tetrahydrofuran  (THF) in the P2 group; APV has a single THF while DRV incorporates bis-THF.  
The bis-THF of DRV introduces more hydrogen bonds with PR main chain atoms, and DRV has 
demonstrated high potency and clinical efficacy on resistant viral infections (Ghosh, Kincaid et al. 1998; 
Surleraux, Tahri et al. 2005). Recently, a third THF ring was added to enlarge P2 and fit better in the S2 
binding pocket of PR, leading to the novel PI called GRL-0519 (1) (Figure 1A). The incorporation of the 
third ring endows inhibitor 1 with excellent antiviral activity on drug resistant virus (Ghosh, Xu et al. 
2010).  
The crystal structure of inhibitor 1 complexed with wild type PR (PRWT) was reported previously 
(Ghosh, Xu et al. 2010). The third THF ring showed new water-mediated hydrogen bonds with conserved 
PR residues Gly27, Asp29 and Arg8’. In order to study the molecular basis for the potency of inhibitor 1 
against drug resistant viral strains, crystal structures of inhibitor 1 complexes with PR mutants bearing 
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single substitutions of R8Q, D30N, I50V, I54M and V82A (PRR8Q, PRD30N, PRI50V, PRI54M and PRV82A) 
were analyzed. The location of these mutations in the PR dimer is indicated in Figure 1B. These muta-
tions, with the exception of R8Q, are common in drug resistant clinical isolates(Johnson, Calvez et al. 
2011). R8Q was one of the first resistant mutants identified in the laboratory for an investigational inhibi-
tor (Ho, Toyoshima et al. 1994). In the wild type enzyme, Arg8 forms an ionic interaction with Asp29’ in 
the other subunit as an important component of the dimer interface (Ishima, Gong et al. ; Weber 1990). 
This intersubunit ionic interaction was eliminated in the mutant with the single substitution of R8Q 
(Mahalingam, Louis et al. 1999). Moreover, in the PRWT-inhibitor 1 complex, the side chain of Arg8 
forms a water-mediated hydrogen bond with the third THF of inhibitor 1 (Ghosh, Xu et al. 2010). There-
fore, it is of particular interest to test how the R8Q mutation affects the binding of inhibitor 1. D30N is a 
major mutation that is associated with resistance to nelfinavir (NFV) (Jarvis and Faulds 1998). Asp30 
forms hydrogen bond interactions with the bis-THF of DRV, thus mutation of this residue may alter the 
inhibitor binding. Mutations of the flap residues such as Ile50 and Ile54 can alter the conformational dy-
namics of this region, thereby affecting the binding affinity for inhibitors (Pazhanisamy, Stuver et al. 
1996; Liu, Boross et al. 2005; Liu, Kovalevsky et al. 2006; Liu, Kovalevsky et al. 2008). Ile50 is located 
at the tip of the flap where its side chain forms hydrophobic interactions with inhibitors. Mutation of I50V 
to a shorter side chain is expected to reduce the binding affinity for inhibitors. Indeed, PR with I50V mu-
tation exhibits significantly reduced inhibition by indinavir, SQV, and DRV (Liu, Boross et al. 2005; Ko-
valevsky, Tie et al. 2006; Liu, Kovalevsky et al. 2008). I50V also has a significant effect in destabilizing 
the PR dimer(Liu, Boross et al. 2005). Mutations of Val82 are found frequently in resistant virus(Johnson, 
Calvez et al. 2011). The mutation V82A in the active site cavity can eliminate interactions with inhibitor, 
and also exhibits a shift of its main chain atoms to adapt to inhibitor (Mahalingam, Wang et al. 2004; Tie, 
Boross et al. 2004; Tie, Kovalevsky et al. 2007). Here, the inhibitor 1 complexes with PR mutants PRR8Q, 
PRD30N, PRI50V, PRI54M and PRV82A are analyzed in relation to the PRWT -inhibitor 1 complex and the inhi-
bition values.
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2.3 Experimental Section 
2.3.1 General 
Inhibitor 1 has shown analytical purity of >98% by HPLC (Ghosh, Xu et al. 2010). The structure 
was confirmed by 1H and 13C NMR spectral analysis, and high resolution mass spectrometry. HRMS 
(ESI) [M+Na]+ calcd for C30H40N2O9SNa: 627.2352, found: 627.2359.   
2.3.2  Protein expression and purification 
In order to prevent PR autoproteolysis, a PR clone (Genbank HIVHXB2CG) engineered with five 
mutations (Q7K, L33I, L63I, C67A and C95A) was used as a template. Mutants (R8Q, D30N, I50V, 
I54M and V82A) were generated by using the Quick-Change mutagenesis kit (Stratagene, La Jolla, CA). 
The expression, purification and refolding were performed as previously described (Wondrak and Louis 
1996; Mahalingam, Louis et al. 2001). 
2.3.3 Enzyme kinetics 
Kinetic parameters were determined by a fluorescence assay. The fluorogenic substrate was Abz-
Thr-Ile-Nle-p-nitro-Phe-Gln-Arg-NH2, where Abz is anthranilic acid and Nle is norleucine (Bachem, 
King of Prussia, PA, USA), with the sequence derived from the p2 ⁄NC cleavage site of the Gag 
polyprotein. 10 µl protease (final concentration of 70-120 nM) diluted in 98 µl reaction buffer (100 mM 
Mes, pH 5.6, 400 mM sodium chloride, 1 mM EDTA and 5% glycerol) and 2 µl dimethylsulfoxide or 
inhibitor (dissolved in dimethylsulfoxide) were incubated at 37 °C for 5 min. The reaction was initialized 
by adding 90 µl substrate. The reaction was monitored over 5 min in the POLARstar OPTIMA microplate 
reader at wavelengths of 340 and 420 nm for excitation and emission. Data analysis was performed using 
the program sigmaplot 9.0 (SPSS Inc., Chicago, IL, USA). Km and kcat values were obtained by standard 
data fitting with the Michaelis–Menten equation. The Ki value was obtained from the IC50 values estimat-
ed from an inhibitor dose–response curve using the equation Ki = (IC50) [E] ⁄ 2) ⁄ (1 + [S] ⁄Km), where [E] 
and [S] are the PR and substrate concentrations. 
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2.3.4 Crystallographic Analysis 
Crystals were grown by the hanging drop vapor diffusion method using protein solutions 
preincubated with inhibitor, which was dissolved in dimethylsulfoxide, in a molar ratio of 1:5-10. The 
final crystallization drop was 1.6-2 µl with reservoir solution and protein in a 1:1 ratio by volume. Crys-
tallization conditions for different complexes were as follows: 22%-24% saturated Ammonium Sulfate, 
130-135 mM Sodium Phosphate, 0.05 M Sodium Citrate, pH 6.1 for PRR8Q; 1.46 M NaCl, 0.1 M Sodium 
Citrate, pH 5.0 for PRD30N; 1.26-1.46 M NaCl, 0.06 M Sodium Acetate, pH 5.0-5.4 for PRI50V; 0.6-0.93 M 
NaCl, 0.06 M Sodium Acetate, pH 4.6-5.0 for PRI54M; and 10% Ammonium Sulfate, 0.05M Citrate-
Phosphate, pH 5.6 for PRV82A. The crystals for X-ray data collection were soaked in the reservoir solution 
with 20-30% glycerol as cryoprotectant for ∼1 min and frozen immediately in liquid nitrogen. X-ray data 
for all the complexes were collected on the SER-CAT beamline at the Advanced Photon Source, Argonne 
National Laboratory. Data were processed using HKL2000 (Otwinowski and Minor 1997). The structures 
were solved by molecular replacement using PHASER (McCoy, Grosse-Kunstleve et al. 2005) in the 
CCP4i suite of programs(Potterton, Briggs et al. 2003). Crystal structures were refined with SHELX97 
(Sheldrick 2008). Manual adjustments and rebuilding were performed using the molecular graphics pro-
gram COOT(Emsley and Cowtan 2004). Figures of the structures were prepared with PYMOL 
(http://www.pymol.org). 
2.4 Results 
2.4.1 Compound 1 inhibition of PRWT and selected mutants 
The kinetic parameters and inhibition constants (Ki) of compound 1 for PRWT and selected mu-
tants PRR8Q, PRD30N, PRI50V, PRI54M and PRV82A are shown in Table 1. The catalytic efficiency (kcat/Km) of 
PRV82A showed 2.7-fold increase, PRI54M was essentially identical and PRR8Q had a slight decrease relative 
to PRWT. The lowest catalytic efficiency of 10% of PRWT was observed for PRD30N and PRI50V. The rela-
tive catalytic efficiency of PRD30N measured here is consistent with previous reports using a different sub-
strate (Kovalevsky, Tie et al. 2006). The relative activities of PRI50V and PRV82A are slightly different from 
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those reported earlier; however, the trends are identical, with decreased kcat/Km for PRI50V and increased 
kcat/Km for PRV82A. Compound 1 showed a range of inhibition of up to 60-fold for the various mutants 
relative to the wild type enzyme. The inhibition constant of PRR8Q for compound 1 was not significantly 
different from the value of 0.5 nM for PRWT. The PRI54M and PRV82A showed 7- and 6-fold increased Ki for 
compound 1 relative to PRWT. Again, the mutants PRD30N and PRI50V showed the most significant changes 
with 18- and 60-fold worse inhibition, respectively.  
2.4.2 Crystallographic analysis of inhibitor 1 complexes 
Crystal structures of PR mutants PRR8Q, PRD30N, PRI50V, PRI54M and PRV82A were obtained in com-
plex with inhibitor 1 and the structures were refined at resolutions of 1.06-1.49 Å. The crystallographic 
data collection and refinement statistics are summarized in Table 2. All five complexes were determined 
in space group P21212 and refined with anisotropic B-factors, solvent molecules, and hydrogen atoms to 
the R-factors of 13.8-16.3
. 
The asymmetric unit contains one PR dimer of residues labeled 1–99 and 1’–
99’ for each monomer. Well defined electron density was observed for the PR residues, as illustrated for 
the mutated residues in Figure 2. The mutated residues, except for Ala82, show alternative conformations. 
The side chain of mutated Asn30 in both subunits of PRD30N-inhibitor 1 structure has two alternative con-
formations with relative occupancies of 0.55⁄0.45. Alternative conformations of the side chains of mutated 
Met54 and Gln8 with relative occupancies of 0.58⁄0.42 and 0.55⁄0.45, respectively, were observed in one 
subunit in the PRI54M and PRR8Q-complexes. Mutated residue Val50 showed alternative conformations for 
both main chain and side chain atoms in both subunits of PRI50V-inhibitor 1 with relative occupancies of 
0.7⁄0.3. Inhibitor 1 has two alternative conformations related by 180° in all five complexes with relative 
occupancies listed in Table 2. 
The residues 48-51/52 at the tip of the flaps show alternative conformations in all the complexes, 
which was associated with approximately 180 rotation of the peptide bond between Ile50 and Gly51 
and alternative conformations of the carbonyl group of Gly48 in both subunits. The electron density map 
of residues Gly48-Gly52 from the atomic resolution (1.06 Å) structure of PRI54M-inhibitor 1 illustrates 
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clearly the alternative conformations (Figure 3A). Similar disorder in the flaps was observed in the wild 
type complex with inhibitor 1. However, alternative conformations are unusual for Gly48 in complexes 
with other inhibitors.  Here, in each conformation of the flap residues, the carbonyl oxygen of Gly48 
forms several C-H…O interactions with the tris-THF P2 group and Gly48’ forms a C-H…O interaction 
with the P2’ aniline in the corresponding conformation of inhibitor 1 (Figure 3B). The two conformations 
of Gly48 may arise from steric hindrance due to the tight fit of the tris-THF group in the S2 subsite.    
The mutant dimers superimpose on the PRWT-inhibitor 1 complex (PDB ID: 3OK9) with pairwise 
root mean square deviations (RMSD) of 0.13-0.24 Å on 198 Cα atoms.  Both alternative inhibitor confor-
mations are considered, except for the minor conformation of inhibitor in PRI50V-inhibitor 1, which has 
the low relative occupancy of 0.3. Hydrogen bond interactions of inhibitor 1 with all five mutants are sim-
ilar except for variation in interactions of residue 30. The side chain of Asn30/30’ in PRD30N forms a hy-
drogen bond interaction with the first THF oxygen of inhibitor 1  as observed for the major conformation 
of inhibitor 1 in the PRWT complex; however, this interaction was not observed for Asp30/Asp30’ in the 
other four mutants. Interatomic distances for hydrogen bond interactions (O−H···O, N−H···O, etc.) are 
considered in the range of 2.4−3.4Å, C−H···O interactions at 3.0−3.7 Å separation, C−H···π interactions 
for distances of <4.0 Å, and van der Waals contacts when distances are 3.8−4.2 Å, as described previously 
(Kovalevsky, Liu et al. 2006). Structural changes are described for each mutant separately or in related 
pairs in the following sections. 
2.4.3  Influence of D30N on PR structure and its interaction with inhibitor 1 
Residue 30 is located at one end of the active site cavity and interacts with the inhibitor, although 
the side chain frequently has alternate conformations. In PRWT–inhibitor 1, the side chain and main chain 
amide of the major conformation of Asp30’ form hydrogen bond interactions with the first THF ring of 
inhibitor 1 (Figure 4A).  The main chain of residue 30’ lies in essentially the same position in PRD30N–
inhibitor 1 and PRWT–inhibitor 1, thus the hydrogen bond interaction of the main chain amide of Asp30’ 
with O26 of inhibitor 1 is preserved in the mutant (Figure 4A). In addition, the major conformation of the 
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side chain (occupancy of 0.55) of residue 30’ was similar in both structures and retained the hydrogen 
bond interaction with inhibitor. However, the minor conformation (occupancy of 0.45) of the side chain 
differs in the mutant and the wild type enzyme, especially the position of Oδ1 atom, due to  the Cγ 
movement of approximately 0.9 Å as well as rotation of the side chain (approximately  90°) of Asn30’ 
compared to Asp30’ of PRWT. As a result, the side chain of Asn30’ in the mutant forms a hydrogen bond 
with a water molecule, which further interacts with the side chain of Asn88’ as well as the main chain of 
Thr74’ (Figure 4B). This water also forms hydrogen bond interactions with the main chain and side chain 
of Thr31’ in both wild type and mutant (not shown in Figure 4B). In the other subunit (1-99), the Asn30 
side chain in PRD30N forms a hydrogen bond with the minor conformation of inhibitor 1 , which was not 
observed in PRWT (Figure 4C). The interactions of Asn30 with neighboring residues are similar to those 
shown in Figure 4C for Asn30’. It seems that the observed 18-fold increase in the inhibition constant of 
the inhibitor 1 for PRD30N does not arise from changes in the direct interactions between residue 30 and 
the inhibitor. Instead, the elimination of the negative charge of Asp30 and alterations within an internal 
network of interactions may provide indirect effects on inhibition. Similar changes in interactions of resi-
dues 30 and 88 have been reported in mutants containing D30N and N88D and are also proposed to effect 
inhibition (Mitsuya, Winters et al. 2006; Kozisek, Bray et al. 2007). 
 
2.4.4 Mutations I54M and V82A produce compensating shifts in the 80’s loop residues 
Ile54, which is located in the flap region, does not contact inhibitors directly, but it forms many 
hydrophobic interactions with surrounding residues, including residues in the 80’s loop (residues 78-82) 
and Ile50’. In the subunit comprising residues 1-99, Met54 had two alternative conformations as shown in 
Figure 2. Compared with Ile54 in PRWT, both the major (Figure 5A) and minor (Figure 5B) conformations 
of Met54 in PRI54M formed one more inter-subunit van der Waals contact with the major and minor con-
formations of Ile50’. The 80’s loop in PRI54M has shifted to accommodate the larger side chain of Met54 
compared with Ile54 in PRWT. Pro79 has shifted away from residue 54 by about 0.8Å at the Cα atom to 
maintain their van der Waals interactions. The major conformation of Met54 (relative occupancy of 0.58) 
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formed the same number of van der Waals contacts with Pro79 (Figure 5A). In addition, it formed one 
new van der Waals interaction with the major conformation of Thr80. The minor conformation of Met54 
(relative occupancy of 0.42) formed the same number of van der Waals contacts with the proline ring 
(Figure 5B); however, it gained a new C-H…O interaction with the main-chain carbonyl oxygen atom of 
Pro79 and one more van der Waals interaction with the minor conformation of Thr80 compared with Ile54 
in PRWT. In the other subunit 1’-99’, Met54’ had a single conformation and formed one less inter-subunit 
van der Waals contact with both the major (Figure 5C) and minor (Figure 5D) conformations of Ile50 
compared with Ile54’ in PRWT.  Unlike subunit 1-99, the 80s loop residue Pro79’ in subunit 1’-99’ exhib-
ited two alternative conformations. A larger shift of approximately 1.1Å was observed for the major con-
formation of Pro79’ whereas the minor conformation showed an insignificant change of 0.2 Å. Although 
Met54’ had less van der Waals interactions with the major conformation of Pro79’, it gained a new one 
with Thr80’ (Figure5C). The interactions of residue 54’ with the minor conformations of proline were 
identical for PRWT and the mutant (Figure 5D). However, it gained new interactions with the C atoms of 
Pro79’ and Thr80’. Taken together, there are either two conformations of Met54 or the 80s loop residues 
to accommodate the large side chain of the mutated Met54. Ile50 exhibits two alternative conformations 
in all structures as mentioned previously. Met54 in PRI54M has a similar number of intersubunit van der 
Waals contacts with Ile50’ as does Ile54 in PRWT (Figures 5A-D).  The separation of Pro79 and residue 54 
is increased in the mutant so that their van der Waals interaction is retained. The new interactions between 
Met54 and Thr80 may help maintain the conformation of the rest of the 80’s loop residues despite the 
shift of Pro79/79’. As shown in Figure 5E, the hydrophobic interactions of Val82 and 82’ with the P1 and 
P1’ groups of inhibitor 1 are retained in PRWT and PRI54M. Therefore, the similar catalytic efficiency of 
PRI54M and PRWT may reflect the similar internal contacts of residue 54. Moreover, the hydrogen bond 
between the major conformation of inhibitor 1 and Asp30 in PRWT was not observed in PRI54M, which 
may contribute to the 7-fold lower inhibition for PRI54M.  
Val82/82’ has extensive C-H…π interactions with the P1 phenyl group and a van der Waals con-
tact with the P1’ group of inhibitor 1 in PRWT (Figure 5F). Mutation V82A introduces the smaller Ala side 
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chain, leading to the loss of C-H…π interactions with the P1 phenyl group of inhibitor 1 compared with 
those in the wild type complex. However, the main chain of Ala82’ has shifted toward the inhibitor by 
around 0.5 Å compared to the wild type complex, which preserves the hydrophobic interaction with the 
P1’ of inhibitor 1 (Figure 5F). The interactions of Val82/82’ with the major and minor conformations of 
the inhibitor were identical, thus only those with the major conformation of the inhibitor 1 are shown. 
Similar to PRI54M, the hydrogen bond between the major conformation of inhibitor 1 and Asp30 in PRWT 
was also not observed in PRV82A. The absence of a hydrogen bond plus fewer interactions of Ala82 with 
the P1 phenyl of inhibitor 1 may be responsible for the decreased inhibitory activity of inhibitor 1 for 
PRV82A. However, the compensation mechanisms observed in PRI54M and PRV82A may explain why there 
was only 6-7 fold decrease of the inhibition constants for these two mutants relative to PRWT. 
2.4.5 Mutations I50V and R8Q alter the dimer interface and interactions with inhibitor 1 
The side chain of Ile50’ in PRWT had intensive interactions with inhibitor 1, including C-H…O 
and C-H…π interactions (Figure 6A). However, the interactions with the P2’ group of inhibitor were 
eliminated for the small Val50’ side chain in the mutant PRI50V and only two C-H…O interactions with 
the sulfonamide oxygen were maintained. Similarly, the two van der Waals interactions between Ile50 
and the P2 tris-THF group of inhibitor 1 were lost in the other subunit of PRI50V (Figure 6B). Similar to 
PRI54M and PRV82A, the hydrogen bond between the major conformation of inhibitor 1 and Asp30 in PRWT 
was also absent in PRI50V. Taken together, the considerably reduced interactions of mutant PRI50V with 
inhibitor 1 are consistent with the significantly decreased inhibition (60-fold) for PRI50V compared to the 
PRWT. 
The mutation of Ile50 to Val50 also affects the inter-subunit interactions. In PRWT, the Ile50’ side 
chain had hydrophobic interactions with the side chains of Ile84 and Ile47, and the same inter-subunit 
interactions were also observed for Ile50. However, the interactions of Val50’ with both Ile84 and Ile47 
are eliminated in the PRI50V mutant as illustrated in Figure 6C. The loss of the interaction between Val50 
and Ile47’ was also observed in the other subunit. These findings are consistent with our previously anal-
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ysis of PRI50V structures(Liu, Boross et al. 2005), and the overall decreased interaction between subunits 
may account for the 10 fold decrease of its catalytic efficiency as well as likely contributing to the signifi-
cantly worse inhibition relative to PRWT.  
In contrast to mutant PRI50V, mutation of R8Q has altered the type of interaction rather than elim-
inated interactions. In the wild type PR, Arg8’ forms an ionic interaction with Asp29 in both subunits 
(Figure 7A & B). However, this inter-subunit ionic interaction is eliminated in PRR8Q (Figure 7C & D). In 
one subunit of PRR8Q, a direct hydrogen bond is formed between the side chains of Gln8 and Asp29’ (Fig-
ure 7C). The side chain of Gln8 in PRR8Q has shifted away from Arg8 in PRWT by approximately 0.9 Å, 
thus gaining new hydrogen bond interactions with conserved water molecules C and D and a water-
mediated interaction with the tris-THF of inhibitor. In the other subunit, Gln8’ has two alternative con-
formations with relative occupancies of 0.55/0.45 (Figure 7D). The side chain of Gln8’ in the major con-
formation forms two direct and one water-mediated hydrogen bond with Asp29, whereas that of the minor 
conformation forms one water-mediated hydrogen bond with Asp29. Overall, direct as well as water-
mediated inter-subunit hydrogen bonds between Gln8 and Asp29’ were observed in both subunits, sug-
gesting that these new interactions might compensate for the loss of the inter-subunit ionic interactions in 
the wild type enzyme (and many other mutants).  
The conserved water molecule D also has a hydrogen bond interaction with the oxygen of the 
third THF ring of inhibitor 1 in both PRWT and PRR8Q (Figure 7). This water mediates a hydrogen bond 
interaction between the inhibitor 1 and Gln8/8’, which is not seen for Arg8/8’ in PRWT (Figure 7C & D). 
Moreover, conserved water molecule C mediates an additional hydrogen bond between the major con-
formation of inhibitor 1 and the side chain of Gln8, which resembles the interaction between the minor 
conformation of inhibitor 1  and Arg8’ in PRWT (Figure 7B).  
In summary, although PRR8Q has lost the strong inter-subunit ionic interaction between Arg8 and 
Asp29’, compensation is provided by new direct and water mediated hydrogen bonds. Meanwhile, even 
though the hydrogen bond between the major conformation of inhibitor 1 and Asp30 in PRWT was not 
seen in PRR8Q, the water-mediated hydrogen bond interaction between inhibitor 1 and Gln8/8’ was en-
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hanced to some extent. Therefore, there is little absolute change in the interaction of PRR8Q with inhibitor 
1. In contrast, PRI50V showed significant loss of interactions with inhibitor 1. These structural changes 
explain why inhibitor 1 has 60-fold worse inhibition for PRI50V while its inhibition for PRR8Q was not af-
fected significantly.  
2.5  Discussion and Conclusions                                                          
Inhibitor 1 is a novel inhibitor incorporating a unique tris-THF group at P2 to target drug resistant 
HIV-1 PR mutants. Previously inhibitor 1 was reported to possess potent antiviral activity against wild 
type HIV-1 and multidrug-resistant strains (Ghosh, Xu et al. 2010). Here, structural and kinetic analyses 
are described for inhibitor 1 with selected PR mutants. The single mutants showed various effects. Substi-
tution of the smaller side chains in PRI50V and PRV82A resulted in the loss of their interactions with inhibi-
tor; however, mutation V82A caused a shift of its main chain atoms to compensate for the loss. Mutation 
to larger side chain in PRI54M pushed the Pro79 (80’s loop) away from residue 54 maintaining their inter-
actions; moreover, new interactions were formed between Met54 and Thr80. The elimination of the inter-
actions caused by the change of the residue size in PRI50V and PRV82A may be related to their worse inhibi-
tion (Ki) by inhibitor 1. In addition, the mechanisms PRV82A and PRI54M adopted to compensate for the loss 
of the interactions may account for the moderate decrease (6~7-fold) in Ki for PRV82A and PRI54M com-
pared to significant reduction (60-fold) in Ki for PRI50V. Moreover, inter-subunit interactions were lost in 
PRI50V, which is expected to contribute to the worse inhibition. Mutations in PRD30N and PRR8Q eliminated 
the negative and positive charges of Asp30 and Arg8, respectively.  In PRR8Q, new hydrogen bond inter-
actions of Gln8 replaced the inter-subunit ionic interaction of Arg8 with Asp29’. Meanwhile, Gln8 
formed new water-mediated hydrogen bonds with inhibitor 1, which may explain why inhibitor 1 has 
similar inhibition for PRR8Q and PRWT. In terms of hydrogen bonds with inhibitor 1, PRWT and all five mu-
tants are similar except for variation in interactions with residue 30 due to the mobility of its side chain. 
The variation in Asp30/30’ and its interaction with inhibitor did not appear to be a major factor in the Ki 
for these mutants. 
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PRD30N differs from the other mutants since the major changes are loss of negative charge for 
Asp30 and altered internal interactions of residue 30/30’ to account for 18-fold decrease of its Ki value for 
inhibitor 1. D30N mutation is the major mutation associated with resistance to NFV(Johnson, Calvez et al. 
2011), which has been suggested to arise from the change of conformational entropy upon inhibitor bind-
ing(Kozisek, Bray et al. 2007). Our structural analysis also showed that mutation D30N introduced 
changes in its interactions with neighboring residues Thr74 and Asn88. In PRD30N, the side chain of Asn30 
formed water mediated hydrogen bond interactions with both Thr74 and Asn88, whereas, these interac-
tions were absent in PRWT-inhibitor 1. Moreover, the proteolytic activity is sensitive to mutations of resi-
dues Gly86-Arg87-Asn88 (Ishima, Gong et al. ; Ishima, Ghirlando et al. 2001). Considering the positive 
association of mutation D30N and N88D (Mitsuya, Winters et al. 2006), it would be interesting to study 
how N88D influences the structure of D30N in complex with this new inhibitor 1.   
 Compound 1 is an inhibitor designed to fill the S2 binding pocket of PR by incorporating a third 
THF ring in the P2 group relative to DRV (Figure 1A). As analyzed in its complex with PRWT (Figure 7A-
B), the oxygen of the third THF ring  of inhibitor 1 gains a hydrogen bond interaction with a conserved 
water (water D in Figure 7A) and helps stabilize the inter-subunit interaction of Arg8’ with Asp29 and 
other surrounding residues. In the mutant PRR8Q, the interaction of the newly incorporated ring of inhibi-
tor 1 with this conserved network was maintained, which is consistent with almost identical inhibition for 
PRWT and PRR8Q. Mutation R8Q, however, has rarely been found in resistant clinical isolates. DRV has a 
Ki value of 6.6 nM for mutant PRD30N and up to 18 nM for PRI50V consistent with resistance to virus with 
these mutations22, (Kovalevsky, Tie et al. 2006). Similarly, our study suggests that viral strains containing 
D30N or I50V are likely to show resistance to inhibitor 1 given their Ki values of 8.9 and 30.9 nM for 
PRD30N and PRI50V, respectively. Inhibitor 1 shows moderate effects on the other two mutants, PRV82A and 
PRI54M, similar to their effects with DRV (Tie, Boross et al. 2004; Liu, Kovalevsky et al. 2008). Therefore, 
mutations D30N, I50V, I54M, and V82A exhibit similar effects on both inhibitors, although inhibitor 1 is 
less effective than DRV on PRI50V. Mutation R8Q exhibits higher sensitivity to compound 1 than other 
mutations studied here, suggesting that compound 1 may be a good inhibitor against viral strains bearing 
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R8Q mutation. Drug resistant clinical isolates generally have more than one mutation, however, and pre-
vious studies of single and double mutations indicate that the changes in structure and other properties of 
the respective single mutants may not be preserved in the double mutants(Mahalingam, Boross et al. 2002; 
Kozisek, Bray et al. 2007). More importantly, the influence of drug resistant mutants on the viral infec-
tivity depends not only on the inhibitor sensitivity, but also on the protease activity, especially for those 
mutations lacking direct interactions with the inhibitors(Henderson, Lee et al. 2012). Their study showed 
that mutant PRI50V had the most negative effect on viral infectivity. Our previous studies suggested that 
the loss of dimer stability due to I50V mutation was a major contributor to the diminished catalytic activi-
ty and inhibition of PRI50V (Liu, Boross et al. 2005). Mutant PRD30N also showed ~50% loss of infectivity 
(Henderson, Lee et al. 2012) in agreement with our previous observation of altered activity on different 
precursor cleavage sites(Mahalingam, Louis et al. 1999). Therefore, a single mutation may have a variety 
of effects on inhibition, dimer stability, catalytic activity and viral replication. Finally, since inhibitor 1 
possesses the large tris-THF P2 group, our structural analysis suggests it may fit better with the mutants 
that have an expanded S2/S2’ pocket, such as the extreme multiple mutant PR20 (Agniswamy, Shen et al. 
2012). 
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Table 2.1 Kinetic parameters for substrate hydrolysis and inhibition of compound 1 
Protease Km 
 (µM)  
kcat  
(min-1)  
kcat/Km 
 
(min-1·µM-1)  
Relative 
kcat/Km  
Ki  
(nM)  
Relative 
 Ki  
PRWT a 30±5  190±20  6.5±1.30  1.0  0.50±0.06  1  
PR
R8Q  38±2  161±4  4.2±0.25  0.6  1.20±0.08  2  
PR
D30N
  76±8  48±2  0.6±0.72  0.1  8.9±0.4  18  
PR
I50V
 a
 109±8  68±5  0.6±0.03  0.1  30.9±0.6  60  
PR
I54M
 
a
 41±5  300±40  7.3±0.80  1.1  3.5±0.2  7  
PR
V82A
 
b
 29±3  512±26  17.7±2.00  2.7  3.2±0.2  6  
aKm and kcat values previously reported in (Liu, Kovalevsky et al. 2008) 
bKm and kcat values previously reported in (Chang, Yu et al. 2012) 
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Table 2.2 Crystallographic Statistics for PR Mutants in Complex with Inhibitor 1 
 
Crystal of PRD30N- Inhibitor 1 was obtained by Dr. Johnson Agniswamy; crystallization of PRI50V- Inhibi-
tor 1 and PR
I54M
- Inhibitor 1 was done by Chen-Hsiang Shen. 
 
 
 
 
 
 
 
 
 
 
Inhibitor 1 complex PRR8Q  PRD30N  PRI50V  PRI54M  PRV82A  
Space group P21212  P21212  P21212  P21212  P21212  
Unit cell dimensions: (Å)          
  a 58.37  58.72  58.59  58.78  58.61  
  b 85.96  86.24  85.95  85.84  86.15  
  c 46.18  45.90  46.07  46.02  46.33  
Resolution range (Å) 1.46  1.49  1.22  1.06  1.29  
Unique reflections 40,949  37,721  64,041  103,379 59, 015  
Rmerge (%) overall (final shell) 5.3 (49.7)  6.2 (42.1)  5.3(47.4)  6.3 (56.8)  5.6 (40.7)  
I/σ(I) overall (final shell) 30.8 (2.6)  25.5 (2.1)  31(2.1)  26.7 (2.1)  18.9 (2.2)  
Completeness (%) overall (final shell) 99.2 (94.8)  97.0 (76.3)  91.5(65.4)  97.4 (85.6)  99.0 (92.7)  
Data range for refinement (Å) 10-1.46  10-1.49  10-1.22  10-1.06  10-1.29  
  R (%) 15.8  15.6 16.5  14.9  16.3  
  Rfree (%) 21.0  21.4  20.3  17.8 20.9  
No. of solvent atoms  
(total occupancies) 175(170.5) 189 (144.2) 251(237.6) 248(234.5) 182(179.0) 
RMS deviation from ideality      
  Bonds (Å) 0.010 0.010 0.014 0.016 0.012 
  Angle distance (Å) 0.029 0.030 0.034 0.038 0.031 
Average B-factors (Å2)      
  Main-chain atoms 15.0 17.5 12.9 12.6 13.0 
  Side-chain atoms 21.1 24.1 19.6 19.1 19.8 
  Solvent 31.6 33.7 30.8 28.8 30.5 
Inhibitor 22.6 25.3 19.5 17.1 19.3 
Relative Occupancy of 1 0.55/0.45 0.55/0.45 0.7/0.3 0.53/0.47 0.6/0.4 
  
 
 
 
Figure 2.1 The structure of inhibitor compound 1 and PR. 
The chemical structures of protease inhibitor compound 1
The HIV-1 protease dimer is shown in light blue cartoon representation. The inhibitor 
residues at the mutation sites are indicated by differently colored sticks. The same residues on the two 
subunits are shown in the same color with only o
 
 
 
 (A). The structure of HIV-1 
ne of them labeled (B). 
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PRWT/inhibitor 1. 
1 and wild-type 
 Figure 2.2 Fo-Fc omit maps for the mutated residues
The magenta sticks indicate the alternative conformations of Asn30, Met54 and Val50. 
 
Figure 2.3 Fo-Fc omit map of flap residues and their interactions with inhibitor 1. 
(A) Fo-Fc omit map (contoured at 3.0 
inhibitor 1 (1.06Å). Carbon atoms are colored cyan and 
respectively. (B) Interactions of Gly48/48’ with inhibitor 1 in complex PR
pancy). The major and minor conformations of Gly48/48’ and the inhibitor 1 
with carbon atoms colored cyan and lines with carbon atoms colored 
teractions between the major conformations are indicated by dash
interactions between the minor conformations are the same but not shown here for clarity.
 
 
 (contoured at 3.0 σ).  
 
σ) for the flap residues Gly48 - Gly52 in complex PRI54M
magenta for the major and minor
I50V–inhibitor 1 (0.7/0.3 occ
are represented by sticks 
magenta, respectively
-dot lines with distances in Å. C
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. C-H…O in-
-H…O 
 
 Figure 2.4 Structural changes of PR
Carbon atoms are colored gray for PR
interactions in PRWT–inhibitor 1 and PR
respectively, with distances in Å. Waters are shown as gray and cyan spheres for PR
PRD30N–inhibitor 1, respectively. Occupancies for a
Asp/Asn30’. (A) Interactions of Asp/Asn30’ with the major conformation of inhibitor 1. (B) Interactions 
of Asp/Asn30’ with the neighboring residues. (C) Interactions of Asp/Asn30 with the minor confor
of inhibitor 1. 
 
D30N.  
WT –inhibitor 1 and cyan for PRD30N–inhibitor 1. Hydrogen bond 
D30N–inhibitor 1 are represented by black and red dashed lines, 
WT
lternative conformations are labeled in parentheses for 
52 
–inhibitor 1 and 
mation 
 Figure 2.5 Structural changes of PR
Carbon atoms are colored gray for PR
1. Interactions are indicated by black lines for PR
Waals and C-H…ð interactions are indicated by dotted lines.  (A
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3 STRUCTURAL AND KINETIC CHANGES IN HIV-1 PROTEASE WITH DRUG-
RESISTANT MUTATIONS I47V AND N88D/S 
 
3.1 Abstract  
SQV and DRV are two potent clinical inhibitors that were designed to target the wild type PR and 
its drug resistant mutants, respectively. The crystal structures of PR mutants PRI47V, PRN88D/s in complex 
with DRV and mutants PRI47V and PRN88D in complex with SQV with resolutions of 1.13-1.72 Å were 
analyzed. Mutation I47V gained more hydrophobic interactions with DRV and SQV. Interestingly, the 
structural changes did not affect the inhibition for PRI47V (relative Ki is 0.7 and 1 for DRV and SQV, re-
spectively)
. 
DRV and SQV showed 8-fold increase in Ki for PRN88D and only small local changes have 
been observed in the structures suggesting that inhibition is influenced by the gain of a negative charge 
due to the N88D mutation. DRV showed a modest reduction in Ki for PRN88S probably due to transfer of 
the distal structural changes to the active site.  In sum, this study provided fundamental information for 
understanding of drug resistance and future design of potential antiviral drugs. 
3.2 Introduction 
Acquired immunodeficiency syndrome (AIDS) is a life-threatening disease that interferes with 
the immune system. According to the UNAIDS reports, approximately 35 million people were globally 
living with HIV/AIDS at the end of 2012 (UNAIDS, 2013). Although there is no effective vaccine availa-
ble (Girard and Bansal 2008), highly active antiretroviral therapy (HAART), which employs a combina-
tion of different antiretroviral drugs, has greatly improved the lives of AIDS patients (Sepkowitz 2001; 
Brenner, Turner et al. 2002). Antiviral drugs that inhibit the HIV-1 protease (PR) have been an important 
component of HAART since their first introduction in combination therapy in 1996 (Naggie and Hicks 
2010).  
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PR cleaves the viral precursor polypeptides Gag and Gag-Pol into the mature structural and en-
zymatic proteins (Darke, Nutt et al. 1988; Oroszlan and Luftig 1990). Inhibition of this PR leads to imma-
ture noninfectious virus (Gottlinger, Sodroski et al. 1989; Louis, Ishima et al. 2007). Thus PR is an effec-
tive target for antiviral drugs. HIV-1 PR is catalytically active as a homodimer of two subunits designated 
as residues 1-99 and 1’-99’. It is a member of the aspartic protease family and contains conserved catalyt-
ic triplet Asp25-Thr26-Gly27 as a key part of active site cavity. Early studies also identified a second 
conserved triad Gly86-Arg87-Asn88 in HIV-1 PR (Pearl and Taylor 1987; Rao, Erickson et al. 1991). 
Whereas Asp25-Thr26-Gly27 is conserved in all aspartic acid proteases, Gly86-Arg87-Asn88 in the α-
helix is only shared by retroviral proteases (Pearl and Taylor 1987; Rao, Erickson et al. 1991; Louis, 
Weber et al. 2000). The dimer interface, including the catalytic Asp25 from each subunit, interactions of 
Arg8 with Asp29 and Arg87’ from the other subunit (Weber 1990), the flexible flaps comprising residues 
45 to 55 and the four-stranded beta sheet formed by the termini,  is also critical for PR activity and stabil-
ity (Mahalingam, Louis et al. 1999; Weber and Agniswamy 2009). 
The most severe challenge to the long-term efficacy of protease inhibitors (PIs) in HAART  ther-
apy is the frequent emergence of drug-resistant mutants of PR due to the infidelity of the HIV reverse 
transcriptase (Condra, Schleif et al. 1995; Richman, Morton et al. 2004; Mehellou and De Clercq 2010; 
Menendez-Arias 2010). These mutants show much lower affinity for PIs while their critical PR function 
in viral replication is still maintained (Miller 2001). Extensive structural and kinetic studies of HIV-1 PR 
and its drug resistant mutants have been investigated in the absence or presence of substrates or inhibitors 
in order to reveal the molecular mechanisms of drug resistance and to contribute to the structure-based 
design of HIV-1 PR inhibitors (Weber and Agniswamy 2009). Up to date, there are nine clinical PIs ap-
proved for AIDS therapy. Saquinavir (SQV, figure 1A), which was the first clinical inhibitors, was de-
signed to bind tightly in the active site cavity of the wild type enzyme. The binding affinity of SQV, how-
ever, can be readily lowered by mutations in the PR. The most recently approved drug darunavir (DRV, 
figure 1A) was designed to target drug resistant PR mutants by incorporating more hydrogen bond inter-
actions with PR main chain atoms. DRV contains two tetrahydrofuran groups (bis-THF) at the P2 posi-
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tion and has demonstrated high potency on resistant viral infections in the laboratory (Koh, Nakata et al. 
2003; Surleraux, Tahri et al. 2005) and in clinic (de Meyer, Vangeneugden et al. 2008). 
 Mutation I47V is associated commonly with DRV resistance in the clinic (De Meyer, 
Lathouwers et al. 2009). Residue 47 lies in the flap region; therefore, mutation of this residue may affect 
the conformation and flexibility of the flap, thus influencing the binding affinity of the substrates or inhib-
itors. Moreover, the side chain of Ile47 (green sticks in Figure1B) points towards the active site cavity 
and provides several van der Waals interactions to stabilize the inhibitor binding to PR. Mutation I47V 
was found to confer resistance to almost all FDA approved drugs including DRV, with the only exception 
of SQV. Therefore, we investigated how PR bearing the I47V mutation (designated PRI47V) exhibits dif-
ferent effects on DRV and SQV.  
Mutations of Asn88 to Asp or Ser are also common in drug resistance. Similar to the catalytic tri-
ad Asp25-Thr26-Gly27, Gly86-Arg87-Asn88 triad is also conserved in retroviral proteases (Pearl and 
Taylor 1987; Rao, Erickson et al. 1991; Louis, Weber et al. 2000). Two aspartic acids at residue 25 from 
two subunits form the central active site and are essential for enzyme activity. The mutation of Asp25 
leads to complete loss of the enzyme’s ability to hydrolyze the substrate peptide bonds (Kohl, Emini et al. 
1988; Seelmeier, Schmidt et al. 1988). Although the Gly86-Arg87-Asn88 triad does not directly contact 
the substrate or inhibitor, it is located close to the active site loop and dimer interface. The inter-subunit 
salt-bridge between R87 and D29 is crucial for dimer stability of the mature PR (Weber 1990); It has been 
shown that both the D29N and R87K mutants increased the dimer dissociation constant (Kd) by several 
orders of magnitude(Ishima, Torchia et al. 2007). The increased dimer dissociation caused by R87K mu-
tants then drastically diminished the catalytic activity of HIV-1 PR (Ishima, Torchia et al. 2007). The role 
of the G86 residue in dimer formation and catalytic activity was also studied by the same group (Ishima, 
Gong et al. 2010). They have demonstrated that G86 mutants also exhibited extremely low catalytic activ-
ities. However, G86 mutants reduced the catalytic activities without significantly increasing the dimer 
dissociation constants. Structural studies by NMR and X-ray crystallography indicated that G86 mutants 
have conformational changes in G86 site and these changes also influence the active site region, thus hav-
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ing an impact on substrate/inhibitor binding. While these residues in conserved region either severely af-
fect the catalytic activity (such as G86 and R87) or completely diminish the enzyme activity (Asp25), mu-
tations on residue 88 was the only one selected in drug resistance. Therefore, it is very important to ad-
dress whether and how N88 influences the structure and activity of HIV-1 PR. 
Residue Asn88 is located in the alpha helix (labeled yellow in Figure 1B) and its side chain inter-
acts with the residues Asp29, Thr31 and Thr74. Mutation from N88 to D/S may change these interactions, 
which may be related to decreased catalytic activity for PR with the N88D mutation (Mahalingam, Louis 
et al. 1999). In the complex of PRD30N with the investigational antiviral inhibitor GRL-0519, the side 
chain of Asn30 formed water mediated hydrogen bond interactions with both Thr74 and Asn88 (Zhang, 
Wang et al. 2013). Thus, residue 88 may interact indirectly with the inhibitor binding site through interac-
tions with Asp29, Thr31 and Asp30. Moreover, the occurrence of D30N facilitates selection of mutations 
N88D and L90M during evolution of drug resistance (Mitsuya, Winters et al. 2006). Mutation N88D is 
usually found in the treatment of nelfinavir (NFV) as an accessory mutation, which compensates for the 
loss of catalytic activity due to the major change of D30N (Parera, Fernandez et al. 2007). Mutations of 
N88 are not associated with DRV resistance, however, mutation N88S confers resistance to SQV (Rhee, 
Taylor et al. 2010). Hence, we are also interested in comparing the structural and kinetic effects of N88S 
and N88D on two typical clinical drugs SQV and DRV.   
3.3 Experimental Section 
3.3.1 Protein expression and purification  
In order to prevent PR autoproteolysis, a PR clone (Genbank HIVHXB2CG) engineered with five 
mutations (Q7K, L33I, L63I, C67A and C95A) was used as a template. Mutants (I47V, N88S and N88D) 
were generated by using the Quick-Change mutagenesis kit (Stratagene, La Jolla, CA). The expression, 
purification and refolding were performed as previously described (Wondrak and Louis 1996; 
Mahalingam, Louis et al. 2001). 
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3.3.2 Enzyme kinetics 
Kinetic parameters were determined by a fluorescence assay. The fluorogenic substrate was Abz-
Thr-Ile-Nle-p-nitro-Phe-Gln-Arg-NH2, where Abz is anthranilic acid and Nle is norleucine (Bachem, 
King of Prussia, PA, USA), with the sequence derived from the p2/NC cleavage site of the Gag 
polyprotein. 10 µl protease (final concentration of 70-120 nM) diluted in 98 µl reaction buffer (100 mM 
Mes, pH 5.6, 400 mM sodium chloride, 1 mM EDTA and 5% glycerol) and 2 µl dimethylsulfoxide or 
inhibitor (dissolved in dimethylsulfoxide) were incubated at 37 °C for 5 min. The reaction was initialized 
by adding 90 µl substrate. The reaction was monitored over 5 min in the POLARstar OPTIMA microplate 
reader at wavelengths of 340 and 420 nm for excitation and emission. Data analysis was performed using 
the program sigmaplot 9.0 (SPSS Inc., Chicago, IL, USA). Km and kcat values were obtained by standard 
data fitting with the Michaelis–Menten equation. The Ki value was obtained from the IC50 values estimat-
ed from an inhibitor dose–response curve using the equation Ki = (IC50) [E] ⁄ 2) ⁄ (1 + [S] ⁄Km), where [E] 
and [S] are the PR and substrate concentrations. 
3.3.3 Urea denaturation assay 
The urea denaturation effect was measured using a fluorescence assay. The PR activity was 
measured in 200 µl solution: 50 µl urea with the final concentration ranging from 0 M to 4.0 M; 10 µl PR 
at the final concentration of 20 nM to 35 nM; 90 µl anthranylyl substrate at the final concentration of 72 
µM and 50 µl denaturation buffer (200 mM MES, 800mM sodium chloride, 2mM EDTA, 10% glycerol 
at pH 5.6). The UC50 values were determined by plotting the initial velocities against increasing urea con-
centration using SigmaPlot 8.02. 
3.3.4 Crystallographic Analysis 
Crystals were grown by the hanging drop vapor diffusion method using protein solutions 
preincubated with inhibitor, which was dissolved in dimethylsulfoxide, in a molar ratio of 1:5. The final 
crystallization drop was 2 µl with reservoir solution and protein in a 1:1 ratio by volume. Crystallization 
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conditions for different complexes were as follows: 0.41M sodium chloride, 0.1M Citrate phosphate, pH 
5.8 for PRI47V-DRV; 1.35M sodium chloride, 0.1M Citrate phosphate, pH 6.0 for PRI47V-SQV; 0.4M sodi-
um chloride, 0.1M sodium acetate,  pH 4.4 PRN88S-DRV; 0.26 sodium chloride, 0.1M Tris-HCl, pH 6.5 
for PRN88D-SQV; 1.5M Sodium Chloride, 0.1M Citrate-Phosphate, pH 5.6 for PRN88D-DRV. The crystals 
for X-ray data collection were soaked in the reservoir solution with 20-30% glycerol as cryoprotectant for 
1 min and frozen immediately in liquid nitrogen. X-ray data for all the complexes were collected on the 
SER-CAT beamline at the Advanced Photon Source, Argonne National Laboratory. Data were processed 
using HKL2000(Otwinowski and Minor 1997). The structures were solved by molecular replacement us-
ing PHASER(McCoy, Grosse-Kunstleve et al. 2005) in the CCP4i suite of programs(Potterton, Briggs et 
al. 2003). Crystal structures were refined with SHELX97(Sheldrick 2008). Manual adjustments and re-
building were performed using the molecular graphics program COOT(Emsley and Cowtan 2004). Fig-
ures of the structures were prepared with PYMOL (http://www.pymol.org). 
3.4 Results 
3.4.1 DRV and SQV inhibition of catalytic activity of PRWT and drug resistant mutants 
The kinetic parameters and inhibition constants (Ki) of DRV and SQV for PRWT and its drug re-
sistant mutants PRI47V, PRN88S and PRN88D are shown in Table 1. The catalytic efficiency (kcat/Km) of 
PRI47V was essentially identical (1.2-fold) or slightly increased relative to PRWT. Both PRN88D and PRN88S 
had a slight decrease (0.6 and 0.7-fold, respectively) in the catalytic efficiency relative to PRWT. While 
PRI47V and PRN88S showed slight decrease (0.7, 0.3-fold respectively) in their inhibition constants (Ki) for 
DRV relative to PRWT, PRN88D exhibits approximately 8-fold increase for both DRV and SQV. The Ki of 
PRN88S for SQV also increased, but only 3-fold, relative to PRWT. Mutant PRI47V has the same Ki for SQV 
as PRWT.  
The dimer stability of PRWT as well as three PR mutants PRI47V, PRN88S and PRN88D was measured 
by using urea denaturation assay. UC50 value, which is the concentration of denaturing urea when the PR 
activity drops to 50% of the initial value, was obtained to evaluate the stability of PRWT and its mutants 
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(Table 2).  The UC50 value of PRI47V was increased by approximately 40% of the wild type value, while 
those of PRN88D and PRN88S were decreased by approximately 50%. These results suggest that the muta-
tion of flap residue Ile47 increased the PR dimer stability, whereas the mutation Asn88 decreased the PR 
dimer stability. 
3.4.2 Crystallographic analysis 
Crystals of PR mutants PRI47V, PRN88D and PRN88S in complex with DRV and mutants PRI47V and 
PRN88D in complex with SQV were obtained by using the hanging drop vapor diffusion method. The crys-
tal structures were refined at resolutions of 1.13-1.72 Å as shown in Table 3. All five complexes were 
determined in space group P21212 and refined with solvent molecules to the R-factors of 12.5-21.7. All 
complexes except PRN88D_DRV were also refined with anisotropic B-factors and hydrogen atoms.   The 
asymmetric unit contains one PR dimer composed of residues labeled 1–99 and 1’–99’ for the two mon-
omers. The mutated residues in five complexes were clearly shown by the electron density maps illustrat-
ed in Figure 2. The mutated residues I47V in complex PRI47V-SQV and N88D in complex PRN88D_DRV 
showed one conformation. Two alternative conformations of the mutated residue in one of the subunits 
were observed for the other three complexes, as illustrated in Figure2. DRV and SQV have two alterna-
tive conformations related by 180° in all five complexes with relative occupancies listed in Table 3. Both 
alternative conformations are considered in PRI47V-DRVcomplex. Structural changes were analyzed by 
comparing the mutants with wild type PR. The mutant dimers superimposed on the PRWT-DRV or PRWT-
SQV complexes with pairwise root mean square deviations (RMSD) of 0.13-0.51 Å on 198 Cα atoms. 
Slightly larger differences were seen for the surface loops of residues 37-42/37’-42’ in the SQV
 
complex-
es, which is probably due to the different space groups since PRWT_SQV was determined in space group 
P212121 (Mahalingam, Wang et al. 2004).  
3.4.3 Comparison of PRI47V _DRV and PRWT_DRV  
In the PRWT_DRV, Ile47 is located in the hydrophobic pocket and interacts with Val32, Leu76, 
and residues in the flap region, including Lys45, Ile54 and Val56, and also forms intersubunit interactions 
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with Ile50’ (Figure3A). Similar to Ile47, Ile47’ in another subunit interacted with its surrounding residues 
Val32’, Leu76’, lys45’, Ile54’, Val56’ as well as Ile50. Furthermore, it showed a C-H…O interaction 
with one alternative conformation of the side chain of Asp30’ (Figure3B).  The I47V mutation to a small-
er side chain might be expected to eliminate interactions with inhibitor. However, the side chain of Val47 
showed two alternative conformations and partially compensated for the lost interactions. One side chain 
conformation (with occupancy of 0.58) of Val47 has lost van der Waals contacts with Leu76, Val32 and 
Lys45, nevertheless, the other conformation (with occupancy of 0.42) of Val47 retained interaction with 
Leu76 (Figure3C). In addition, the intersubunit interaction between residue 47 and Ile50’ is preserved due 
to a small shift of the main chain.  Similar to Ile47, Ile47’ in another subunit interacted with its surround-
ing residues Val32’, Leu76’, lys45’, Ile54’, Val56’ as well as Ile50. Furthermore, it showed a C-H…O 
interaction with one alternative conformation of the side chain of Asp30’ (Figure3B).  The I47V mutation 
to a smaller side chain might be expected to eliminate interactions with inhibitor. However, the side chain 
of Val47 showed two alternative conformations and partially compensated for the lost interactions. One 
side chain conformation (with occupancy of 0.58) of Val47 has lost van der Waals contacts with Leu76, 
Val32 and Lys45, nevertheless, the other conformation (with occupancy of 0.42) of Val47 retained inter-
action with Leu76 (Figure3C). In addition, the intersubunit interaction between residue 47 and Ile50’ is 
preserved due to a small shift of the main chain. Val47’ in the other subunit also lost interactions with 
neighboring residues Asp30’, Val32’, Lys45’and Ile54’ compared to the wild type complex, while the 
intersubunit contact with Ilr50 is preserved (Figure3D). The shift in main chain position as well as rota-
tion of the side chain of Val47/47’ also leads to shorter C-H…π interactions with DRV (Figure3C-D). 
The hydrogen bond interactions of DRV are essentially identical in the mutant and wild type enzyme. 
Therefore, the major structural change is the loss of internal hydrophobic interactions of residue 47 in the 
mutant, which may tend to increase flap mobility and hence lower the affinity for inhibitor. This effect 
would be consistent with the association of I47V with resistance to DRV (Johnson, Calvez et al. 2013). 
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3.4.4 Comparison of PRI47V _SQV and PRWT_SQV  
Ile47 in PRWT_SQV has hydrophobic interactions with Val32, Leu76, and flap residues Lys45, 
Ile54 and Val56 similar to the complex with DRV, however there is no van der Waals contact with Ile50’ 
from the other subunit (Figure4A). In addition, Ile47 has a hydrophobic interaction with SQV. In the oth-
er subunit, Ile47’ formed similar interactions (Figure4B). In the mutant PRI47V _SQV, Val47 has lost in-
teractions with Val32 compared with those in the wild type protease complex, as shown in Figure 4C. In 
addition, the closest interatomic distance between Val47 and SQV is slightly out of the range for good 
van der Waals interactions. The interactions of Val47’ are the same as those of Val47 except for an addi-
tional CH…O interaction with Asp30’ (Figure4D).  Analysis of SQV interactions with residues of PRI47V 
showed that hydrogen bond interactions were conserved in the mutant and wild type enzyme. However, 
the 80s’ loop of PRI47V_ SQV was shifted towards SQV so that the hydroxyl group of Thr80 forms a new 
CH…O interaction with SQV. The flap region in the other subunit also shifted so that new CH…O inter-
actions were formed between SQV and residues Gly48’, Val47’ and Asp30’ (Figure 4E). Taken together, 
SQV in complex PRI47V_SQV has lost a hydrophobic contact with mutated Val47 in one of the subunits; 
however, it has gained several CH-O interactions with the enzyme. The observed gain of interactions of 
this mutant with SQV is in excellent agreement with clinical results suggesting that mutation I47V does 
not alter susceptibility for SQV(Johnson, Calvez et al. 2013). 
3.4.5 Structural change of PRN88D_DRV and PRN88S_DRV relative to PRWT_DRV 
Asn88 has important connections with residues in the active site cavity and the dimer interface. In 
the wild type structure of PRWT_DRV, Asn88 forms hydrogen bond interactions with Thr74, Thr31 and 
Asp29 in both of the subunits (Figure 5A-B), while Asp29 has an intersubunit ionic interaction with 
Arg87’. In the mutant PRN88D _DRV, Asp88 in one subunit formed interactions resembling those in 
PRWT_DRV (Figure5C). However, the direct hydrogen bond betweet Asp88’ and Thr74’ is lost in the 
other subunit, instead, the side chain of Asp88’ rotates to allow entry of a water molecule forming water-
mediated interactions linking Asp88’ with Thr74’ and Thr31’ (Figure5D-E). Superimposition of the two 
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complexes showed that the carbonyl group of Asp88’ rotates 12° towards Thr91’ side chain and forms a 
new hydrogen bond (Figure5E). The side chain of Asp88’ also swings 20° towards Gly86’ forming an-
other new hydrogen bond. Compared to PRWT_DRV, the main chain of Thr74’ in PRN88D _DRV shifts 1Å 
away from Asp88’. The concerted shift of residues 73’ to 75’ is further transmitted to the outer strand of 
residues Gln58’-Ile62’ to preserve the β-sheet (Figure5E). In addition to these structural changes and in-
troduction of a water molecule near Asn88’, PRN88D_DRV has lost a water-mediated hydrogen bond ob-
served between DRV and side chain of Asp30 in the wild type complex. These structural changes are as-
sumed to contribute to the loss of catalytic activity and increased sensitivity to urea observed for this mu-
tant; however, they do not appear to produce large changes in the interaction with DRV.  The increased Ki 
measured for DRV inhibition may be related to the addition of a negative charge for N88D.   
In the other mutant PRN88S_DRV, the side chain of Ser88 is rotated 19° outwards from Thr74 and 
Thr31 and forms a direct hydrogen bond with Asp30 side chain. The additional space allows introduction 
of water–mediated hydrogen bonds that compensate for the loss of direct hydrogen bonds with Thr74 and 
Thr31 (Figure 6A).  In the other subunit, Ser88’ has two alternative conformations, one rotates 15° out-
wards and the other rotates 19° inwards (Figure 6B). The inward movement of the second alternate con-
formation enables the hydroxyl group of Ser88’ to form hydrogen bonds with Thr31’ resembling those 
observed for the amino group of Asn88’ in the wild type enzyme (Figure 6B). However, the first alternate 
conformation of Ser88’ allows two waters to occupy the space between Ser88’ and Thr74’, Thr31’ and 
form a network of interactions among these residues (Figure6C).  Similar to PRWT_DRV, the hydrogen 
bond interaction between the main chain atoms of residue 88 and Asp29 in PRN88S_DRV was observed in 
both subunits. Presumably, the shorter serine side chain due to the N88S mutation and the introduction of 
internal water is responsible for the lower activity and stability observed for PRN88S, while these structural 
changes produce little change in inhibitor of DRV, in agreement with the lack of association of N88D 
mutation with resistance to DRV 
66 
 
3.4.6 Comparison of PRN88D _SQV and PRWT_SQV 
In PRWT_SQV, Asn88 formed direct hydrogen bond interactions with Thr74 and Thr31. Thr74 is 
also linked with Asp30 through waters (Figure7A-B). Compared to wild type enzyme, the side chain of 
Asp88 in PRN88D_SQV shifts 18° towards Asp30 and loses the hydrogen bond with the carbonyl oxygen 
of Thr74 even through it is compensated by a water-mediated interaction (Figure 7C). There is a change 
in the position but not the linkage of one of two waters which mediate the interactions among residues 88, 
30, 31 and 74. The direct hydrogen bond interaction of residue 88 with Thr31 is retained in the mutant 
and wild type enzyme. The Cα of Asp88’ in the other subunit of PRN88D_SQV shifts approximately 0.6 Å, 
thus eliminating the direct hydrogen interaction with Thr74’. The side chain of Asp88’ has two alternative 
conformations rotated 43° and 113°, respectively, as shown in Figure 7D. While one conformation of 
Asp88’ forms a water-mediated hydrogen bond interaction with Thr74’, the other exhibits no interaction 
with Thr74’. As for the DRV complexes, the structural changes due to N88D involve changes in water-
mediated interactions around residues 88, 30-31 and 74, which are likely due in part to the introduction of 
a negative charge in the mutant with Asp88. 
3.5 Discussion  
SQV and DRV are two potent clinical inhibitors that were designed to target the wild type prote-
ase and its drug resistant mutants, respectively. Here, we performed structural and kinetic analysis of 
SQV and DRV with single substitution mutants PRI47V and PRN88D/S. Substitution of the smaller side chain 
in PRI47V is expected decrease its interactions with surrounding residues. However, mutation I47V in 
PRI47V-DRV maintained most of its hydrophobic interactions with surrounding residues (Figure3). These 
changes are largely due to the main chain shift and side chain rotation of I47V. The hydrophobic interac-
tions of mutated Val47 with adjacent residues in the structure of PRI47V-SQV were also preserved (Figure 
4A-D). Meanwhile, the shifts of the 80s’ loop and the flap region observed in the structure of PRI47V-SQV 
enables the formation of new CH…O interactions with SQV as well as between Val47’ and Asp30’ (Fig-
ure 4E).  The alteration of the interaction between PRI47V and SQV does not affect the inhibitory activity 
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of SQV (relative Ki=1), which agrees with the clinical observation showing little effect of the I47V muta-
tion on susceptibility to SQV.  
Our previous study of HIV-1 protease in complexes with its reaction intemediates demonstrated 
that the substitution of Ile47 by the shorter side chain residue Val47 completely eliminates its internal 
hydrophobic contacts with neighboring residues including Val32, Val56, Leu76, Ile54 and Ile50′ from the 
other subunit (Shen, Tie et al. 2012). This alteration caused by the mutation I47V differs from what we 
observed here in complexes with clinical inhibitors DRV and SQV. Comparison of three superimposed 
structures (product complex [PDB ID: 4FLG]/with DRV/with SQV) of PRI47V with PRWT indicates that the 
retained interactions of I47V with adjacent residues in complexes PRI47V-DRV and PRI47V-SQV are main-
ly caused by rotation of its side chain or/and significant main chain shift (Figure 4E). The presence of the 
inhibitor in the complexes may induce these conformational changes. Indeed, DRV formed new interac-
tions with mutated residue Val47 in complex PRI47V-DRV, and SQV gained interactions with Gly48’ and 
Thr80 in PRI47V-SQV. In addition, the side chain flexible conformations of Asp30 may contribute to the 
main chain shift of Val47’ in PRI47V.  
The structure and inhibition of HIV PR with the mutation I47A was described (Saskova, Kozisek 
et al. 2008). Substitution of Ile47 by Ala is rarely seen in HIV-positive patients and emerges with the pro-
longed treatment of lopinavir (LPV). They showed that SQV exhibited 2-fold increase in Ki value for the 
mutant with I47A relative to the wild type enzyme; however, no structure was reported for PRI47V with 
SQV. The structure of PRI47V-LPV shows a loss of interaction with LPV. This result is more extreme than 
the alteration induced by I47V, partly due to the further decrease of the side chain.  
Replacement of Asn at residue 88 with Asp (N88D) or Ser (N88S) is frequently found with pro-
longed exposure to NFV. In PRN88D complex with DRV (Figure5), even though the side chain of mutated 
Asp88 in both subunits rotates towards Gly86’, in one subunit there is no significant change in its interac-
tion with surrounding residues (Figure5A, C), whereas in the other subunit the direct hydrogen bond be-
tween Asp88’ and Thr74’ is replaced by a water-mediated interaction and coordinated shifts of the adja-
cent beta strands (Figure 5B, D, E). In PRN88S complex with DRV, the flexibility and the presence of two 
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alternative conformations of Ser88’ not only enable a direct hydrogen bond with Asp30 side chain, but 
also comparable connections with Thr74 and Thr31 as seen in the wild type complex. However, the link-
age of Ser88’ with Asp30’ eliminates the hydrogen bond interactions between Asp30’ and DRV. In 
PRN88D-SQV (Figure7), the most significant alteration between the wild type and mutant is the loss of hy-
drogen bond between Asp88 and Thr47.  
Consistent with the unliganded structure of PRN88D (Zhang, Wang et al. 2013), both structures of 
PRN88D in complexes with DRV and SQV showed the presence of water-mediated hydrogen bond be-
tween Asp88 and Thr74 in the mutant instead of the direct hydrogen bond seen in the wild type enzyme 
(Figure5&Figure7). However, the water-mediated connection of Asp88 with Asp30 reported in the 
unliganded structure of PRN88D was observed in PRN88D-SQV (Figure7C-D) but not in PRN88D-DRV (Fig-
ure5C-D). This configuration was not observed in the native unliganded structure of PRN88D but found in 
PRWT-SQV (Figure5A-B). Therefore, we cannot conclude that the presence of this connection is due to 
the mutation or affected by the presence/type of the inhibitors
. 
Even though Asp30 does not have a hydro-
gen bond interaction with Asp88, DRV still lost its interaction with Asp30 in PRN88D-DRV. This may be 
related to the single conformation of Asp30 in the mutant. Our kinetic analysis suggested that DRV and 
SQV exhibit the same inhibitory effects on PRN88D (relative Ki =8). It seems that the interaction of Asp30 
with inhibitor does not have significant effect on the Ki for some mutants as we reported previously 
(Zhang, Wang et al. 2013). 
Similar to the unliganded structure of PRN88S (Zhang, Wang et al. 2013), the direct hydrogen 
bonds of residue 88 with Thr74 and Thr31 in the complex of PRN88S-DRV are lost in both subunits. In one 
of the subunits of PRN88S-DRV, their connections are replaced by water-mediated hydrogen bonds (Fig-
ure6A). In another subunit, Ser88’ exhibited two alternative conformations, one conformation formed 
direct hydrogen bonds with Thr31’, thus filling the role of Asn88’ ND2 in wild type protease (Figure6B). 
The other conformation of Ser88’ interacted with Thr74’ and Thr31’ through two waters which fill the 
bigger cavity created by mutation N88S (Figure6C). Therefore, the interactions among residue88, thr74 
and Thr31 do not alter as much as in the unliganded structure of PRN88S. Compared to the wild type 
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unliganded PR, unliganded PRN88S gained a direct hydrogen bond interaction between Ser88 and Asp30. 
In complex PRN88S-DRV, Ser88 gained direct hydrogen bond with Asp30 in one subunit (Figure6A) and 
water mediated hydrogen bond in another one (Figure6C). However, this did not affect the interaction 
between Asp30 and DRV. The inhibitory effect of DRV for PRN88S (relative Ki =0.3) is much higher than 
for PRN88D (relative Ki =8). However, it is hard to address how exactly these structural alterations influ-
ence the inhibitory effects, maybe indirectly through the network of interactions connecting residue 88 
with Asp29-Asp30 in the active site cavity.  
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Table 3.1 Kinetic Parameters for Substrate Hydrolysis and Inhibition of DRV and SQV. 
Protease 
Km  
(µM) 
kcat  
(min-1) 
kcat/Km  
(min-1•µM-1) 
Relative  
kcat/Km 
DRV SQV 
Ki (nM) Relative Ki Ki (nM) Relative Ki 
PRa 30±5 194±23 7.4±1.2 1.0 0.58±0.10 1 0.42±0.07 1 
PRI47V 24±3 225±11 9.0±1.5 1.2 0.42±0.12 0.7 0.42±0.04 1 
PRN88S 37±4 200±27 5.4±1.3 0.7 0.18±0.01 0.3 1.18±0.08 3 
PRN88D 65±13 265±29 4.1±1.2 0.6 4.39±0.46 8 3.14±0.33 8 
a Km and kcat values previously reported in Liu et al.2008 
 
 
Table 3.2 Urea Denaturation 
Protease  UC50(M)  Relative UC50  
PR  0.94  1  
PRI47V  1.33  1.41  
PRN88D  0.51  0.54  
PRN88S  0.50  0.53  
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Table 3.3 Crystallographic Statistics for PR Mutants in Complex with DRV and SQV 
Complex Name I47V-DRV N88S-DRV N88D-DRV I47V- SQV N88D-SQV 
Space group P21212 P21212 P21212 P21212 P21212 
Unit cell dimensions: 
(Å)      
a 58.70 57.94 58.78 58.79 58.77 
b 85.80 85.82 86.36 86.04 85.90 
c 46.15 46.16 46.20 46.30 46.35 
Resolution range (Å) 50-1.13 50-1.49 50-1.72 50-1.18 50-1.40 
Unique reflections 81393 37,269 26,112 70571 40,036 
Rmerge (%) overall (final 
shell) 5.2(31.4) 6.9(44.2) 7.6(43.3) 7.2(28.7) 8.1(47.0) 
I/σ(I) overall (final 
shell) 32.0(2.9) 17.8(2.2) 16.8(10.9) 18.0(3.0) 16.5(2.0) 
Completeness (%) 
overall (final shell) 92.2(53.4) 97.0(84.0) 100.0(99.9) 90.9(66.3) 85.3(64.9) 
Data range for refine-
ment (Å) 10-1.13 10-1.49 10-1.72 10-1.18 10-1.40 
R (%) 12.5 20.4 21.68 14.8 14.9 
Rfree (%) 15.6 24.6 26.85 17.7 19.8 
No. of solvent atoms 
(total occupancies) 272(202.0) 188(137.3) 117(114.5) 183(136.4) 182(140.9) 
RMS deviation from 
ideality      
Bonds (Å) 0.015 0.010  0.014 0.010 
Angle distance (Å) 0.035 0.030  0.033 0.029 
Average B-factors (Å2)      
Main-chain atoms 11.32 16.2 22.6 13.14 12.9 
Side-chain atoms 15.87 22.6 29.3 18.61 19.1 
Inhibitor 9.12 14.6 17.5 12.26 12.4 
Solvent 23.74 25.8 36.4 24.05 23.9 
Inhibitor occupancy 
(%) 0.58/0.42 0.65/0.35 0.65/0.35 0.63/0.37 0.7/0.3 
 
Crystallization and structure refinement was partially done by Xiaxia Yu. 
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 Figure 3.4 Structural changes of PR
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interactions. (A,B) Interactions of Ile47 with surround
actions of Val47’ with surrounding residues in complex PR
PRWT_SQV. The C−H···O interactions of SQV with neighboring residues. The atom shifts in Å are ind
cated by red arrows.  
 
 
 
I47V in complex with SQV.  
WT and green for PRI47V. Carbon atoms are colored yellow for SQV 
WT_SQV. C−H···O and van der Waals intera
ing residues in complex PRWT _SQV. (C
I47V_SQV. (E) PRI47V_SQV superimposed with 
75 
c-
-D) Inter-
i-
 Figure 3.5 Structural changes of PR
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 Figure 3.6 Structural changes of PR
PRN88S_DRV is superimposed with 
surrounding residues are indicated by the dashed lines with distances in Å, whereas hydrogen bond inte
actions in PRWT_DRV refer to Figure 5 A
Ser88’ with the surrounding residues are indicated in B and C, respectively. Carbon atoms are colored 
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Figure 3.7 Structural changes of PR
The hydrogen bond interactions of Asn88/Asn88’ (A
are indicated by the dashed lines with distances in Å. Carbon atoms are colored gray for
for PRN88D. Water molecules are shown as red spheres. The shift is labeled by arrow with distances in Å 
and the rotation of the chain is also labeled in degree.
N88S_DRV.  
PRWT_DRV. Hydrogen bond interactions of Ser88 (A) /88’(B
-B. The hydrogen bond interactions of the two conformations of 
. Water molecules are shown as red spheres for PR
 between two waters in panel C was omitted for clarity. 
N88S relative to wild type is indicated in degrees.
N88D_SQV.  
-B) and Asp88/88’(C-D) with surrounding residues 
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4     OVERALL SUMMARY AND DISCUSSION 
HIV-1 PR is an effective target for treatment of HIV/AIDS. The employment of PIs in antiviral 
therapy has made successful progress in reducing mortality and improving the life quality of AIDS pa-
tient.  However, the long-term efficacy of PIs is challenged by the rapid emergence of drug-resistant mu-
tants of PR. To understand the underlying mechanisms of drug resistance, structures and activities of 
HIV-1 PR and its drug resistant mutants have been extensively studied. Various effects have been ob-
served for these mutations located in different regions of PR. Generally, the mutations in the inhibitor 
binding sites result in the loss of their interactions with inhibitors, thus the PR variants show reduced 
binding affinity for the inhibitors. In contrast, the mutations located in the distal region lead to subtle and 
indirect effects on the structure and activity of PR. Mutation of residues located in the flap region may 
contribute to dimer stability of PR and its interactions with inhibitors.   
In this study, PR mutants PRR8Q, PRD30N, PRI50V, PRI54M, PRV82A, PRI47V, and PRN88D/S bearing sin-
gle substitutions have been investigated by crystallography and kinetics. These mutations, with the excep-
tion of R8Q, are common in drug resistant clinical isolates. The structural and kinetic effects of mutations 
from different regions including active site (PRD30N, PRI50V, PRV82A), flap region (PRI50V, PRI54M) and di-
mer interface (PRR8Q, PRI50V) were analyzed with a novel potent inhibitor GRL-0519. PR variants bearing 
mutations at the active site (PRD30N, PRI50V) had lowest binding affinity with inhibitors. V82A also is lo-
cated in the active site cavity but the alteration in its interactions with inhibitor was moderate due to the 
compensatory effects from the main chain shift. Flap residues may also be components of the active site 
cavity as well as the dimer interface, which is exemplified by Ile50. Due to its critical role in these im-
portant regions, mutation of these residues may influence the flap conformation, inhibitor binding affinity 
and dimer stability. This explains why mutant PRI50V had the most severe effects: 60-fold decrease in its 
inhibition relative to PRWT and 50% loss of dimer stability (Liu, Boross et al. 2005; Zhang, Wang et al. 
2013). Even though PRI54M also has a mutated flap residue, Ile54 does not interact with inhibitor or form 
inter-subunit interactions. The moderate effect of I54M is also due to the compensating shifts in the 80’s 
79 
 
loop residues. The most significant effect of mutations in dimer interface is the alteration in inter-subunit 
interaction and consequently dimer stability (Mahalingam, Louis et al. 1999). Our study demonstrated 
that the inhibitory activity of GRL-0519 on PRR8Q is similar to that of PRWT. However, the maintained 
binding affinity with the inhibitor may be attributed
 
to the large S2 group of GRL-0519 and its water me-
diated hydrogen bond interactions with Gln8.  
The effects of mutations occuring in the flap region (I47V)
 
and a distal region (N88D/S) of PR 
were analyzed with inhibitors SQV and DRV.  Compared to mutation I50V, which lost the extensive in-
teractions formed with inhibitor GRL-0519 in wild type PR, I47V did not cause significant change in its 
interaction with inhibitors SQV and DRV: either loss or gain of one van der Waals interaction with the 
inhibitor. Similarly, there was no significant alteration observed in inter-subunit interaction in mutant 
PRI47V.  This may in part due to the shift of main chain and rotation of side chain of I47V. Therefore, mu-
tation of flap residues may exhibit various effects, depending on how much they are involved in its inter-
action with inhibitor and dimer stability. Residue 88 is located in the distal region of PR. Asn88 is part of 
the triplet Gly-Arg-Asn that is conserved in retroviral PRs (Pearl and Taylor 1987; Louis, Weber et al. 
2000). It has been reported that the effects caused by mutations on distal regions can be transferred to the 
active site and affect the properties of PR indirectly (Liu, Boross et al. 2005). Indeed, structural analysis 
of PRN88S-DRV showed that Ser88’ formed a new hydrogen bond with Asp30’ side chain. The linkage of 
Asp30’ with Ser88’ makes Asp30’ move away from DRV, thus eliminating the hydrogen bond interac-
tions between Asp30’ and DRV. However, the loss of interaction between Asp30 and DRV did not cause 
much change on the inhibitory effects of DRV partially due to the flexibility of Asp30. Our previous 
study has shown that the variation in Asp30/30’ and its interaction with inhibitor did not appear to be a 
major factor in the Ki for the mutants (Zhang, Wang et al. 2013)  
GRL-0519 is an inhibitor designed to fill the S2 binding pocket of PR by incorporating a third 
THF ring in the P2 group relative to DRV. Our investigation of the inhibitory effects of GRL-0519 on 
mutants PRD30N, PRI50V, PRI54M, and PRV82A was compared with previous inhibitory study of DRV on the 
same mutation. It seems that mutations D30N, I50V, I54M, and V82A exhibit similar effects on both in-
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hibitors, although GRL-0519 is less effective than DRV on PRI50V (Tie, Boross et al. 2004; Kovalevsky, 
Tie et al. 2006; Liu, Kovalevsky et al. 2008; Zhang, Wang et al. 2013). However, the large tris-THF 
group at P2 of GRL-0519 provides a good fit with the mutants that have an expanded S2/S2’ pocket, such 
as the extreme multiple mutant PR20 (Agniswamy, Shen et al. 2012). The structural and kinetic effects of 
SQV and DRV on the same drug resistant mutants were also compared and no significant difference of 
was observed.  
In this study, only PR mutants bearing single substitutions have been investigated by crystallog-
raphy and kinetics. Drug resistant clinical isolates generally have more than one mutation, however, and 
previous studies of single and double mutations indicate that the changes in structure of the respective 
single mutants are usually conserved in the double mutants while other properties may not be preserved 
(Mahalingam, Boross et al. 2002; Kozisek, Bray et al. 2007). It is more difficult to apply the information 
from single mutation to multiple mutations or extreme mutations such as clinically derived PR20 (Louis, 
Aniana et al. 2011; Agniswamy, Shen et al. 2012). In addition, the development of mutation is so fast and 
our studies are always behind. It is always better to prevent the selection of the mutations than to combat 
the endless mutations that have already emerged. One way to limit the development of drug resistance is 
to have the inhibitor to fill the whole active site. A good start for this strategy is the development of the 
antiviral inhibitor GRL-0519, which possesses a large tris-THF group at P2. Our most recent study 
showed that the large tris-THF group fits the expended hydrophobic S2 pocket of PR20 much better than 
others (Agniswamy, Shen et al. 2013). In addition, targeting the flexible flap region may be an efficient 
way to limit the emergence of resistance. First, the flap residues are components of both active site and 
dimer interface. Additionally, the flexibility of the flap is very closely related to inhibitor binding affinity. 
Finally, it has been reported that the potent inhibitor DRV has a second binding site on the flap regions 
(Kovalevsky, Liu et al. 2006). In sum, inhibitors that are designed to have more polar interactions with 
the flap residues and have large P2/P2’ could be highly efficient to limit the emergence of viral resistance. 
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 APPENDICES  
Appendix A: List of crystal structures 
Protein Ligand PDB code Resolution (Å) 
PR
R8Q 
GRL-0519 4HEG 1.46 
PR
D30N
 GRL-0519 4HDB 1.49 
PR
I50V
 
GRL-0519 4HDP 1.22 
PR
I54M
 GRL-0519 4HE9 1.06 
PR
V82A
 GRL-0519 4HDF 1.29 
PR
I47V
 DRV  1.13 
PR
I47V
 SQV  1.18 
PR
N88S
 DRV  1.49 
PR
N88D
 DRV  1.72 
PR
N88D
 SQV  1.40 
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2Appendix B.1 Canonical D1 Receptor Signal Transduction Cascade Potassium Current in the 
Pyloric Network by the Cell Specific Dopamine Modulation of the Transient 
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Abstract 
Dopamine (DA) modulates motor behaviors in many systems through well conserved transduc-
tion cascades. To better understand how DA modulates motor activity from the cellular to network levels, 
we study a small circuit. The pyloric network located within the stomatogastric ganglion (STG) of the 
spiny lobster, Panulirus interruptus, consists of 14 identifiable neurons, and an extensive literature exists 
on DA modulation of cellular properties and circuit output. We demonstrate that DA consistently altered 
cellular properties but had variable effects on circuit output. In keeping with previous work, two electrode 
voltage clamp (TEVC) showed that in >90% of the cells examined, DA excited the lateral pyloric (LP) 
and inhibited the pyloric dilator (PD) neurons, in part by decreasing and increasing the peak transient po-
tassium current (IA), respectively. However, DA had variable effects on cycle frequency. We previously 
demonstrated that PD expressed type 2 DA receptors (D2Rs), but not type 1 (D1Rs). Here we show that 
LP expressed somatodendritic D1Rs, but not D2Rs. LP D1Rs were concentrated near synapses and cou-
pled with Gs-AC-cAMP-PKA to modulate IA. We characterized specific antagonists in a heterologous 
expression system: Flupenthixol had a ten-fold higher affinity for D1Rs while metoclopramide specifical-
ly antagonized D2Rs. Flupenthixol and metoclopramide completely blocked DA-induced changes in LP 
and PD IA, respectively. Metoclopramide always blocked DA-induced changes in cycle frequency while 
                                                     
 
2
 Appendix B.1 was published in Zhang et al. 2010 Journal of Neurophysiology 
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flupenthixol had variable effects. Antagonist application to a spontaneously active network had subtle and 
variable effects, and suggested that endogenous levels of DA continuously modulated the spontaneous 
rhythmic activity produced by a network.  
 
Keywords: Panulirus interruptus; neuromodulation; dopamine receptors; signal transduction; 
cAMP; shal channel; pharmacology 
 
Introduction 
The crustacean pyloric network is a powerful model for studying neuromodulation of rhythmic 
behaviors. All the major cells and their circuit connections are known. Many projection and sensory neu-
rons that modulate the network have been defined (Stein, DeLong et al. 2007; Blitz, White et al. 2008; 
Daur, Nadim et al. 2009; DeLong, Beenhakker et al. 2009; Hedrich, Smarandache et al. 2009), and the 
neuromodulatory effects of monoamines and peptides on this circuit have been extensively studied 
(Nusbaum and Beenhakker 2002; Marder and Bucher 2006; Stein 2009). 
 Bath applied DA alters circuit output by differentially modulating pyloric neuron synaptic and 
intrinsic firing properties (Harris-Warrick, Johnson et al. 1998). This is partially mediated by DA modula-
tion of several ion channels (Harris-Warrick, Coniglio et al. 1995; Harris-Warrick, Coniglio et al. 1995; 
Cleland and Selverston 1997; Harris-Warrick, Johnson et al. 1998; Kloppenburg, Levini et al. 1999; 
Kloppenburg, Zipfel et al. 2000; Peck, Nakanishi et al. 2001; Johnson, Kloppenburg et al. 2003; Peck, 
Gaier et al. 2006). In this manuscript, we focus on DA modulation of IA, which helps determine the rate of  
post-inhibitory rebound and spike frequency in pyloric neurons and influences pyloric cycle frequency 
(Tierney and Harris-Warrick 1992).  
DA can change the voltage dependence of IA in a cell specific manner. For example, bath-applied 
DA shifts IA voltage dependence negatively in PD neurons (Kloppenburg, Levini et al. 1999) and posi-
tively in LP neurons (Harris-Warrick, Coniglio et al. 1995). Differences in DA transduction cascades may 
underpin these opposing effects, since shal channels mediate IA and appear to have the same subcellular 
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distribution in both identified cell types (Baro, Coniglio et al. 1996; Baro, Levini et al. 1997; Baro, Ayali 
et al. 2000). 
DA acts on several highly conserved DA receptors (DARs) that belong to the G protein-coupled 
receptor (GPCR) superfamily. All DARs can be classified into two types based on their structure and sig-
naling mechanisms: D1Rs and D2Rs. DARs can signal through many pathways including G protein de-
pendent and independent cascades. In the canonical pathways, D1Rs increase and D2Rs decrease cAMP 
(Neve, Seamans et al. 2004). The two spiny lobster D1Rs, D1αPan and D1βPan, and the singleD2R, 
D2αPan, signal through canonical pathways when overexpressed in HEK cells (Clark and Baro 2006; 
Clark and Baro 2007) and in native stomatogastric membrane preparations (Clark, Khan et al. 2008). In 
addition, lobster DARs can signal through conserved, non-canonical pathways. In STG membrane prepa-
rations D1αPan can couple with Gq as well as Gs, and D2αPan can couple with PLCβ via Gβγi/o in HEK cells.   
We have recently shown that PD neurons express D2Rs, but not D1Rs (Oginsky, Rodgers et al. 
2010). These receptors are concentrated in perisynaptic regions and appear to receive volume DA trans-
missions. In the present study, we test the hypothesis that DA has opposing effects on PD and LP neurons, 
because LP neurons express D1Rs while PD neurons express D2Rs. Further, the effects of endogenous 
DA and individual DARs on spontaneously active pyloric circuits have never been investigated. As a first 
step toward understanding the innate role of DA in generating a rhythmic motor output, here we define 
DAR antagonists and apply them to spontaneously active preparations.   
 
Materials and Methods 
Drugs 
Drugs were all purchased from Sigma (St. Louis, MO) except Rp-cAMP, tetrodotoxin (TTX) and 
H-89 (Tocris Bioscience, Bristol, UK). 
Animals 
California spiny lobsters, Panulirus Interruptus, were purchased from Don Tomlinson Commer-
cial Fishing (San Diego, CA, USA) and kept in aerated and filtered artificial saltwater tanks.  
107 
 
 Dissection and cell identification 
Lobsters were cold-anaesthetized for at least 30 min and the Stomatogastric Nervous System 
(STNS) was dissected as previously described (Bierman and Tobin 2009; Tobin and Bierman 2009). The 
STNS was pinned in a Sylgard-lined dish and continuously superfused with Panulirus (P.) saline (in 
mM): 479 NaCl, 12.8 KCl, 13.7 CaCl2, 39 Na2SO4, 10 MgSO4, 2 Glucose, 4.99 HEPES, 5 TES; pH 7.4. 
Cells were identified using standard intracellular and extracellular recording techniques as previ-
ously described (Harris-Warrick, Coniglio et al. 1995; Harris-Warrick, Coniglio et al. 1995). Neuronal 
activity was monitored with intracellular somatic recordings using 20–40 MΩ glass microelectrodes filled 
with 3 M KCl and Axoclamp 2B or 900A amplifiers (Axon Instruments, Foster City, CA). Extracellular 
recordings of identified motoneurons were obtained using a differential AC amplifier (A-M Systems, Ev-
erett, WA) and stainless steel pin electrodes. Neurons were identified by their distinct waveforms, the tim-
ing of their voltage oscillations, and correlation of spikes on the extracellular and intracellular recordings. 
LP dye fills 
The identified LP neuron was filled with a lysine fixable, dextran coupled Texas Red fluorophore 
that was impermeable to gap junctions ( Molecular Probes), as previously described (Clark, Khan et al. 
2008). A 1% solution of the fluorophore in 0.2 mol/L KCl was pressure injected (8-20 psi, 200ms pulse, 
0.05 Hz) using a 8–15 MΩ glass microelectrode and a PicoSpritzerIII (General Valve / Parker Hannifin). 
The fluorophore was injected until the cell became dark purple (typically 15-25 min, depending on the 
microelectrodes resistance).  
Single cell RT-PCR  
The single cell RT-PCR protocol consisted of three steps: cell isolation, reverse transcription and 
PCR.  
Cell Isolation: After cell identification, the ganglion was incubated at room temperature with 1.2 
mg/ml of collagenase type IA (Sigma) or 2 mg/ml collagenase/Dispase (Sigma) in P. Saline without Ca2+ 
until the cells were loosened from the ganglion (typically 10 min). The identified LP neuron was then 
physically isolated from the STG using mouth suction and a fire polished micropipette that was previous-
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ly baked at 75ºC to ensure that it was RNase free. Using a dissecting microscope, the LP neuron was 
blown into the cap of a microcentrifuge tube. The cap containing the neuron was replaced on the tube and 
immediately stored on dry ice. 
Reverse Transcription: Individual LP neurons were processed for reverse transcription using a 
cells-to-cDNA kit (Ambion) as described in (Oginsky, Rodgers et al. 2010) 
PCR: 4.5 µl aliquots of the reverse transcribed cDNA from a given LP neuron served as templates 
for four PCRs, each containing a different primer set specific for one of the three lobster DARs or α-
tubulin (Oginsky, Rodgers et al. 2010). Advantage Taq polymerase (Clontech) was used according to the 
manufacturer’s instructions. PCR products were run on a 10% polyacrylamide gel (70 V for 1:30 hrs) and 
stained with ethidium bromide for 15min. The bands were visualized under UV light using a Fluochem 
8800 gel imager (Alpha Innotech, San Leandro, CA).  
Immunohistochemistry (IHC) 
The LP neuron was filled with the Texas Red fluorophore, and the STNS was bathed in L-15 cul-
ture media (1 package of L-15 compounds dissolved in 2 L of the P. saline + 100 unit/ml penicillin-
streptomycin + 0.05 mg/ml neomycin) for 4-24 hrs at room temperature to allow the fluorophore to dif-
fuse. The preparation was then fixed and DAR protein distributions were determined using wholemount 
STG preparations in IHC experiments, followed by confocal microscopy. The IHC protocol was as previ-
ously described (Baro, Ayali et al. 2000; Clark, Dever et al. 2004). The primary, affinity purified antibod-
ies against the three lobster DARs (D1αPan, D1βPan and D2αPan) and their respective specificities were pre-
viously described (Clark, Khan et al. 2008; Oginsky, Rodgers et al. 2010). Data were acquired with a 
LSM510 Confocal Laser Scanning Microscope from Carl Zeiss Microimaging (Oberkochen, Germany).  
cAMP assays in a heterologous expression system 
Receptors were transiently expressed in human embryonic kidney (HEK) or COS7 cells as previ-
ously descrinbed (Spitzer, Cymbalyuk et al. 2008). DA induced changes in cAMP were measured using 
an ELISA assay kit (Assay Designs), as previously described (Clark and Baro 2006; Clark and Baro 2007; 
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Spitzer, Cymbalyuk et al. 2008; Spitzer, Edwards et al. 2008). The IC50s of flupenthixol and metoclo-
pramide were determined for each lobster DAR by exposing cells that over-expressed a given receptor to 
DA, or DA plus varying concentrations of a given antagonist. Data were analyzed with Prism (GraphPad) 
and Excel (Microsoft) software. 
 TEVC 
IA was analyzed with TEVC as previously described using an Axoclamp 2B or 900A amplifier 
and Clampex 8.2 software (Baro, Levini et al. 1997). Briefly, the desheathed STN and STG were sur-
rounded by two Vaseline wells. The STG was continuously superfused at room temperature with P. saline 
using a Rainin Dynamax peristaltic pump. Experiments on LP were performed at ambient temperature 
(20-22°C); and those on PD at16-18°C. After cell identification, descending inputs were removed with a 
sucrose block (30% sucrose in distilled water plus 0.3423g/ml, 0.005% Fast Green) applied to the well 
surrounding the single input nerve, stomatogastric nerve (stn), for 1 hr. These are termed, deafferented 
preparations. Glutamatergic synaptic inputs were blocked with picrotoxin (10-6M). All known voltage 
dependent ion channels except IA were blocked with TTX (10-7M), TEA, (2x10-2M), CsCl (5×10-3M) and 
CdCl2 (2×10-4M). 
The LP neuron was impaled with low resistance (5–9 MΩ) microelectrodes filled with 3 M KCl. 
Cells were held at -50mV. Protocols to determine the voltage of activation consisted of a series of 10mV 
steps from -50mV to +60mV, with or without a hyperpolarizing prepulse to -90mV. IA was further isolat-
ed by digitally subtracting recordings obtained without prepulses from those with prepulses. Steady state 
inactivation was recorded at +20mV following a series of hyperpolarizing steps from -110mV to -20mV 
with 10mV increment. In most experiments drugs were continuously superfused into the STG well. How-
ever, in order to save on costs, during Rp-cAMP application, perfusion pumps were stopped after the drug 
was applied to the bath and the bath volume had been replaced at least 5 times. Pumps were started again 
for washout. No change in holding currents was observed during this process. In all experiments the con-
centration of DA was 10µM, except the Rp-cAMP experiments where DA was reduced to 5µM to save on 
costs. In some experiments, the order of application was reversed to show that the drug had the same ef-
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fect regardless of whether or not it was preceded by DA application (e.g., antagonist alone and antagonist 
+DA applications were before the DA application). 
Data were analyzed with Clampfit v.8.2 (Axon Instruments), Prism v.4 and 5 (Graphpad) and Ex-
cel (Microsoft). After digital subtraction, peak currents measured at each voltage step were converted into 
conductance using G=Ipeak/(V- Ek), assuming Ek=-86mV. The calculated conductance and the correspond-
ing voltage were then used to construct conductance-voltage plots. The plots were fit with a first-order 
Boltzmann equation to obtain the maximal conductance (Gmax), the apparent voltage of half activation 
(V1/2 activation ) and voltage of half inactivation (V1/2 inactivation ).  
Statistical analyses: 
Unless otherwise indicated, data are shown as mean ± SEM. Student’s t-tests were performed 
with Excel software. One-way repeated measures ANOVA and curve fitting were performed with 
GraphPad Prism software. Tukey’s post hoc tests were performed where appropriate. Statistical signifi-
cance was determined as p< 0.05. 
 
Results 
Expression of DARs in the LP neurons 
In order to understand how DA effects changes in LP IA, we first defined LP DAR expression. LP 
neurons were electrophysiologically identified, physically isolated and processed for single cell RT-PCR. 
In spiny lobsters, there are two D1Rs, D1αPan and D1βPan, and one D2R, D2αPan (Clark and Baro 2006; Clark 
and Baro 2007). Each LP was tested for the presence of all three lobster DAR, as well as α-tubulin tran-
scripts (Figure 1). As shown in Table 1, while all LP neurons expressed α-tubulin, DAR expression ap-
peared to vary amongst preparations. 
To determine whether or not protein expression similarly varied, we performed IHC experiments 
on STG wholemount preparations, each containing a dye-filled LP neuron. Three custom made, affinity 
purified antibodies, each specific for one of the three lobster DARs, were used in conjunction with confo-
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cal microscopy as previously described (Clark, Khan et al. 2008; Oginsky, Rodgers et al. 2010). Whereas 
DARs may be localized to multiple subcellular compartments, shal channels are exclusively targeted to 
the somatodendritic compartment  (Baro, Ayali et al. 2000). Overlapping 1µm confocal optical sections 
throughout the somatodendritic compartment of a given LP neuron were therefore examined for the pres-
ence of the receptor. The data suggested that receptor expression in the somatodendritic compartment was 
consistent across preparations: D1αPan and D1βPan receptors were always observed in LP neurons, but D2αPan 
receptors were never detected (n=5 for each DAR; Figure 2).  
Similar to our findings for PD D2Rs (Clark, Khan et al. 2008; Oginsky, Rodgers et al. 2010), LP 
D1Rs appeared to be located in endomembrane structures and transported to synaptic varicosities. Both 
D1αPan and D1βPan receptors were observed in LP perinuclear vesicles (Figure 2A, B &F) although vesicu-
lar staining was less obvious for D1αPan receptors. D1Rs were also detected in cytoplasmic transport vesi-
cles in primary and higher order neurites (Figure 2C, D &G). Careful examination of the optical sections 
suggested that receptors were not associated with the plasma membrane in these structures. Receptors 
were most highly concentrated in varicosities along, or at the terminals of fine neurites (Figure 2C, E, H 
&I), which are known to represent synaptic structures (King 1976; King 1976). D1αPan and D1βPan receptors 
often appeared to be in the plasma membrane of synaptic varicosities, as there was no rim of red cyto-
plasm surrounding receptor immunoreactivity (Figure 2E &I). 
 Our previous studies suggested that D1Rs may be expressed in glial cells (Oginsky, Rodgers et al. 
2010). Figure 2 illustrates that D1βPan receptors were highly expressed in the processes of glial and/or oth-
er support cells in the STG. It was not clear from our IHC experiments whether or not D1αPan and D2αPan 
receptors were expressed in glial cells. They are not obviously in the membrane of glial somata, as are 
shal channels (Baro, Ayali et al. 2000). If these DARs are expressed in glia, they have a punctate distribu-
tion and cannot be differentiated from neuronal staining. 
In sum, the LP neuron consistently expressed D1Rs, but not D2Rs in the somatodendritic com-
partment. Receptor expression patterns in other compartments are unknown. LP DAR transcript expres-
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sion patterns appeared to vary, but it is not clear whether this is a biological reality or technical artifact 
(see Discussion).  
 
LP D1Rs couple with IA through a Gs-AC-PKA but not Gq cascade 
We previously showed that D1αPan and D1βPan couple with Gs, and D1αPan can also couple with Gq 
in STNS membrane preparations (Clark, Khan et al. 2008). If DA acts exclusively through LP D1Rs, then 
DA effects on LP may be mediated by Gs and/or Gq transduction cascades. A pharmacological dissection 
of the DA induced transduction cascades modulating LP IA was therefore performed using TEVC.   
Consistent with previous reports (Harris-Warrick, Coniglio et al. 1995), a 10min bath application 
of 10-5 M DA reversibly decreased the peak IA evoked by a depolarizing test pulse following a hyperpolar-
izing prepulse to remove all channel inactivation (Figure 3A). DA induced positive shifts in IA voltage 
dependence (Fig. 3B). Regardless of their initial voltage dependencies, most cells showed similar depolar-
izing shifts in their apparent voltages of half activation (3.4 ± 0.3 mV) and inactivation (3.9 ± 0.3 mV, 
Figure 3C). It is noteworthy that < 10% of the cells examined did not respond to DA, or responded with a 
smaller negative shift. Whereas DA also decreased IA Gmax, this reduction was not reversible, and will 
not be considered further here.  
We first tested whether DA decreased LP IA via a Gs cascade. Adenylyl cyclase (AC) converts 
ATP to cAMP, and Gs can stimulate AC activity. We asked whether or not forskolin, an AC activator, 
could mimic and, at saturating concentrations, occlude the effects of DA on LP IA.  A 10 min 10-5 M DA 
application was followed by a 30 min washout, and forskolin (50 µM) was applied for 10 min followed 
by a 10 min application of DA (10-5 M) plus forskolin (50 µM). LP IA was recorded at the end of each 
drug application and wash. Forskolin shifted the LP IA V1/2 activation by 6.2 ± 0.8 mV and the V1/2 inacti-
vation by 3.8 ± 0.7 mV (n=5, Figure 4). These shifts were significantly different from control (p<0.01), 
but not from the shift induced by DA alone. Thus, forskolin mimicked the effects of DA on LP IA. More-
over, addition of 10-5 M DA to preparations that previously received 50 µM forskolin did not produce fur-
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ther significant shifts in the voltage dependence (P > 0.05). Thus, saturating levels of forskolin can oc-
clude the effects of DA on LP IA. In order to exclude the possibility that forskolin acted directly on shal 
channels, rather than on AC, we examined the effect of 1, 9-dideoxyforskolin (dd-forskolin), a structural 
analogue of forskolin that does not activate AC. We found that dd-forskolin had no significant effects on 
LP IA (n=3). Taken together, these data suggest that DA shifts the voltage dependence of IA at least par-
tially through AC.  
If LP D1Rs couple with Gs to stimulate AC, then an increase in cAMP should mimic the effects 
of DA on LP IA. We tested this hypothesis by bath applying varying concentrations of the membrane 
permeable cAMP analogue, 8-Bromo cAMP. We found that cAMP and DA produced similar dose-
dependent changes in the voltage dependence of LP IA (Figure 5). 
PKA is one of the major effectors of cAMP. In order to test whether PKA was involved in the 
signaling pathway that mediated DA’s effect on LP IA, we examined whether or not PKA inhibitors could 
block DA’s actions. In this experiment the preparation was exposed to 10-5 M DA for 10min, followed by 
a 30 min wash. The PKA inhibitor, H-89 (20µM), was then applied for 10 min at 20µM followed by an 
application of H-89 plus DA. IA was recorded prior to DA application, at the end of each of the drug 
treatment, and after the 30 min wash. The voltages of half activation and inactivation were determined for 
each condition, and the change from baseline was plotted in Figure 6, where baseline is the V1/2 prior to 
drug treatment (DA) or after the wash (H89, H89+DA). The data demonstrate that H-89 inhibited the DA 
effect. A 10 min bath application of 10-5 M DA caused a significant shift in V1/2 activation (Figure 6A, 6.2 
± 0.3 mV, p < 0.001) and inactivation (Figure 6B,  6.2 ± 0.5 mV, p<0.001) that could be washed out. 
However, application of DA plus H89 had no significant effect on IA voltage dependence.  Because H89 
can also inhibit other kinases, such as PKG, we repeated the experiment with a specific and expensive 
PKA inhibitor, Rp-cAMP. To save on the cost of the inhibitor in this experiment, the concentration of DA 
was reduced to 5 µM. Whereas 5 µM DA induced a significant and reversible shift in IA V1/2 activation 
(Figure 6C, p<0.001) and inactivation (Figure 6D, p<0.01), Rp-cAMP blocked this effect. Interestingly, 
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Rp-cAMP itself significantly altered IA V1/2 inactivation (P < 0.05). This might suggest that PKA constitu-
tively modulates the IA V1/2 inactivation. Indeed, all of the PKA blockers shifted IA voltage dependence in 
the opposite direction to DA, but in most cases the changes were not statistically significant. Taken to-
gether, our data suggest that the Gαs-AC-cAMP-PKA signaling pathway mediates DA modulation of IA 
in the LP neuron, consistent with the fact that LP expresses somatodendritic D1Rs, but not D2Rs. 
As mentioned above, D1αPan receptors also couple with Gq in STNS membrane preparations. 
Therefore, we wanted to test whether DA also modulated LP IA via a Gq cascade. Phospholipase Cβ ( 
PLCβ ) is the downstream target of activated Gαq subunits. Using the aforementioned experimental para-
digm, we asked whether ET-18-OCH3, a PLCβ inhibitor, could block DA modulation of LP IA. Addition 
of ET-18-OCH3 did not prevent the DA induced shift in voltage dependence (Figure 7). Therefore, we 
conclude that DA modulates LP IA through a Gs, but not Gq cascade. 
Flupenthixol and metoclopramide are specific antagonists for lobster D1 and D2 receptors, re-
spectively  
To further confirm that DA modulates IA exclusively through D1Rs, we sought to obtain antago-
nists specific for lobster D1Rs and D2Rs. It is well established that monoamine receptor pharmacology is 
not conserved between vertebrate and invertebrate receptors (Blenau and Baumann 2001; Tierney 2001; 
Spitzer, Cymbalyuk et al. 2008; Spitzer, Edwards et al. 2008). We therefore performed a preliminary 
screen using a cadre of drugs (n = 1 per drug) and found candidate antagonists specific for lobster D1Rs 
(flupenthixol) and D2Rs (metoclopramide). The effects of these drugs were characterized in detail using a 
transient, heterologous expression system and assays for DA induced changes in cAMP concentration in 
the presence and absence of flupenthixol and metoclopramide. 
Consistent with previous studies (Clark and Baro 2006; Clark and Baro 2007), DA altered cAMP 
levels in both D1R and D2R expressing HEK cells. Flupenthixol blocked the DA induced cAMP increase 
in D1αPan (flupenthixol IC50=2.2×10-8 M; n=3) and D1βPan (flupenthixol IC50=1.4×10-8 M; n=6) expressing 
HEK cells (figure 8); however, metoclopramide did not antagonize the DA effect on these cells even at 
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concentrations of 100µM (n=4 for each DAR). On the other hand, DA induced changes in cAMP were 
prevented by metoclopramide in D2αPan expressing HEK cells (metoclopramide IC50=1.2×10-7 M; n=3). In 
addition, flupenthixol also antagonized DA effects on D2αPan expressing HEK cells (IC50=2.3×10-7 M; 
n=5). These data indicate that metoclopramide is a specific antagonist for lobster D2R signaling and 
flupenthixol has a ten-fold higher affinity for D1Rs than D2Rs expressed in HEK cells.  
DAR specific antagonists confirm that DA acts on LP D1Rs and PD D2Rs 
Figure 2 suggests that LP neurons exclusively express D1Rs in their somatodendritic compart-
ment, and we previously showed that PD neurons exclusively express D2Rs (Oginsky, Rodgers et al. 
2010). DA modulates IA in opposing directions in PD and LP, largely by shifting the voltage dependence 
of activation positively (LP, Figure 3) or negatively (Kloppenburg, Levini et al. 1999).  If DA acts on LP 
and PD neurons exclusively through D1Rs and D2Rs, then flupenthixol should block DA modulation of 
LP but not PD IA, and metoclopramide should block DA modulation of PD but not LP IA.  Figure 9 illus-
trates that this is indeed the case. Using TEVC, we measured the DA induced change in the V1/2 activation 
in LP and PD in the presence and absence of each antagonist. In these experiments, DA (10-5 M) was bath 
applied for 10 min and washed for 30 min; then, 10µM antagonist was bath applied for 5 min, followed 
by a 10 min application of antagonist plus DA followed by a 30min wash. IA V1/2 was measured at the end 
of each drug application and the wash periods. In some cases, the application order was altered as de-
scribed in Materials and Methods. We found that 10µM flupenthixol reversibly blocked the DA induced 
shift in LP IA by 73.2± 8.4% (p< 0.001) but had no significant effect on DA induced changes in PD IA. On 
the other hand, metoclopramide reversibly blocked the DA induced shift in PD IA by 71.6 ± 11.7% (p< 
0.001) but had no significant effect on DA induced changes in LP IA.  
We next tested the effects of the antagonists on DA induced changes in an ongoing rhythm (Fig-
ures 10&11). It is possible to remove all descending input to the STG with a sucrose block (deafferented 
preparation), and then to test the effect of a given modulator, such as DA, on network output. It was pre-
viously shown that under these conditions, DA altered the resting membrane potential and spike frequen-
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cy of LP (increased) and PD (decreased) (Flamm and Harris-Warrick 1986). We tested whether our an-
tagonists could block these effects. The STNS was dissected and pinned in a dish; descending input was 
blocked by applying sucrose to the desheathed stn. Under these conditions, the normally rhythmically 
bursting LP was silent and rhythmic PD bursting slowed (Figure 10A). A ten minute bath application of 
10-5 M DA significantly depolarized LP on average by 2.0 ± 0.5 mV (p<0.001) (Figure 10 B&C) and in-
creased spike frequency (Figure 10 D&E). Flupenthixol (Figure 10 B&D) but not metoclopramide (Fig-
ure 10 C&E) blocked these effects. DA significantly hyperpolarized PD by 1.9 ± 0.5mV (p<0.01) (Figure 
10 B&C) and decreased spike frequency by 6.4 ± 2.6 Hz (p<0.05) (Figure 10 D&E). Metoclopramide 
(Figure 10 C&E), but not flupenthixol (Figure 10 B&D), prevented these changes. Taken together, the 
pharmacological experiments confirm that DA alters LP IA via D1Rs and PD IA via D2Rs. 
D1 and D2 receptors contribute to DA induced changes in cycle frequency in deafferented prepa-
rations 
In addition to altering the intrinsic properties of individual neurons, DA altered network output in 
deafferented preparations (Figures 10&11). On average a 10 min, 10µM DA bath application reduced 
cycle frequency from 0.78 ± 0.07 Hz to 0.48 ± 0.1 Hz (P< 0.05, n=15). However, as can be seen in Figure 
11, individual preparations varied such that DA could also increase cycle frequency or have little to no 
effect in ~27% of the preparations examined. We asked whether D1Rs and/or D2Rs contributed to chang-
es in cycle frequency. In every case, metoclopramide blocked the DA induced change in cycle frequency.  
On the other hand, the effect of flupenthixol varied from no effect to a complete block of the DA induced 
change in cycle frequency.  
DA appears to have subtle and variable effects on ongoing, spontaneous rhythmic activity 
Pyloric output is driven by a conditional pacemaker kernel, such that rhythmic activity is ulti-
mately dependent upon the presence of neuromodulators, such as DA (Bal, Nagy et al. 1988). The STG 
resides in a blood vessel and is constantly bathed by hemolymph, which may contain nM concentrations 
of DA (Sullivan, Friend et al. 1977). In addition, monoaminergic systems often use volume neurotrans-
mission, which results in the continuous presence of nM concentrations of monoamines in the extracellu-
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lar space (Zoli and Agnati 1996). We have recently shown that DARs in the STG receive volume trans-
missions from dopaminergic projection neurons (Oginsky, Rodgers et al. 2010). Thus, it is reasonable to 
think that STG neurons in a combined preparation (no sucrose block on stn) may be continuously exposed 
to low concentrations of DA with localized, transient increases (up to hundreds of nMs) depending upon 
projection neuron activity. We used the DAR antagonists to begin to decipher the effect of endogenous 
DA on spontaneous network activity.   
In order to determine D1R and D2R function in combined preparations, prior to and after bath 
applying 10 µM flupenthixol and/or 10 µM metoclopramide for 10 min, we  measured pyloric cycle fre-
quency as well as PD and LP membrane potential and firing parameters, including burst duration, spikes 
per burst and spike frequency. Figure 12 shows that antagonist effects were subtle and variable. Antago-
nists applied alone or together could cause an increase, decrease or no change in cycle frequency, and 
they never altered cycle frequency by more than 9% (Figure 12A). Application of both antagonists affect-
ed a larger number of preparations (67%) than application of either metoclopramide (33%) or flupenthixol 
alone (33%). Antagonist application appeared to have little effect on LP and PD membrane potential 
(Figure 12B). Receptor blockade never produced more than a 14% change in spike frequency, and often 
had no effect (Figure 12C). Metoclopramide changed spike frequency more frequently then flupenthixol 
(33% vs. 8%). Spike frequency (Figure 12C) is the product of burst duration (Figure 12D) and spikes per 
burst (Figure 12E). The same symbol (e.g. open blue circle) represents the same cell for panels 12C-E 
within each column. The figure illustrates that changes in spike frequency could be due to changes in 
burst duration and/or spikes per burst. 
 
Discussion 
DA is known to modulate intrinsic neuronal firing properties and synaptic strengths in a number 
of systems by acting on a plethora of targets in a single cell (Nicola, Surmeier et al. 2000; Surmeier, Ding 
et al. 2007). DA induced changes in circuit output is less well studied, often because a circuit cannot be 
isolated and manipulated in its entirety. To better appreciate the basic organizing principles of modulatory 
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systems, we study a small model circuit, the pyloric network, which can be examined from the cellular to 
circuit levels.  
The differential effects of DA on LP and PD neurons are due to differences in receptor expression 
It was previously shown that DA has opposing effects on two identified cell types of the pyloric 
motor circuit, LP and PD (Flamm and Harris-Warrick 1986; Flamm and Harris-Warrick 1986; Harris-
Warrick, Coniglio et al. 1995; Harris-Warrick, Coniglio et al. 1995; Kloppenburg, Levini et al. 1999; 
Kloppenburg, Zipfel et al. 2000; Johnson, Kloppenburg et al. 2003; Peck, Gaier et al. 2006). DA increases 
LP excitability by increasing calcium currents (ICa) and a hyperpolarization activated inward current (Ih), 
while decreasing IA. DA inhibits PD firing by decreasing ICa and increasing IA. DA has no effect on PD Ih. 
Here we demonstrated that the cell specific effects of DA were due to differences in the DA transduction 
cascade in each cell type.  In particular, LP expresses D1Rs and PD expresses D2Rs.  
DAR expression was consistent at the protein level for both cell types. Every LP examined ex-
pressed somatodendritic D1αPan and D1βPan, but not D2αPan receptors. Every PD examined expressed D2Rs, 
but not D1Rs (Oginsky, Rodgers et al. 2010). However, protein levels were not quantified, and receptor 
number for a given cell type may vary across preparations. Surface receptors in both cell types appeared 
to be concentrated in synaptic varicosities within the somatodendritic compartment. It is not clear if LP 
D1Rs are restricted to a subset of synapses, as is the case for PD D2Rs (Oginsky, Rodgers et al. 2010).LP 
DAR transcript and protein expression were not consistent. Based on protein expression, we would expect 
to always observe D1αPan transcripts and never observe D2αPan transcripts in LP cells. Instead, D1αPan and 
D2αPan transcripts were observed in ~60-70% of the cells. This discrepancy is most likely due to receptor 
expression in glial cells, the fact that the number of glial cells isolated with neuronal somata was uncon-
trolled and low LP D1aPan transcript numbers. This idea is consistent with previous work that suggests 
that D1Rs and D2Rs are expressed in mammalian and STG glial cells (Bal, Bachelot et al. 1994; Zanassi, 
Paolillo et al. 1999; Miyazaki, Asanuma et al. 2004; Farber, Pannasch et al. 2005; Oginsky, Rodgers et al. 
2010). Variable D2αPan transcript levels may also indicate variable D2αPan receptor expression in cellular 
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compartments not examined here, such as the axon (Bucher, Thirumalai et al. 2003) or axon terminal 
(Clark, Dever et al. 2004).  
D1 transduction cascades operate in LP neurons 
Here, for the first time, we defined a signal transduction cascade operating in an identified pyloric 
neuron. We showed that DA modulates LP IA by acting on D1αPan and D1βPan receptors that couple with a 
Gs-AC-cAMP-PKA pathway.  Interestingly, there is no consensus cAMP-dependent phosphorylation site 
on shal channels (Baro, Coniglio et al. 1996). Shal channels may contain atypical PKA phosphorylation 
sites (Shi, Wu et al. 2007). Alternatively PKA may not act directly on the pore-forming subunit of the A-
channel (i.e., shal subunits), but rather, target an auxiliary subunit such as KChip (An, Bowlby et al. 
2000), or  a downstream enzyme (e.g. phosphatase) that then modifies shal subunits.  
The fact that DA reduced the peak LP IA through D1R induced changes in cAMP may suggest 
that DA increases the peak IA in PD via a D2-Gi/o coupled cascade that decreases cAMP and PKA activi-
ty. Indeed, this is the case in D2R expressing striatal MSNs (Perez, White et al. 2006).  However, DA 
may not act simply by reciprocally altering cAMP levels in LP and PD, as DARs can act through non-
canonical cascades: D2Rs can signal through PLCβ (Hernandez-Lopez, Tkatch et al. 2000; Clark and 
Baro 2007) and D1Rs can couple with Gq.  
DA elicits consistent changes in IA, but variable changes in circuit output in deafferented prepa-
rations 
We previously showed that bath applied serotonin (5-HT) had a variable effect on circuit output 
in deafferented preparations, and could increase, decrease or produce no change in cycle frequency 
(Spitzer, Cymbalyuk et al. 2008). In contrast, 5-HT activation of pyloric 5-HT1 or5-HT2 receptors pro-
duced a consistent effect (e.g., increase in a synaptic strength), but the amplitude of the effect varied due 
to undetermined phenomena (e.g., synaptic plasticity). Our data suggested that since 5-HT had opposing 
actions on different components of the circuit, the overall effect of 5-HT on circuit output varied accord-
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ing to the relative weights of the individual components. This study provides similar findings for the do-
paminergic system operating on the pyloric network.  
When applied to deafferented preparations, DA produced variable effects on circuit output and 
could increase, decrease or have no effect on cycle frequency. In contrast, DA consistently altered indi-
vidual components of the system. In > 90% of the preparations examined, DA decreased the peak LP IA 
and increased the peak PD IA by shifting A-channel activation voltage dependencies positively or nega-
tively, respectively. However, the amplitude of the change in IA varied, due in part to cell specific differ-
ences in the initial baseline V1/2, and the absolute value of the shift in the V1/2.  Other phenomena might 
also have contributed to the variability, including animal-to-animal variability in ion channel transcript 
number (Schulz, Goaillard et al. 2007) or D1R number.  
Variable effect of DA on combined preparations  
Previous studies on the pyloric network suggested that modulators constantly regulate ion current 
densities (Khorkova and Golowasch 2007). Our discovery that the Panulirus dopaminergic system em-
ploys volume neurotransmission in the STG suggested that nM levels of DA may continuously modulate 
the pyloric network in a combined preparation (descending neuromodulatory input intact). Here, for the 
first time, we examined the function of endogenous DA neurotransmission on circuit output. 
We first defined specific antagonists for lobster D1Rs (flupenthixol) and D2Rs (metoclopramide) 
in order to block DA actions. Interestingly, the flupenthixol IC50 at D2Rs was ~10-7M in HEK cells, but 
10-5M flupenthixol had no significant effect on DA induced changes in PD IA or membrane potential. It 
seems that the actions of flupenthixol at D2Rs are dependent on the cell type and/or function examined, 
which is similar to the functional diversity observed for another D2R ligand, aripiprazole (Shapiro, 
Renock et al. 2003). These types of observations can be explained by the ‘functional selectivity’ hypothe-
sis, which proposes that ligand-receptor interactions are dictated, in part, by the effector system coupled 
with the receptor (Urban, Clarke et al. 2007). Thus, differences in effector proteins across cell types could 
change receptor conformation and thereby ligand interactions. 
121 
 
We next applied the antagonists, individually or together, to a combined preparation generating a 
spontaneous rhythmic pyloric output. The general caveat that the drugs may have unknown effects at oth-
er receptors applies. Whereas the data suggested that endogenous levels of DA modulated spontaneous 
activity in the intact preparation through D1Rs and D2Rs; in all cases examined, the effects of the antago-
nists were small and variable. The subtle responses may be due to low endogenous concentrations of DA. 
In addition, DA is one of a number of modulators acting on the STG (Marder and Bucher 2006). It may 
be that cell and network outputs are stabilized by the actions of all modulators, so that changes in any giv-
en modulator alone will have small effects. This is consistent with the fact that the natural variability ob-
served for a given parameter was significantly greater than the change induced by removal of D1Rs 
and/or D2Rs (e.g., a >2-fold variation in cycle frequency was observed in the population, but DAR antag-
onists induced a < 10% change in cycle frequency in any given preparation). It is important to note that 
low extracellular levels of DA may have a greater effect on cellular attributes not examined here. For ex-
ample, endogenous levels of DA in the striatum appear to be involved in continuously maintaining chro-
matin structure (Bertran-Gonzalez, Hakansson et al. 2009). 
The variable responses to antagonists may stem from a variety of phenomena. Differences in 
states, synaptic inputs and/or levels of ion channel/receptor expression in LP or PD neurons could vary 
across preparations, and this could cause preparation-to-preparation variability in cell and circuit respons-
es to the antagonists (Goaillard, Taylor et al. 2009). However, this need not be the case, as the drug-
induced changes in LP and PD firing parameters suggested that several antagonist effects were indirect. 
For example, both flupenthixol and/or metoclopramide application could alter spike frequency in both LP 
and PD, though each cell type is known to express a single type of DAR that is sensitive to only one of 
the two drugs. 
 
Conclusion 
Our present work illuminates the molecular mechanisms underlying DA neuromodulation, which 
is a prerequisite for understanding normal network function. Moreover, the use of DAR antagonists to 
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decipher the innate contribution of DA to network output suggests that modulator function varies across 
individuals and most likely makes only a small contribution to network output, at least under the condi-
tions studied here. It may be that DA plays a more prominent role in regulating circuit characteristics over 
the long-term. The discrepant localization of DARs and their target channels raises the issue of spatial 
modulation, which needs to be addressed in the future.  
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Table 1. List of drugs tested to screen DAR antagonists 
Drugs 
(-)-Butaclamol 
Clozapine 
Sulpiride 
Haloperidol 
Spiperone HCl 
Methiothepin mesylate 
Metoclopramide 
Cyproheptadine HCl 
N-R(+)-SCH 23390 
Chlorpromazine 
(+)-Butaclamol 
Domperidone 
Eticlopride 
Fluphenazine 2HCI 
Flupenthixo 
 
 
130 
 
 
Figure 1: D1αPan, D1βPan but not D2αPan receptors distributed in the LP somatodendritic compartment. 
Wholemount STG preparations, each containing a single Texas red filled LP, were stained with anti-
D1βPan (A-E), anti-D1αPan (F-I) or anti-D2αPan (J-L). n > 5 wholemount preparations for each receptor type. 
Yellow staining indicates DAR expression in the LP. Green staining represents DAR expression in uni-
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dentified cells. Merged confocal projections were made from serial 1 µm confocal optical slices. A.  
Merged, 3 µm confocal projection from a wholemount preparation showing D1βPan receptor expression in 
LP perinuclear vesicles (yellow puncta) and unidentified cells (green projections and punta). B. A 3 µm 
merged confocal projection from the center of the LP soma showing D1βPan receptor expression in the 
perinuclear vesicles. C. A 4 µm merged confocal projection from deep within the synaptic neuropil show-
ing D1βPan receptor in the cytoplasmic transport vesicles in higher order neurites (arrows). Arrowheads 
point to putative synaptic varicosities containing D1βPan receptors. D. High magnification 1 µm optical 
slice showing cytoplasmic transport vesicles in higher order neurite. E. High magnification 3-4 µm pro-
jection showing a cluster of LP synaptic terminals, some of which contain D1βPan receptors.  The arrow 
points to the terminal lacking red ring structure. F-H. 4 µm merged confocal projection showing D1αPan 
receptor expression in the LP soma, primary neurite, higher order neurites and synaptic terminals (pointed 
by arrows). I. High magnification 1µm optical slice showing the presence of D1αPan receptors on LP syn-
aptic terminals. Arrow points to the terminal lacking red ring structure. J. A 37 µm merged confocal pro-
jection showing the absence of detectable D2αPan in the LP soma and primary neurites. Green staining rep-
resents the D2αPan from unidentified neurons. K. A 4 µm confocal projection from deep within the synap-
tic neuropil showing the absence of D2αPan in the higher order neurites and terminals. L. High magnifica-
tion 1 µm optical slcice showing a cluster of LP synaptic terminals lacking D2αPan receptors. 
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Figure 2: DA induced positive shifts in the voltage dependence of LP IA.  A. TEVC recordings under con-
trol conditions, with 10min bath application of 10-5 M DA and after 30 min washout of DA. Current trac-
es were obtained in response to a series of depolarizing testpulses (from -50mV to +60 mV in 10mV in-
crements) following a hyperpolarizing prepulse to -90mV. All voltage dependent ion channels except IA 
were pharmacologically blocked. Scale bars represent 100ms and 50nA. B. Conductance-voltage plots for 
activation (circles) and inactivation (squares) fit with a 1st-order Boltzmann equation. Plots were obtained 
in the presence (open symbols) and absence (solid symbols) of DA. n>5 for each data point. C-D. Prepa-
ration-to-preparation variability. Each dot represents the IA V1/2 activation (C) and inactivation (D) for a 
single individual in the presence (y axis) versus absence (x axis) of 10µM DA. The line indicates unity 
and points above and below the line indicate that DA increased or decreased the V1/2, respectively. 
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Figure3: An AC activator mimicked and, at saturating concentrations, largely occluded the effects of DA 
on LP IA. IA was recorded before (baseline) and 10 min after application of 10µM DA, 50µM forskolin, 
DA+forskolin, or dideoxy-forskolin (dd-forskolin). Every preparation received only one of the four drug 
treatments. Each drug except dd-forskolin induced a significant and reversible shift in LP IA V1/2 activa-
tion (A) and inactivation (B). Asterisks indicate significant difference from DA treatment using a one way 
ANOVA with a Tukey posthoc test.  
 
Figure 4: The cAMP analog, 8-Br-cAMP, mimicked DA effects on LP IA. IA was measured before (base-
line) and 10 min after application of DA (A) or 8-Br-cAMP (B). Every preparation received only one 
dose of either drug. The change from baseline is plotted for IA V1/2 activation (squares) inactivation (cir-
cles).  
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Figure 5: The PKA blockers, H-89 and Rp-cAMP, prevented DA induced changes in LP IA. IA was meas-
ured before and after a 10min 10µM DA application and after a 30min wash from DA. Measurements 
from the first recording served as baseline for the DA and wash comparisons. After the wash, a 10min 
application of 20µM H89 was followed by a 10minute application of DA+H89. IA was measured at the 
end of each 10 min application. Measurements from the previous wash served as baseline for H89 com-
parisons. The change from baseline was plotted for V1/2 activation (A) and V1/2 inactivation (B). C-D. 
The same experiment was performed except that the concentration of DA was 5µM and 1mM Rp-cAMP 
was substituted for H89. Asterisks indicate significant difference from baseline as determined with paired  
t-tests. 
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Figure 6: The PLCβ inhibitor, ET-18-OCH3, did not block DA’s effects on LP IA. IA was measured be-
fore and during a 10min, 10µM DA application, after a 30min washout, and after sequential 10minute 
applications of 10µM ET-18-OCH3 and ET-18-OCH3+DA. Measurements from the first recording 
served as baseline for DA and washout comparisons. The washout measurements served as baseline for 
all subsequent drug applications. Asterisks indicate significant differences from baseline (DA) or washout 
(DA+ ET-18-OCH3) as determined with a One way ANOVA followed by a Tukey posthoc test.  
 
 Figure 7: Dopamine receptor antagonists. cAMP was measured (pmol/mg protei
D1αPan,D1βPan, and D2αPan receptors in the presence of 10
flupenthixol or metoclopramide. Data for a given experiment were normalized to the change in cAMP 
evoked by DA in the absence of antagon
percent of the change induced by DA alone (indicated as 100%, 
separate experiments and a given point was the average of duplicates within each experimen
 
 
 
 
 
 
n) in cells expressing 
-5
 M DA and increasing concentration of 
ist. The change induced by DA + antagonist are expressed as a 
- - -). Plots represent the average of
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3Appendix B.2 Serotonin Transduction Cascades Mediate Variable Changes in Pyloric Net-
work Cycle Frequency in Response to the Same Modulatory Challenge 
Nadja Spitzer1*, Gennady Cymbalyuk2, Hongmei Zhang1, Donald H. Edwards1, Deborah J. Baro1 
 
Abstract 
A fundamental question in systems biology addresses the issue of how flexibility is built into 
modulatory networks such that they can produce context dependent responses. Here we examine flexibil-
ity in the serotonin (5-HT) response system that modulates the cycle frequency (cf) of a rhythmic motor 
output. We found that depending upon the preparation, the same 5min bath application of 5-HT to the 
pyloric network of the California spiny lobster, Panulirus interruptus, could produce a significant in-
crease, decrease or no change in steady state cf relative to baseline.  Interestingly, the mean circuit output 
was not significantly different among preparations prior to 5-HT application. We developed pharmaco-
logical tools to examine the preparation-to-preparation variability in the components of the 5-HT response 
system. We found that the 5-HT response system consisted of at least three separable components: A 5-
HT2βPan-like component mediated a rapid decrease followed by a sustained increase in cf.  A 5-HT1αPan-
like component produced a small and usually gradual increase in cf.  At least one other component associ-
ated with an unknown receptor mediated a sustained decrease in cf. The magnitude of the change in cf 
produced by each component was highly variable, so that when summed they could produce either a net 
increase, decrease or no change in cf depending upon the preparation.  Overall, our research demonstrates 
that the balance of opposing components of the 5-HT response system determines the direction and mag-
nitude of 5-HT induced change in steady state cf relative to baseline. 
 
                                                     
 
3
 Appendix B.2 was published in Zhang et al. 2008 Journal of Neurophysiology 
 
138 
 
Keywords: serotonin receptor; Stomatogastric; crustacean; plasticity; pharmacology; 
neuromodulation 
 
 
Introduction 
 Rhythmic motor patterns such as locomotion, respiration and chewing are essential to the 
function and survival of an animal.  The central pattern generators (CPGs) responsible for producing such 
rhythmic outputs depend on neuromodulation to maintain their cycle and to appropriately modify their 
output parameters (Thoby-Brisson and Simmers 1998; Marder and Bucher 2001; Fenelon, Le Feuvre et 
al. 2004; Hooper and DiCaprio 2004; Selverston 2005; Marder and Bucher 2007).  It has been shown that 
the responses of neural circuits to the same neuromodulator can change depending on the experience or 
physiological state of the animal (Edwards, Heitler et al. 1999; Marder and Bucher 2001). This can occur 
through changes in synaptic strength, intrinsic neuronal properties, cell morphology and gene expression; 
however, the signaling cascades leading to these changes, and the way in which these mechanisms are 
restructured in a behaviorally relevant manner, are not clear (Kandel 2001; Mitchell and Johnson 2003; 
Carlisle and Kennedy 2005; Davis 2006; Yuan and Chen 2006).  The first step in understanding this plas-
ticity in neuromodulatory response systems is to delineate the components of the system and how they 
vary across preparations in response to the same modulatory input. 
The stomatogastric nervous system (STNS) of crustaceans is a well-established model for inves-
tigating the circuitry and neuromodulation of motor pattern generation.  The STNS contains several small, 
defined circuits, each of which drives a different set of muscles to produce a patterned activity associated 
with a specific function.  One such circuit, the pyloric network, located in the stomatogastric ganglion 
(STG), consists of 14 identified neurons that fall into 6 cell types (Selverston, Russell et al. 1976).  The 
intrinsic firing properties and synaptic connectivities of each cell type have been described in detail 
(Harris-Warrick, Marder et al. 1992; Nusbaum and Beenhakker 2002; Selverston 2005).  In addition, the 
effects of neuromodulators, including serotonin (5-HT), have been investigated at the cellular and circuit 
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levels (Beltz, Eisen et al. 1984; Flamm and Harris-Warrick 1986; Flamm and Harris-Warrick 1986; Katz 
and Harris-Warrick 1990; Harris-Warrick, Nagy et al. 1992; Harris-Warrick, Johnson et al. 1998; Ayali 
and Harris-Warrick 1999; Peck, Nakanishi et al. 2001).   
In the California spiny lobster, Panulirus interruptus, 5-HT is not found in STG nerve terminals.  
Instead, it acts solely as a neurohormone to directly alter the firing properties of several pyloric neurons.  
A ten minute 5-HT application intended to mimic neurohormonal transmission elicited bursting from the 
anterior burster (AB) neuron (Harris-Warrick and Flamm 1987; Ayali and Harris-Warrick 1999), inhibit-
ed firing in the lateral pyloric (LP) and ventricular dilator (VD) neurons, excited the inferior cardiac (IC) 
neuron, and had no effect on the pyloric dilator (PD) or pyloric constrictor (PY) neurons (Flamm and 
Harris-Warrick 1986; Ayali and Harris-Warrick 1999).  In addition, 5-HT modulated the strength of 
electrotonic coupling and chemical synapses within the circuit (Johnson and Harris-Warrick 1990; 
Johnson, Peck et al. 1994; Johnson, Peck et al. 1995).  The effects of 5-HT are mediated, at least in part, 
by cell-specific targeting of ionic currents (Kiehn and Harris-Warrick 1992; Zhang and Harris-Warrick 
1995; Harris-Warrick, Johnson et al. 1998; Peck, Nakanishi et al. 2001).  
Arthropods are known to express multiple 5-HT receptor (5-HTR) types (Tierney 2001).  A total 
of 5 arthropod 5-HTR subtypes have been cloned and characterized to date: two 5-HT1 receptors; two 5-
HT2 receptors, and a 5-HT7 receptor (Witz, Amlaiky et al. 1990; Saudou, Boschert et al. 1992; Colas, 
Launay et al. 1995; Clark, Dever et al. 2004).  In addition, analysis of arthropod genomic databases sug-
gest the presence of three putative monoamine receptors that currently remain uncharacterized (discussed 
in Clark, Dever et al. 2004; Clark and Baro 2007). The arthropod genome therefore most likely contains 
from five to eight genes encoding 5-HTRs.  
Here we investigate the components of the 5-HT response system that control pyloric cycle fre-
quency (cf) in the California spiny lobster. Application of 5-HT to individual preparations that appeared 
to be in the same state uncovered latent preparation-to-preparation variability in the network. We found 
that pyloric networks producing motor outputs with similar cfs could respond to 5-HT application with 
either an increase, decrease or no change in pyloric cf, depending upon the preparation. We then identi-
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fied pharmacological tools to differentiate the actions of the two previously cloned and characterized 
crustacean receptors, 5-HT2β and 5-HT1α (Clark et al., 2004; Sosa et al., 2004; Spitzer et al., 2008). Final-
ly, we used these tools to define the components of the 5-HT response system and determine how each 
component contributes to the variability in a network’s response to the same modulatory input.  
.  
Materials and Methods 
Animals 
 Spiny lobsters, Panulirus interruptus, were obtained from Don Tomlinson Commercial 
Fishing (San Diego, CA) and maintained at 16oC in continually filtered and aerated artificial seawater.  
Animals were fed once per week with raw shrimp.  The number of shrimp added to the tank was 2-5 more 
than the number of lobsters in the tank, but no attempt was made to ensure that each lobster received 
food. 
Chemicals and Cell lines 
 HEK293 cells, EMEM, horse serum, trypsin and penicillin/streptomycin were obtained 
from American Type Culture Collection (Mannassas, VA).  DMEM was from Mediatech Inc. (Herndon, 
VA).  Dialyzed fetal bovine serum (FBS), TRex cell line (293-TR), pDNA4/TO plasmid, blasticidin and 
zeocin were from Invitrogen (Carlsbad, CA).  Cinanserin was obtained from Tocris (Ballwin, MO).  All 
other chemicals were from Sigma (St. Louis, MO).  For pharmacology experiments, fresh amine and ago-
nist stock solutions (10-1M) were made in media or 50% ethanol, respectively.  Two exceptions were 
tyramine which was made fresh as a 10-2M stock in media and methysergide which was made as a 10-2M 
stock in DMSO and stored at –20oC. Antagonist drugs were made as 10-2M stock solutions in DMSO and 
stored at –20oC.  To test the effect of DMSO on deafferented preparations, we applied 5-HT for 5 min, 
washed out for 1 hr, applied DMSO for 5min and then DMSO+5-HT for 5min. In the absence of 5-HT, 
application of DMSO for 5 min did not produce a detectable change in cf (p>0.23, n=4, also see Fig. 5). 
Neither did DMSO application alter the steady-state 5-HT response. The 5-HT induced change from base-
line (average of last ten cycles during 5min 5-HT application/average for last 10 cycles just before 5-HT 
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application) was not significantly different in the absence (0.93+0.21) vs. presence of DMSO (0.96+0.24, 
p>0.71, n=3).  
Electrophysiological recordings 
 Spiny lobsters were anesthetized for at least 30min on ice after which the STNS was dis-
sected out and pinned in a Sylgard lined Petri dish using standard techniques (Selverston, Russell et al. 
1976).  The stomatogastric ganglion (STG) and a portion of the stomatogastric nerve (stn) were 
desheathed.  The preparation was bathed in Panulirus saline consisting of (in mM) 479 NaCl, 12.8 KCl, 
13.7 CaCl2, 39 Na2SO4, 10 MgSO4, 2 glucose, 4.99 HEPES, 5 TES at pH 7.4.  All experiments were car-
ried out at room temperature.  Petroleum jelly (Vaseline) wells (1-2cm across) were built around the STG 
and around the desheathed portion of the stn.  Both wells were always tested for leaks with saline contain-
ing 0.005% Fast Green.  The well around the STG was constantly perfused at 2ml/min with saline or drug 
solutions and tests with Fast Green prior to every experiment showed that the solution in the STG well 
was completely exchanged in less than 20s.  
Extracellular recordings from the pyloric dilator nerve (pdn), medial ventricular nerve (mvn) and 
lateral ventricular nerve (lvn) were obtained with stainless steel pin electrodes and a differential AC am-
plifier (A-M Systems, Everett, WA) as previously described (Baro, Levini et al. 1997).   In some prepara-
tions, the activity of the PD neuron was monitored with intracellular somatic recordings using glass mi-
croelectrodes filled with 3M KCl (20-30 MΩ) and an Axoclamp 2B amplifier (Axon Instruments, Foster 
City, CA).  In these cases, the PD was identified by the characteristic shape of its oscillation, by its timing 
in the motor pattern and by a 1:1 correlation between action potentials recorded intracellularly from the 
soma and extracellularly from the pdn.  
After recording baseline activity for 10min, the saline solution in the stn well was exchanged for 
1M sucrose to block descending neuromodulatory input.  After 1hr in the sucrose block, experiments to 
determine the effects of 5-HT receptor agonists and antagonists were performed.  For experiments to de-
termine the effect of the agonist 1-(m-chlorophenyl)-piperazine (mCPP), 10µM 5-HT was applied for 
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5min and washed out for 1hr, followed by a 5min application of 100µM mCPP which was then washed 
out for 1hr.  The antagonist (+)butaclamol (10µM) was then applied for 5min followed immediately by a 
5min application of (+)butaclamol + mCPP.  After another 1hr wash (+)butaclamol was applied for 5min 
followed by 5min of (+)butaclamol + 5-HT.  The preparation was washed for a final 1h and the experi-
ment was terminated.  In some experiments, the order of 5-HT and mCPP application were reversed with 
no detectable difference in effect.  For experiments involving only 5-HT and antagonists (cinanserin or 
(+)butaclamol), one hour after applying a sucrose block, 5-HT was applied for 5min and washed out for 
1hr.  The antagonist was then applied alone for 5min and then in combination with 5-HT for 5min fol-
lowed by a 1hr wash.  After application of one antagonist the experiment was terminated and the prepara-
tion was not used further.  In several experiments we applied antagonist plus 5-HT before 5-HT only, 
however, we found that the antagonist effects did not appear to wash out between applications (i.e., both 
5-HT applications produced a similar effect, which was not the case when the order was reversed.).   
Electrophysiological data acquisition and analysis.  
Data were acquired using a Digidata 1322A data acquisition board (Axon Instruments) and 
Axoscope software.  The data were subsequently analyzed with DataView 4.7a (W.J. Heitler, University 
of St. Andrews, Scotland),  Microsoft Excel and Matlab (MathWorks, Natick, MA).  We measured ago-
nist- and antagonist-induced changes in 2 parameters: pyloric cf and spikes per burst of the VD (ventricu-
lar dilator) neuron.  One cycle was defined as the period extending from the first spike in one PD burst to 
the first spike in the following PD burst.  The cf and number of VD spikes per cycle were first plotted as a 
function of time for each experiment.   
Baseline cf was determined from 10 cycles just before application of a drug when the preparation 
was in a periodic state (i.e. 1hr after the sucrose block was applied or at the end of a 1hr wash period). 
The time course of the 5-HT effect could be divided into three quantifiable phases. As a measure of phase 
1 we obtained the nadir, i.e., lowest cf (averaged for a 10sec window) during the first 50 sec in 5-HT. As a 
measure of phase 2 we obtained the peak maximal cf (averaged for a ten sec window) from 50 to 120sec 
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of 5-HT application. As a measure of phase 3 (i.e. steady-state) we obtained the average cf during the last 
minute of 5-HT application. 
Difference traces representing the 5-HT2βPan-like component of the 5-HT response system were 
produced by subtracting cf plots obtained in the presence of 5-HT and antagonist from those obtained in 
the presence of 5-HT and absence of antagonist. A script was written in Matlab to perform this function. 
The data accessed by the script are termed the row data. The result of the analysis is to fit a line to the row 
data, and this line is termed a trace average. Examples of these analyses are shown in Fig. 6. Each set of 
left and right panels in Fig. 6 represents the analyses for a single preparation. The left panels show two 
trace averages plotted on top of their respective row data. Consider a single left panel. The set of blue data 
points represents the instantaneous cf recorded during a 5min 5-HT application. These are the data that 
were processed by the script (i.e., the row data) in order to generate the trace average, which is shown as a 
blue line. The row data and trace average for the instantaneous cf obtained in the presence of 5-HT plus 
antagonist are similarly plotted in green. The trace average for a given set of row data was calculated us-
ing uniform 0.15 min time intervals and a sliding window that moved in increments of 0.05min.  Now 
consider the corresponding right panel. The gold trace was obtained by subtracting the green trace aver-
age from the blue trace average. Therefore, the gold difference trace represents the change in cf mediated 
by activation of 5-HT2βPan-like receptors in that preparation. Baselines for the trace averages were arbitrar-
ily set to zero prior to subtraction. Thus, at any given point in time, the 5-HT2βPan component is calculated 
to be: (f5-HT-f5-HT baseline) – (f5-HT+antagonist – fantagonist baseline), where 5-HT baseline and antagonist baseline are 
defined in Fig. 4 and f = frequency.  
Fig. 7A plots the mean of the 24 trace averages obtained in the presence of 5-HT. Figure 7B 
shows the mean of the 24 trace averages obtained in 5-HT + antagonist. The mean of the 24 difference 
traces is shown in Fig. 7C  
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Statistical analyses were performed with Excel (Microsoft) and Prism (GraphPad) as indicated. 
The 3-D plots were generated with Sigmaplot (Systat). Unless otherwise indicated, means are followed by 
the standard error of the mean, and significance was judged to be p<0.05. 
 
Assay of IP release in cells expressing 5-HT2βPan 
5-HT2βPan was transiently expressed in HEK293 cell culture, and inositol phosphate (IP) release in 
cells expressing 5-HT2βPan was assayed using previously described protocols (Clark et. al., 2004; Spitzer 
et al., 2008).  Briefly, transiently transfected cells expressing 5-HT2βPan were split into wells on a 24-well 
plate with 1µCi/ml of 3H-myoinositol (Amersham, Piscataway, NJ) and allowed to grow to 95-100% 
confluency over 48 hours.  The cells were washed with fresh EMEM and then exposed to 10mM LiCl in 
EMEM for 20min at 37oC.  As applicable, antagonists were added to individual wells and allowed to in-
cubate for an additional 10min.  5-HT or agonist drugs were added to test wells and cells were returned to 
37oC for 60min.  The medium was removed and replaced with ice cold 20mM formic acid.  Plates were 
then placed on ice for 30min.  The cell lysate was collected and applied to AG1-X8 columns (BioRad, 
Hercules, CA) equilibrated with 20mM formic acid.  The columns were washed with 50mM ammonium 
hydroxide followed by elution of inositol phosphates (IP) with 10ml of 1M ammonium formate/0.1M 
formic acid.  The IP fraction was scintillation counted.  Membranes attached to the wells were dissolved 
in 1M NaOH and scintillation counted as total phosphatidyl inositols (PI).  Activation results are ex-
pressed as the fraction of radioactivity incorporated in IP over that in IP+PI and normalized to activity 
observed in negative control (no drug) wells for every experiment.  At least three independent experi-
ments were performed for each drug. 
cAMP concentration determinations in cells expressing 5-HT1αPan   
 5-HT1αPan was stably expressed in an inducible expression system and cyclic AMP levels 
were determined using a Direct cAMP kit (Assay Designs, Ann Arbor, MI) as previously described 
(Spitzer et al., 2008).  Briefly, stably transfected cells were plated in 24-well plates and allowed to grow 
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to 100% confluency.  The medium was replaced with 1ml of complete medium containing 1µg/ml tetra-
cycline to induce expression of receptor protein.  After 18-20hr the medium was replaced with 1ml of 
fresh DMEM containing 2.5mM 3-isobutyl-1-methylxanthine to block phosphodiesterase activity and 
plates were incubated for 10min.  Antagonists were added to individual wells (if applicable) and allowed 
to incubate for an additional 10min.  5-HT or agonists and forskolin (250nM), a nonspecific activator of 
adenylyl cyclase, were then added to individual wells and left at 37oC for 30min.  The medium was re-
moved and replaced with 0.5ml of 0.1M HCl containing 0.8% Triton X-100.  Plates were shaken 30min at 
room temperature, the lysate collected, centrifuged 5min at 600g and the supernatant assayed for cAMP 
concentration using the Direct cAMP kit and protein concentration using a BCA Protein Assay Kit 
(Pierce, Rockford, Il).  Data are presented as picomoles of cAMP per milligram of protein.  At least three 
independent experiments were performed for each drug. 
Heterologous expression system data analysis  
Data for all pharmacology assays involving the heterologous expression systems were plotted and 
analyzed in GraphPad Prism v.4.  Dose-response curves were fitted with a standard slope top-bottom or 
bottom-top dose-response curve to calculate EC/IC50 and efficacy values. Unless otherwise indicated, 
means are followed by the standard error of the mean. 
 
Results 
5-HT application produced a stereotypic inhibition of VD but a variable change in cf 
We began this study by establishing the variable actions of 5-HT on pyloric cf. The pyloric circuit 
in the STNS of Panulirus consists of 6 cell types interconnected by electrical and inhibitory chemical 
synapses (Fig. 1A).  The circuit is driven by a pacemaker ensemble consisting of a single AB pacemaker 
interneuron that is electrically coupled to two PD motoneurons.  In addition, two follower motoneurons, 
VD (1 per ganglion) and LP (1 per ganglion), feed back onto the pacemaker kernel and play an important 
role in governing cf (Weaver and Hooper 2003).  Endogenous oscillations in the AB neuron and conse-
quent activity of coupled and follower neurons give rise to an identifiable motor output that can be meas-
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ured extracellularly on efferent motor nerves. We monitored the AB-PD pacemaker kernel with extracel-
lular recordings from the pdn, a motor nerve that exclusively contains the two axons of the 2 PD neurons. 
VD was monitored with extracellular electrodes on the mvn, a motor nerve that exclusively contains the 
axons of the single VD and IC neurons (Fig. 1B, top). Although the LP is also important in governing cf 
(Miller and Selverston 1982; Beltz, Eisen et al. 1984; Ayali and Harris-Warrick 1999; Weaver and 
Hooper 2003), and is directly inhibited by 5-HT (Flamm and Harris-Warrick 1986b), LP was silent under 
our experimental conditions (see below) and not monitored in these studies. 
Descending modulatory input can be blocked by placing a pool of sucrose on the single modula-
tory input nerve (stomatogastric nerve, stn).  After an hour of sucrose block the pyloric cycle stabilizes in 
a basal cycling state; the pacemaker kernel cycles weakly (Fig. 1B, middle), VD firing is reduced (Fig. 
1B, middle) and LP, PY (8 per ganglion) and IC neurons are silenced (not shown).  Once endogenous 
neuromodulation is removed with the sucrose block (deafferented preparation), the effect of individual 
modulators such as 5-HT can be assessed. We used a 5min application of 5-HT to mimic neurohormonal 
transmission. This relatively short application was chosen to minimize the induction of long term effects, 
but still produce a steady state response. The concentration of 5-HT used in these studies (10µM) is likely 
to be several orders of magnitude higher than the normal hormonal concentration. Thus, the actions of 
neurohormonal 5-HT in vivo may not be exactly reproduced in this paper.  Nevertheless, the use of this 
high concentration is appropriate here, as the goal of this study was to investigate the latent variability in 
a network’s response to the same modulatory input. 
Consistent with previous reports, we found that 5-HT altered the activity of both the pacemaker 
kernel and the VD neuron.  Fig. 1B shows serial recordings of pdn and mvn activity from two representa-
tive preparations before sucrose block (top), 1hr after sucrose block (middle) and at the peak of the 5-HT 
effect (bottom).  As expected, there was a sustained reduction in VD firing frequency throughout the 5min 
5-HT application.  The VD was inhibited by 100% from baseline in 27 of 28 experiments, and the remain-
ing preparation showed a 95% decrease in firing frequency. On the other hand, a 5min application of 
10µM 5-HT did not produce consistent alterations in cf. 5-HT could increase (Fig. 1B, left pdn traces), 
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decrease (Fig. 1B, right pdn traces) or produce no change (not shown) in cf relative to baseline, where 
baseline was measured after the 1hr sucrose block, immediately before 10µM 5-HT application.  
Fig. 1C emphasizes the variability in 5-HT effects on cf. The average cf for the last 10 cycles in 
5-HT (i.e., steady state 5-HT) was plotted against the average for the last 10 cycles just prior to the addi-
tion of 5-HT (i.e., baseline) for every deafferented preparation examined (n=44). Each datum represents a 
single preparation and the standard error of the means. The diagonal line represents unity. Experiments in 
which 5-HT had no effect fall along the line; those where 5-HT induced increases or decreases in cf are 
represented by data points above or below the line, respectively. The average steady state 5-HT effect for 
all 44 preparations is plotted in Fig 1D.  The representation of the data in this manner is deceptive as it 
suggests that 5-HT had no significant effect on pyloric cf, which is clearly not the case (Fig. 1C).  
The variable change in cf did not correlate with gender, molt stage, time/date or the pres-
ence/absence of a spermatophore.  It was previously suggested that 5-HT could elicit an increase in cf 
when the LP was silent and a decrease when the LP cell was active (Beltz et al., 1984). However, this did 
not seem to be the case in our hands. We obtained extracellular LP recordings from the lvn in 20 prepara-
tions. After descending modulatory input was removed with a sucrose block, the LP was silent in 17 
preparations, and fired very weakly and irregularly in the remaining 3. Moreover, it was postulated that 
the cf decrease was due to LP inhibition of PD. Using 10-6M picrotoxin to supress glutamatergic transmis-
sion (Bidaut 1980), and hence the LP to PD synapse, we still observed an increase or decrease in cf (n=3, 
data not shown)   
Interestingly, washout of 5-HT for 10min produced a significant increase in cf (Fig. 1D). In order 
to determine whether the washout effect varied with regard to the 5-HT response, we first classified prep-
arations according to their response. Preparations showing more than a 5% decrease in steady state 5-HT 
cf relative to baseline were called Class S for slower. These preparations showed a mean 48+7% decrease 
in cf over baseline (paired t-test p<10-5, n=21), with individual decreases ranging from ~12-100%.   Prep-
arations falling into Class F, for faster, showed a mean 26+6%  increase in steady state 5-HT cf from 
baseline (paired t-test p=0.001, n=17), and individual increases ranged from ~6-107%.   Preparations dis-
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playing less than a 5% change were classified as NC, for no change. These preparations showed a mean 
0.0+1.0% decrease in cf over baseline (paired t-test p>0.71, n=6), and changes ranged from a 4% decrease 
to a 3% increase.  The 5-HT effect washed out immediately and completely for all Class S preparations, 
and then the effect reversed so that by 1hr of wash the cf (averages for last ten cycles of 1hr wash) had 
significantly increased by an average of 26+15% over the original baseline (Fig 2A). Similarly, all Class 
F (Fig 2B) and NC (Fig. 2C) preparations showed a significant increase over baseline by a 1hr wash. 
Thus it appeared that the washout effect was the same for all Classes of preparations regardless of their 
response to 5-HT. 
To assess whether the increased baseline was evoked by 5-HT washout or experimental “drift”, 
we recorded for the same length of time from 6 deafferented preparations that never received 5-HT.  Plots 
of instantaneous cycle frequency vs. time showed that in the absence of 5-HT there was a slow steady 
increase in cf over the course of 70min (Fig 3A). The average of the last10 cycles during the 1hr sucrose 
block represented baseline. Fig 2D illustrates that there was no significant increase in cf over baseline by 
5min (i.e. the time corresponding to 5min in 5-HT); however, there was a significant increase over base-
line at the time corresponding to the 1hr wash. These data suggest that 5-HT independent phenomena 
(e.g., lack of modulatory inputs) could at least partially underpin the changing baseline over the course of 
the experiment. 
We were interested in whether the change in baseline cf over 1hr would alter a deafferented prep-
aration’s response to 5-HT. In several experiments (n=8) we applied 5-HT sequentially to a deafferented 
preparation: 5-HT was applied for 5min, washed out for 1hr and then reapplied for 5min (Fig 3B).  We 
observed that the average response to the first and second applications of 5-HT were not significantly dif-
ferent (average steady-state 5-HT/baseline = 0.58+0.15Hz, 1st application vs. 0.54+0.14Hz, 2nd applica-
tion; paired t-test p=0.17, n=8); however, the second response was usually set atop a higher baseline.  Im-
portantly, these experiments make the point that  5-HT receptors respond in a like manner to serial 5min 
applications of 5-HT spaced at 1hr intervals (see below). 
The three temporal phases of the 5-HT induced changes in cf  
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We next examined the time course of the 5-HT induced changes in cf by plotting the frequency of 
each pyloric cycle before, during and after 5-HT application (n=37).  Six representative examples are 
shown in Fig. 3,C-H.  In ~75% of the experiments (Fig. 2C-F) the time course could generally be de-
scribed as having three phases: An immediate decrease within the first 50sec of 5-HT application (Phase 
1), followed by a slow increase over the next 70 sec (Phase 2), which ended in an apparent steady state 
(Phase 3).  The time course and absolute value of the peak within each phase varied according to the 
preparation. Once peak cf was reached in phase 2, it was either maintained or gradually reached a new 
apparent steady state (e.g. Fig. 3E vs. 3F).  Cycle frequencies were fairly stable after 3min in 5-HT; how-
ever, steady state 5-HT effects varied greatly, such that the three aforementioned Classes of responses 
were observed (Fig. 3C, Class F; Fig. 3D; Class S; Fig. 3E&F, Class NC).  The remaining 25% of the ex-
periments were atypical with regard to time course. These preparations either exhibited no significant re-
sponse to 5-HT (not shown; Class NC), displayed a small, gradual, significant increase over baseline 
throughout 5-HT application (Fig. 3G; Class F) or showed a fairly dramatic, significant decrease relative 
to baseline, followed by an apparent steady state (Fig. 3H; Class S). 
Function and Pharmacology of 5-HT2βPan 
We next sought pharmacological tools that would allow us to characterize the roles of the two 
previously cloned Panulirus 5-HT receptors in generating the 5-HT response. The Panulirus 5-HT2βPan 
receptor has been shown to respond specifically to 5-HT and to couple to the inositol phosphate (IP) sig-
naling pathway when stably expressed in HEK cells (Clark, Dever et al. 2004).  In this study we transient-
ly expressed 5-HT2βPan in HEK cells and measured IP release in response to amines and putative pharma-
cological agents.  Non-transfected parental HEK cells did not respond to 5-HT in the IP assay.  IP levels 
showed a dose dependent increase in response to 5-HT in cells expressing 5-HT2βPan with an EC50 of 
52nM (Fig. 4A, Table 1).   
In order to determine a pharmacological profile for 5-HT2βPan we tested a suite of putative agonist 
and antagonist drugs.  In an initial overview, all drugs were tested at 10-3M (agonists) or 10-5M (antago-
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nists).  Agonists that produced a significant increase in IP levels in transfected but not parental lines, and 
antagonists that inhibited the 5-HT induced increase but had no effect on the parental lines, were then 
used to generate dose response curves.  Typical dose response curves for agonists and antagonists are 
shown in Fig. 4A.  From these curves we determined the potency and efficacy of each drug. The EC50 or 
IC50 are measures of the potency of a drug and reflect its binding affinity at the receptor.  Because the 
maximum effect, or efficacy, achieved by any drug is dependent on the number of receptors expressed, 
we ran a parallel dose-response curve for 5-HT in every experiment and normalized all drug efficacies to 
the maximum 5-HT response, set at 100%.  These data are summarized in Tables 1 and 2. 
The following agonist potency rank profile was determined for 5-HT2βPan:  5-HT > methysergide 
> 8-OH-DPAT >  2-Me-5-HT > MeOTryp > α-Me-5-HT > DOI > 5-CT.  While most agonists achieved 
above 75% of 5-HT activation levels, methysergide and DOI were only partial agonists of 5-HT2βPan with 
efficacies of less than 50% of the 5-HT effect.  No change in IP level was detected after application of 10-
3M N-acetyl-5-HT, quipazine, or mCPP.  None of the drugs had significant effects on non-transfected 
parental HEK cells. 
The rank potency of effective antagonists at 5-HT2βPan was (+)butaclamol > ritanserin > 
methiothepin > cinanserin > clozapine.  Ritanserin and (+)butaclamol, however, were only partially effec-
tive in inhibiting activation of 5-HT2βPan by 5-HT even at the highest antagonist concentration.  Of the 
antagonists tested, ketanserin, spiperone, prazosin, (-)butaclamol, gramine and atropine had no effect at 
10-5M.  Putative antagonists had no effect on non-transfected parental HEK cells.  
Function and Pharmacology of 5-HT1αPan 
We have functionally characterized crustacean 5-HT1αPan receptors using a heterologous expres-
sion system and demonstrated that these receptors negatively couple with cAMP (Spitzer et al., 2008).  In 
this expression system the 5-HT1αPan gene is stably integrated into the genome of 293-TR-5-HT1αPan cells, 
but the cells do not express the receptor until they are chemically induced to do so. Thus, the negative 
control for this assay is not parental cells, but rather, non-induced 293-TR-5-HT1αPan cells. 
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We tested the same suite of potential agonists as above on induced and non-induced 293-TR-5-
HT1αPan cells.  Fig. 4B shows the effect of increasing concentrations of 5-HT1αPan agonists on cAMP levels 
in 293-TR-5-HT1αPan cells that were or were not induced to express 5-HT1αPan 18-20hr prior to performing 
the cAMP assay.  Though their potencies (EC50) and efficacies (% 5-HT effect) were different, both 5-HT 
and mCPP elicited a dose dependent inhibition of forskolin stimulated cAMP accumulation in induced, 
but not non-induced cells.  Some agonists (DOI, 2-Me-5-HT, quipazine) had significant effects on non-
induced 293-TR-5-HT1αPan cells, and could therefore not be tested on induced cells (indicated as Bkd in 
Table 1).  For each of the remaining drugs, the EC50 and the relative efficacy were calculated from dose 
response curves similar to those shown in Fig. 4B.  In this way we generated an agonist profile for the 
receptor that is summarized in Table 1.  The relative potencies of functional agonists at 5-HT1αPan were: 5-
HT > methysergide > α-Me-5-HT > 5-CT > MeOTryp > 8-OH-DPAT > mCPP.  5-HT1αPan did not re-
spond significantly to 10-3M N-acetyl-5-HT. 
 We also tested antagonists for their ability to inhibit 5-HT1αPan activation by 5-HT (Table 
2).  The antagonist (10-5M) was applied ten minutes prior to 5-HT and forskolin stimulated cAMP levels 
were determined.  Twenty nine drugs were tested (the suite tested on 5-HT2βPan and eighteen additional 
drugs).  Seven antagonists (clozapine, methiothepin, S(-)propanolol, metergoline, cyproheptadine, 
SCH23390, S(-)eticlopride) had significant effects on non-induced 5-HT1αPan cells and could therefore not 
be tested for activity on induced 5-HT1αPan cells (indicated as Bkd in Table 1).  None of the remaining 22 
drugs was able to significantly block the inhibition of cAMP accumulation resulting from 5-HT activation 
of 5-HT1αPan, even when low levels (5x10-8M) of 5-HT were used.   
Identification of drugs to differentiate 5-HT2βPan and 5-HT1αPan.  
Several drugs whose action could differentiate between 5-HT2βPan and 5-HT1αPan were identified 
(Tables 1 and 2).  The agonist mCPP activates 5-HT1αPan but not 5-HT2βPan.  Several 5-HT2βPan antagonists 
that did not block 5-HT1αPan receptors were also identified: (+)butaclamol, cinanserin and ritanserin.  We 
152 
 
next used these drugs on the native system to study the role of the 5-HT2βPan and 5-HT1αPan receptors in 
modulating pyloric cf. 
 
Blocking the 5-HT2βPan transduction cascade significantly alters temporal phases 2 and 3 of the 5-
HT response  
Figs. 1-3 illustrate that the 5-HT induced change in cf could could be divided into 3 temporal 
phases (Ph1, Ph2, Ph3) and could vary with the preparation (e.g., Classes F, S & NC). The mechanisms 
underlying this temporal progression and preparation-to-preparation variability were unknown. We next 
set out to determine whether 5-HT1αPan and 5-HT2βPan receptors were components of the 5-HT response 
system that controlled cf, and if so, how these components varied with time and across preparations.  
We first examined the contribution of 5-HT2βPan receptors to 5-HT modulation of cf. The antago-
nists (+)butaclamol and cinanserin block 5-HT activation of 5-HT2βPan but not 5-HT1αPan  receptors (Table 
2); therefore, we applied cinanserin or (+)butaclamol with 5-HT (Fig. 5). Unfortunately, cinanserin and 
(+)butaclamol could not be used on the same preparation because their antagonistic effects did not wash 
out. This also prevented us from reversing the order of application (i.e., we could not perform 5-HT plus 
antagonist followed by 5-HT alone). Nevertheless, it was clear from qualitative observations (e.g., com-
pare Figs. 5A vs. 5B) and quantitative measurements (see below) that these drugs produced comparable 
results. Additionally, preliminary experiments using the 5-HT2βPan antagonist, ritanserin (Table 2), yielded 
similar findings (not shown). The fact that multiple 5-HT2βPan antagonists have the same effect increases 
the likelihood that these experiments are reporting on 5-HT2βPan receptor mediated changes in cf.  
Representative experiments are shown for cinanserin (Fig. 5A, n=8) and (+)butaclamol (Fig. 5B, 
n=22).  In these serial experiments, modulatory input was blocked with sucrose on the stn and the prepa-
ration stabilized in a basal cycling state for 1hr.  Baseline measurements of cf were obtained immediately 
before a 5min application of 10µM 5-HT (labeled 5-HT baseline in Fig. 5). 5-HT application was fol-
lowed by a 1hr wash. Since baseline increased and remained steadily elevated throughout these experi-
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ments (Figs. 2D&3A), a new baseline (labeled antagonist baseline in Fig. 5) was measured immediately 
before application of antagonist and represented the last ten cycles of the 1hr wash. Antagonist (10µM) 
was applied alone for 5min and then together with 10µM 5-HT for 5min followed by a 1hr wash. Antag-
onists alone had no significant effect on cf (mean cinanserin induced change in cf=-0.5+1.5%, p>0.7, n=8; 
mean (+)butaclamol induced change in cf =0.2+1.4%, paired t-test p>0.8, n=22).  
Regardless of the network’s initial response to 5-HT (e.g. F, S, NC), in approximately 91% of the 
experiments 5-HT2βPan antagonists consistently altered the 5-HT induced change in cf in two respects. 
First, the antagonist abolished the rise in cf usually observed during temporal phase 2 of the 5-HT re-
sponse (see Fig 3C). In the presence of 5-HT alone, cf increased during phase 2 relative to phase 1 in 26 
of 30 experiments (average ∆cf =0.17+0.04Hz; paired t-test for Ph2 peak vs. Ph1 nadir p<10-3, n=30). 
However, in the presence of 5-HT plus antagonist, the phase 2 peak was no longer significantly different 
from phase 1 nadir (average ∆cf {phase 2 peak–phase 1 nadir=-0.03+0.05Hz; paired t-test for Ph2 peak 
vs. Ph1 nadir p>0.56, n=30). Second, whereas 5-HT alone produced no significant change in mean 
steady-state 5-HT cf relative to baseline (see Fig 1D), 5-HT plus antagonist produced a significant de-
crease in mean steady-state 5-HT cf relative to baseline (mean steady-state cf in 5-HT plus antago-
nist/baseline=0.67+0.05, paired t-test p<10-7, n=30). When considered in light of the fact that 5-HT2βPan 
receptors have been localized to the STG neuropil (Clark et al. 2004), these data suggest that 5-HT2βPan 
receptors are part of the 5-HT response system that modulates cf in most preparations. However, because 
pharmacology across paralogs within a class (e.g. 5-HT2α & 5-HT2β) is often conserved (Saudou, 
Boschert et al. 1992), we cannot conclude that the antagonists are acting solely on 5-HT2βPan receptors. 
For this reason we will refer to the component blocked by 5-HT2βPan antagonists as the 5-HT2βPan-like 
component.   
In Fig. 5, application of antagonist plus 5-HT appeared to restore the preparation to its original, 
pre-5-HT cf (i.e., 5-HT baseline).  Based on this figure one might speculate that the second drug applica-
tion removed a long-lasting change initiated by the first 5-HT application.  Several pieces of evidence 
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suggest that this is not the case:  First, the change in cf elicited by antagonist plus 5-HT did not vary ac-
cording to whether the drugs were applied directly to a naive preparation (n=5) or followed a prior expo-
sure to 5-HT and a 1hr wash (Fig. 5), and the drug induced change from baseline resulting from these two 
types of applications were not significantly different (p=0.77).  Second, there was no correlation between 
“5-HT baseline - antagonist baseline” and “antagonist baseline - cf in 5-HT plus antagonist,” (linear re-
gression, p>0.8, n=30). Third, there was no significant correlation between 5-HT baseline and steady state 
cf in 5-HT plus antagonist (linear regression, p=0.07, n=30). 
At least two highly variable components comprise the 5-HT response system  
The experiments represented in Fig. 5 suggested that at least two independent components com-
prised the 5-HT response system that regulated cf: a 5-HT2βPan-like component that was lost upon antago-
nist application and a non-5-HT2βPan component that remained upon antagonist application. We selected 
24 of the original 30 antagonist experiments that were relatively periodic throughout the recording inter-
val and computationally isolated their 5-HT2βPan-like components. Importantly, we have shown that 5-HT 
receptors respond in a like manner to serial 5min applications of 5-HT spaced at 1hr intervals (Fig. 3B).  
Thus, for each experiment we could approximate and visualize the 5-HT2βPan-like component of the 5-HT 
induced change in cf as a difference trace obtained by subtracting the cf plots acquired in the presence vs. 
absence of antagonist, as described in Materials and Methods.  A subset of our 24 analyses that reflects 
the range of observed variability is shown in Fig. 6. This figure makes the point that the 5-HT induced 
change in cf (blue trace in left panels, termed blue trace average, see Materials and Methods) is composed 
of at least two separable and highly distinct components, a 5-HT2βPan-like component (gold trace in right 
panels, termed difference trace, see Materials and Methods) and a non-5-HT2βPan component (green trace 
in left panels, termed green trace average, see Materials and Methods), which can perhaps be further sub-
divided (see below).  Note that any synergistic effects resulting from the interaction between the compo-
nents would be lost upon application of the 5-HT2βPan antagonist, and therefore attributed solely to the 5-
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HT2βPan-like component.  Unfortunately, despite a considerable effort, we could not identify specific 5-
HT2βPan agonists to complement the antagonist studies. 
Figure 7 shows the average response for all 24 preparations (Fig. 7A-C) and a quantification of 
the variability between the 24 preparations (Fig. 7 D-F). The mean of the 24 individual blue trace averag-
es is plotted in Fig. 7A. The three previously described temporal phases of the 5-HT response are demar-
cated. To quantify the response for an individual preparation, we measured the change from baseline dur-
ing each of the 3 temporal phases as described in Materials and Methods. The 24 individual preparations 
are plotted as 24 blue circles in 3 dimensional space in Fig. 7D. Each axis represents one of the three tem-
poral phases. For a given axis (temporal phase), numbers > or < 1 represent an increase or decrease in cf 
relative to baseline, respectively. The larger the change, the further the datum is from the number 1. The 
means and the individual variability for the non-5-HT2βPan component (Fig 7B &7E, respectively) and the 
5-HT2βPan-like component (Fig. 7C & 7F, respectively) are similarly plotted. There were statistically sig-
nificant correlations between the amplitudes of the changes in cf relative to baseline during the three tem-
poral phases (e.g. phase 1 cf/baseline vs. phase 2 cf/baseline). It appeared that the larger the decrease in cf 
during phase 1, the smaller the increase over baseline in phases 2 and 3 (p<0.05, Correlation analysis, 
Prism). This was true for both individual components as well as the total response. 
Whereas the 5-HT2βPan-like component was largely responsible for a delayed, sustained increase 
in cf relative to baseline (Fig. 7C), there was a remarkable amount of preparation-to-preparation variabil-
ity in this component (Figs. 6&7F).  In 2 of the 24 experiments, the 5-HT2βPan-like component was com-
paratively small or absent (e.g., Fig. 6G).  In the remaining 22 experiments the difference trace was typi-
cally biphasic, such that 5-HT2βPan-like receptor activation generally produced an initial decrease in cf dur-
ing temporal phase 1, followed by a slower increase that peaked during temporal phase 2 and attained a 
steady state by 5min (i.e., phase 3).  In some experiments, however, one or more of these attributes of the 
5-HT2βPan-like component was absent.  For example, the trough in temporal phase 1 was missing in the 
experiment shown in Fig. 6A, and both the trough and steady state phases were missing in experiment 
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6D.  Despite this variability, the mean nadir in phase 1 and peaks in phases 2 and 3 were significantly dif-
ferent than baseline (mean cf/baseline+stdev=0.76+0.43Hz, 1.51+0.33Hz, and 1.26+0.45Hz; paired t-tests 
p<0.05; n=24).  Note that the calculated mean phase 1 nadir for the 5-HT2βPan-like component (-0.24) dif-
fers from that which is graphed in Fig 7C (>-0.1). This is because the exact time of the nadir varied with 
each preparation (e.g., see Fig 6) so that when all difference traces were averaged, the large nadirs seen in 
individual preparations were smoothed away in the average and thereby obscured. This is also true to a 
lesser extent for the phase 2 peak. 
The non-5-HT2βPan component produced an immediate and sustained decrease in cf relative to 
baseline (Fig.7B).  In some cases the initial decrease in cf could be followed by a small, gradual increase 
(e.g., Figs. 6C&G).  In 3 of the 24 experiments the non-5-HT2βPan component was absent (e.g., Fig. 6B). In 
other experiments there was an obvious shift in the time constants of decay between 30 seconds and 2 
minutes (e.g., Fig. 6A), and in 6 of 24 experiments there was an obvious increase in cf during this period.  
Whereas an unknown element may mediate the increase, it is also possible that the 5-HT2βPan-like compo-
nent was incompletely blocked by antagonist in these preparations. Though variable, the mean decrease in 
cf relative to baseline for the non-5-HT2βPan component was statistically significant during all 3 temporal 
phases (mean cf/baseline+stdev=0.79+0.19Hz (phase 1),  0.77+0.31Hz (Phase 2) and 0.71+0.22Hz (Phase 
3), n=24, paired t-tests p<10-3).   
It might be questioned whether some or all of the variability in the response to 5-HT results from 
the response being sensitive to absolute cf immediately before modulator application. For example, in the 
crab STNS, the crustacean cardioactive peptide (CCAP) hormone consistently increased cycle period dur-
ing a relatively fast gastric mill rhythm but produced inconsistent results during slower rhythms (Kirby 
and Nusbaum 2007). Figs. 1C&2 suggest that the steady-state 5-HT effect is not sensitive to baseline cf. 
We further examined the cycle period dependent effects of 5-HT in all phases of the 5-HT response and 
for the 2 individual components by performing correlation analyses (Prism, GraphPad) on measurements 
from these 24 preparations. Baseline frequency vs. the 5-HT induced change in cf [i.e. (cf in 5-
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HT)/baseline] for each of the three temporal phases in each of the 24 preparations was plotted. None of 
the three correlations were significant (p> 0.05). We performed similar analyses for each temporal phase 
of the non-5-HT2βPan component [i.e., antagonist baseline vs. (cf in antagonist+5-HT)/antagonist baseline] 
and the 5HT2βPan-like component (baseline vs. difference trace measurements) and found no significant 
correlations (p> 0.05 in all cases). Thus, the actions of 5-HT appear to be independent of absolute cf in all 
three temporal phases of the response, even at the level of individual components. 
The sum of the two opposing and variable components determines the Class 
As discussed at the beginning of Results, preparations could be divided into 3 Classes depending 
upon whether cf increased (F), decreased (S) or remained unchanged (NC) relative to baseline after 5min 
in 5-HT. Comparisons of the 3 Classes with a one way ANOVA followed by a Tukey posthoc test 
demonstrated that all Classes were significantly different from each other at steady state (Table 3, last 3 
columns, phase 3). Interestingly, one way ANOVAs indicated that there were no significant differences in 
cycle frequencies between these Classes prior to 5-HT application (p>0.6 for intact preparations; p>0.85 
for preparations with a sucrose block on the stn, data not shown). These data indicate that circuits that do 
not appear to be functionally different (e.g., similar cycle frequencies across individuals) can show differ-
ent responses to the same modulatory challenge.  
The existence of the 3 Classes could be due to Class-specific differences in the components of the 
5-HT response system (e.g., the 5-HT2βPan-like component that increases cf is always large in Class F and 
small in Class S). To address whether or not there were fundamental differences in the 5-HT2βPan-like 
component between the three Classes, we used one-way ANOVAs to compare the changes in cf produced 
by 5-HT2βPan-like receptor activation during a given temporal phase. Table 3 shows that there were no 
significant differences in the 5-HT2βPan-like component between the different Classes for any temporal 
phase. This can also be seen by examining Fig. 6. For example, the preparations in Figs. 6C and 6F be-
long to Classes F and S, respectively, and yet they have highly similar 5-HT2βPan-like components. Com-
parable analyses indicated that neither were there statistically significant differences in the non-5-HT2βPan 
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component between the Classes (Table 3, Fig 6). In sum, the two components displayed preparation-to-
preparation variability within a Class; however, when all preparations were considered, the set of compo-
nents in one Class was no different than in another, and a given component (e.g., producing large vs. 
small change from baseline) was equally likely to be found in any of the three Classes. 
How are different Classes of responses produced from the same set of components? Analyses of 
individual preparations suggested it was the balance of the two components that determined the Class, 
such that at steady state 5-HT2βPan-like>non-5-HT2βPan for Class F, non-5-HT2βPan>5-HT2βPan-like for Class 
S and non-5-HT2βPan=5-HT2βPan-like for Class NC.  
Fig. 6 shows that the 5-HT induced change in cf  was the sum of two highly variable components. 
Initially both components produced a decrease in cf.  The minima of the two components were not neces-
sarily coincident. Whereas the non-5-HT2βPan component continued to decrease throughout phase 1, the 5-
HT2βPan-like component reached its nadir and then began to rise late in phase 1. From this point on the two 
components produced opposing changes in cf, and their balance appeared to determine whether 5-HT ul-
timately produced a net increase, decrease or no change in cf relative to baseline.  This is most clearly 
seen by comparing Figs. 6B, 6E and 6F.  One of the largest 5-HT2βPan-like components is observed in Fig. 
6F (~0.9Hz increase at steady state), but in this experiment 5-HT produced a 32% net decrease in cf at 
steady-state, because the non-5-HT2βPan component was even larger.  The experiment shown in Fig. 6B 
has the smallest 5-HT2βPan-like component (~0.15 Hz increase at steady state), but 5-HT produced a sig-
nificant 14% net increase at steady state, because the non-5-HT2βPan component was absent.  Fig. 6E 
shows an intermediate 5-HT2βPan-like component (~0.4 Hz increase at steady state), yet 5-HT had no net 
effect on cf in this experiment because the non-5-HT2βPan component was equally large. Thus, the steady 
state 5-HT response is determined by the sum of opposing components.  
This idea that each Class represents a different balance of components is further substantiated by 
an examination of the means within a Class. In Class F the average 5-HT2βPan-like component was approx-
imately 1.6 times larger than the average non-5-HT2βPan component at steady state (mean % change from 
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baseline cf at steady state produced by each component: 5-HT2βPan-like=44+8% increase, non-5-
HT2βPan=27+8% decrease, n=11), but the opposite was true for class S preparations (mean % change from 
baseline cf at steady state produced by each component: 5-HT2βPan-like=8+12% increase, non-5-
HT2βPan=38+9% decrease, n=7). Further, using the aforementioned measurements of the 5-HT induced 
change from baseline during phase 3 (see Fig 7E-F) we obtained a ratio of the components for each prepa-
ration at phase 3 (phase 3 5-HT2βPan-like component/phase 3 non-5-HT2βPan component). A Kruskal-Wallis 
followed by a Dunnett’s post-hoc test showed that the ratios were significantly different for Classes F and 
S (Table 4). Together these analyses suggest that the different Classes represent a change in the balance of 
opposing components of the 5-HT response system. 
5-HT1αPan-like receptors mediate a slow increase in cf  
We next examined the role of 5-HT1αPan receptors in mediating the 5-HT effect on cf.  Because we 
were unable to identify specific antagonists for 5-HT1αPan, we used an agonist, mCPP, to investigate the 
role of this receptor.  While mCPP is a relatively weak agonist of 5-HT1αPan, it was the only one tested 
that had no activity at 5-HT2βPan in cell culture (Table 1).  This criterion was important since 5-HT2βPan 
activation contributed significantly to 5-HT induced changes in cf (Figs. 5-7). In these studies 100µM 
mCPP was used to activate 5-HT1αPan receptors, because 10-50µM mCPP was ineffective (Zhang and 
Harris-Warrick 1994).  Given the high concentration of mCPP used, we cannot rule out the action of this 
drug at other receptors. Thus, the component of the 5-HT response system identified by these experiments 
will be referred to as the 5-HT1αPan-like component. 
Fig. 8A shows an example of a typical mCPP experiment. In this preparation a 5min, 5-HT 
(10µM) application slowed cf.  5-HT application was followed by a 1hr wash and a 5min application of 
100µM mCPP.  After a further 1hr wash, (+)butaclamol, a 5-HT2βPan antagonist, was applied for 5min 
followed by butaclamol+mCPP.  In some experiments the order of 5-HT and mCPP applications were 
reversed.   
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Application of mCPP caused an increase in cf in all preparations regardless of the 5-HT effect. 
Figure 8B illustarates that the mean steady state cf, measured as the average during the last minute of 
mCPP application, significantly increased by 33+4.5% relative to baseline.  The time course of the re-
sponse varied so that the peak effect was reached between 1-5min.  In 7 of 9 experiments, a steady state 
was reached within 5min, and in the remaining 2 preparations the cf continued to increase throughout the 
5min 5-HT application.  The mCPP induced increase was not blocked by (+)butaclamol, and its magni-
tude varied across preparations by a factor of 5. After a 1hr wash out of mCPP, there was an increase in cf 
relative to baseline, similar to preparations exposed to 5-HT. As shown in Fig 2D&3A, this increase could 
be due to mCPP independent phenomena. 
These data suggest that 5-HT1αPan-like receptors could contribute a small, gradual increase in cf to 
the non-5-HT2βPan component of the 5-HT response system.  Unfortunately, the lack of a specific 5-
HT1αPan antagonist prevented us from testing this hypothesis further.  However, if this hypothesis is true, 
then there must be at least one additional subcomponent that mediates a decrease in cf and opposes both 
the increases mediated by 5-HT1αPan-like and 5-HT2βPan-like receptors at steady state.   
5-HT effects on  VD could underpin the decrease in cf associated with the non-5HT2βPan compo-
nent   
In the intact system, VD is thought to regulate cf via its rectifying electrical junctions with the 
pacemaker kernel. It was previously shown that VD acts to increase cf, most likely by injecting positive 
current into the AB/PD pacemaker during the depolarizing phase of the pacemaker oscillation (Weaver 
and Hooper 2003). VD’s governance of cf is state dependent, such that VD’s influence is greatest at slow-
er cycle frequencies (e.g., < 1.0), which are typical for the deafferented preparations studied here (Fig. 
1D; average baseline cf = 0.77+0.4Hz, n=44). In the absence of 5-HT, VD is active in deafferented prepa-
rations (Fig. 1B, mvn trace in middle panels); thus, it is likely that VD provides an accelerating influence 
on cf under these experimental conditions. Presumably, phenomena that inhibit VD and/or reduce its elec-
trical coupling with the pacemaker kernel will diminish VD’s accelerating influence on the pacemaker, 
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and thereby slow cf. It was previously shown that (1) 10µM 5-HT reduces the electrical coupling between 
VD and the pacemaker kernel by ~50% (Johnson, Peck et al. 1993);  (2) 10µM 5-HT normally hyperpo-
larizes VD by -10mV to inhibit firing (Flamm and Harris-Warrick 1986); and (3) all else being equal, a -
10mV hyperpolarization of VD can reduce cf by 35-86% (Weaver and Hooper 2003).  The typical time 
course for the 5-HT induced change in VD firing frequency, shown in Fig. 9A, corresponds to that for the 
non-5HT2βPan component of the 5-HT response system (e.g. compare green traces in Figs. 6&7 with Fig. 
9A). Moreover, none of the 5-HT2βPan antagonists had any effect on the VD neuron’s response to 5-HT 
(Figs. 9B-C); and application of mCPP, a 5-HT1αPan agonist, also did not alter the firing rate of the VD 
neuron (Fig. 8C). Thus, neither 5-HT2βPan-like nor 5-HT1αPan-like receptors mediate the 5-HT induced hy-
perpolarization of VD.   Together these data suggest that 5-HT effects on VD could produce the rapid and 
sustained decrease in cf associated with the non-5HT2βPan component of the 5-HT response system. 
5-HT2βPan-like receptors do not mediate the excitation of IC 
The activity of the IC cell is visible on many mvn recordings.  Like LP, IC was silent after the su-
crose block was applied.  However, consistent with previous studies (Flamm and Harris-Warrick 1986), 
in some preparations 5-HT elicited spikes in the IC.  The 5-HT2βPan antagonists had no effect on 5-HT 
induced excitation of IC in any preparation regardless of whether or not 5-HT produced an increase (n=8, 
data not shown) or decrease in cf (n=5, not shown).  Thus, 5-HT2βPan-like receptors do not mediate the 5-
HT induced excitation of IC. 
 
Discussion 
Most previous studies have focused on the reproducibility of modulatory effects, and convention-
al wisdom suggests that a given neuroactive substance will elicit a fairly consistent response from a given 
circuit. However, these teachings are not in keeping with the emerging principles of  metamodulation 
(Katz and Edwards 1999) and plasticity (Nowotny, Szucs et al. 2007). Further, there are several recent 
examples showing that the effect of a neuroactive substance on a given target can be context dependent 
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(Yeh, Musolf et al. 1997; Edwards, Yeh et al. 2002; Mesce 2002; Birmingham, Billimoria et al. 2003; 
Mitchell and Johnson 2003). In our experiments one function of 5-HT modulation was completely stereo-
typed (immediate 5-HT induced hyperpolarization of the VD neuron to inhibit spiking). On the other 
hand, we found that depending upon the preparation, the same 5min, 5-HT application could increase 
(Class F), decrease (Class S) or have no effect (Class NC) on the frequency of the rhythmic output of the 
pyloric CPG at steady state. We developed and implemented pharmacological tools to test the hypothesis 
that the molecular elements mediating 5-HT effects were different between Classes.  We discovered that 
the elements were similar between Classes, and that the 5-HT response system that regulates cf was com-
posed of at least three separable components.  Some of the components produced opposing changes in cf, 
and each component showed a great deal of preparation-to-preparation variability.  Since the effects of the 
components summed, it was the balance of the components that ultimately determined whether 5-HT pro-
duced a net increase, decrease or no change in pyloric cf at any given point in time.  
 
The three components of the 5-HT response system 
Our data suggest that there are at least three distinct components of the 5-HT response system 
controlling cf. The first component of the 5-HT response system is associated with a 5-HT2βPan-like trans-
duction cascade(s). This component is typically biphasic and is characterized by an initial decrease fol-
lowed by a steady state increase in cf.  The biphasic response most likely reflects activation of distinct 
signaling pathways on different time scales.  5-HT2βPan receptors couple with Gq to activate phospholipase 
Cβ and ultimately increase the activity of protein kinase C in HEK cells (Clark, Dever et al. 2004).  In 
mammals, activation of the 5-HT2 family can additionally stimulate Phospholipase A2, NO synthesis, and 
the MAP Kinase cascade (Nebigil, Etienne et al. 2001).  It is not clear whether the mechanism giving rise 
to the bimodal effect we observed involves one or a combination of these (or other) signaling pathways.   
Differential localization of the receptor could also contribute to bimodality.  Arvanov et al. 
(Arvanov, Liang et al. 1999) showed that 5-HT2A receptors generated a biphasic response in rat medial 
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prefrontal cortex because they were located both pre- and post-synaptically.  The subcellular compart-
mentalization of 5-HT2βPan receptors within the synaptic neuropil of the STG is not known.  All STG neu-
rons express 5-HT2βPan, and this receptor is found throughout the synaptic neuropil, but not in the 
plasmalemma surrounding the soma or large diameter neurites (Clark, Dever et al. 2004).  We previously 
demonstrated that 5-HT2βPan receptors were located on distal axon terminals in PD and PY cells (Clark et 
al., 2004). Here we have shown that 5-HT2βPan receptors do not mediate 5-HT inhibition of VD or excita-
tion of IC; hence, 5-HT2βPan receptors may also be localized to the peripheral regions of these neurons. 5-
HT is known to regulate multiple conductances in the AB pacemaker neuron that ultimately enhance its 
excitability and synaptic output to increase steady-state cf (Flamm and Harris-Warrick 1986; Harris-
Warrick and Flamm 1987; Johnson, Peck et al. 1993).  Furthermore, the 5-HT2βPan antagonist, cinanserin, 
blocks 5-HT elicited AB/PD bursting in the crab, Cancer borealis, (Zhang and Harris-Warrick 1994).  
The most parsimonious interpretation of all the data is that the 5-HT2βPan-like receptors responsible for 
increasing steady-state cf reside in the AB synaptic neuropil.  However, it is also possible that these re-
ceptors reside on the terminals of modulatory projection neurons, and that some of the varied effects of 5-
HT on cf are mediated by local interactions between these terminals and their targets (Coleman, Nusbaum 
et al. 1992; Coleman and Nusbaum 1994; Goaillard, Schulz et al. 2004).  
The second component of the 5-HT response system is mediated by a 5-HT1αPan-like transduction 
cascade.  This component produces a small, gradual increase in cf. 5-HT1αPan receptors couple with Gi/o 
in HEK cells to decrease cAMP (Spitzer et al., 2008).  The location of this receptor is presently unknown, 
though it is unlikely to be found in the VD synaptic neuropil as the 5-HT1αPan agonist did not affect VD 
activity.   
The third component of the 5-HT response system results in an immediate and sustained decrease 
in cf, but the receptors involved are currently unknown.  The three uncharacterized GPCRs in the arthro-
pod genome are unlikely candidates because they are not homologous to known 5-HT receptor subtypes 
(Clark and Baro 2007). We have shown that this component is independent of 5-HT1− and 5-HT2-
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like receptors. The only remaining known arthropod 5-HT receptor is 5-HT7 which couples with Gs 
(Schlenstedt, Balfanz et al. 2006).  
Our results are consistent with the notion that the third component is at least partially localized to 
the VD follower neuron. However, this idea is called into question by Ayali and Harris-Warrick (1999), 
who showed that when modulatory inputs were intact, the 5-HT induced change in cf was not significant-
ly different between the isolated AB neuron, the isolated AB-PD pacemaker kernel, and the intact net-
work. This suggested that 5-HT acted solely on the AB neuron to control cf.  Interestingly, in their hands 
5-HT always produced an increase in cf. A major difference between the two studies was the presence 
(Ayali and Harris-Warrick) vs. the absence (this manuscript) of descending modulatory inputs.  It is 
noteworthy that when modulatory inputs to the network are intact (i.e., non-deafferented preparation), LP 
and VD are both active and have reciprocal effects on cf (Weaver and Hooper, 2003), and that 5-HT acts 
directly to hyperpolarize both LP and VD to the same extent (Flamm and Harris-Warrick, 1986b). Con-
versely, in our deafferented preparation, LP is hyperpolarized prior to 5-HT application. Thus, 
deafferentation may remove a fourth component of the 5-HT response system that resides on the LP and 
produces an increase in cf. 
 
Sources of component variability  
The variability in the three components of the 5-HT response system is striking. Because the py-
loric network was isolated from all descending modulatory input in our studies, the variability must be 
due to relatively stable differences in inherent cellular and/or circuit properties across preparations. In-
deed, it has been shown theoretically (Prinz, Bucher et al. 2004) and experimentally (Bucher, Prinz et al. 
2005; Schulz, Goaillard et al. 2006) that considerable variability may exist in the cellular and molecular 
parameters underlying the pyloric network.  
The most obvious sources for variability in the response to 5-HT are the proteins comprising the 
transduction cascades. Receptor function and/or expression can be state-dependent (Ango, Prezeau et al. 
2001; Bockaert, Marin et al. 2003; Cirelli and Tononi 2004; Dwivedi, Mondal et al. 2005) (Wohlpart and 
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Molinoff 1998; Anji, Sullivan Hanley et al. 2001; Riad, Watkins et al. 2001).  5-HT1α expression is highly 
variable in the crayfish CNS (Spitzer, Antonsen et al. 2005) and preliminary studies suggest this may also 
be true in the lobster STG (J. Dever, T. Dever, D. Baro, unpublished).  On the other hand, overall 5-
HT2βPan expression appeared to be relatively constant (Clark, Dever et al. 2004), though it was never quan-
tified nor examined in single cells.  In addition, one or more downstream components of the 5-HT signal 
transduction cascades could vary (Kreienkamp 2002; Werry, Sexton et al. 2005).  For example, alterations 
in the signaling pathway could occur at the level of the final target.  In this regard, ion channel activity 
and expression in pyloric neurons is known to vary significantly across individuals (Golowasch, Abbott et 
al. 1999; Bucher, Prinz et al. 2005; Schulz, Goaillard et al. 2006), and neuromodulatory input can regulate 
expression of ionic currents and channels over the long-term (Mizrahi, Dickinson et al. 2001; Khorkova 
and Golowasch 2007).  
Synaptic plasticity may also contribute to variability between preparations.  5-HT alters the 
strengths of glutamatergic synapses between the pacemaker kernel and follower LP and VD neurons, as 
well as electrical coupling between VD and the pacemaker kernel (Johnson and Harris-Warrick 1990; 
Johnson, Peck et al. 1994; Johnson, Peck et al. 1995). In preliminary experiments, ablation of 
glutamatergic synapses did not prevent a variable 5-HT response. To our knowledge, the degree of prepa-
ration-to-preparation variability in the strength of electrical coupling between VD and the pacemaker ker-
nel is presently unknown. 
State dependent effects that are independent of changes in protein expression and/or morphology 
could also account for the variability observed here. Many effects of G protein coupled receptors are 
made manifest only under certain conditions. For example, in prefrontal cortex neurons, activation of do-
pamine type 1 receptors (D1) significantly reduced EPSP decay time and integral at membrane potentials 
near spike threshold (i.e., upstate), but not at more hyperpolarized potentials (i.e., downstate). The D1 
effect was mediated by changes in the phosphorylation state of Na+ channels (Rotaru, Lewis et al. 2007). 
D1 activation consistently led to Na+ channel phosphorylation regardless of membrane potential (Carr, 
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Day et al. 2003); however, phosphorylation resulted in the enhancement of intinsic slow inactivation, 
which is a voltage-dependent process that is maximal at depolarized potentials (Carr, Day et al. 2003; 
Chen, Yu et al. 2006). Thus D1 activation reduced Na+ channel availability in the upstate, but not in the 
downstate! Working on STG neurons, Nargeot (2003) demonstrated that the long term effect of a neuro-
modulator could be consistent at the molecular level, and yet evoke opposite changes in neuronal activity 
depending upon the cell’s membrane potential. Similarly, state dependent effects have been observed at 
the network level. For example, it has been shown that the influence of the same modulatory change (i.e., 
change in the strength of an identified synapse) can vary according to network cycle frequency 
(Thirumalai, Prinz et al. 2006).  
In sum, the variablity we observed could be due to a variety of mechanisms ranging from changes 
in gene expression to changes in ion channel phosphorylation states that alter membrane potential. With 
regard to the latter, it is important to note that the effects of endocrine and paracrine modulation can last 
well beyond the removal of their inputs (Turrigiano and Selverston 1990; Di Prisco, Pearlstein et al. 1997; 
Wood, Manor et al. 2004; Blitz, White et al. 2008). This depends, in part, upon the mechanisms for re-
moval of neuroactive substances outside the synapse (Coleman, Konstant et al. 1994; Wood and 
Nusbaum 2002), as well as the stability of the change induced by the modulator. Since we examined 5-
HT actions roughly 2-4 hours after removing hormonal inputs, and only one hour after removing synaptic 
and paracrine modulatory inputs, their long-term actions could still be in effect.   
 
Stability vs. variability of neuromodulatory effects on STNS circuits 
In direct contrast to our findings, there exists a vast literature (too large to fully cite here) docu-
menting the reproducibility of neuromodulatory actions on STNS circuits. This apparent discrepancy is 
easily explained for work examining modulation by  projection neurons onto circuit neurons (Saideman, 
Blitz et al. 2007; Stein, DeLong et al. 2007) and/or extrinsic inputs onto these projection neurons 
(Beenhakker, Kirby et al. 2007; Blitz, White et al. 2008). Since these types of studies usually employ an 
intact preparation (i.e., non-deafferented), it may be that reproducibility is maintained through stabilizing 
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mechanisms involving additional modulatory inputs and/or feedback from STG neurons to input neurons 
(Coleman and Nusbaum 1994; Coleman, Meyrand et al. 1995; Wood, Manor et al. 2004). The existence 
of these mechanisms was implied in our studies by the fact that when we removed modulatory input, cy-
cle frequency drifted over time. Additionally, in studies involving projection/sensory neurons, transmis-
sion can be highly localized so that only one or a few components of a multi-component modulatory sys-
tem are activated by a given modulator (e.g., only the excitatory or the inhibitory components). Likewise, 
the apparent discrepancy is understandable for studies that bath apply neuroactive substances to non-
deafferented preparations (Krenz, Nguyen et al. 2000; Szucs, Abarbanel et al. 2005). While the bath ap-
plied modulator would not be localized, the aforementioned stabilizing feedback mechanisms could still 
enter into picture.  
Considering only studies in which modulators were bath applied to deafferented preparations, one 
observes a large literature reporting consistent effects of modulators on isolated ionic currents in identi-
fied neurons (Kloppenburg, Zipfel et al. 2000; Swensen and Marder 2000; Peck, Nakanishi et al. 2001; 
Peck, Gaier et al. 2006). It must be noted that reproducibility was impossible to validate in these studies, 
as individual variability was usually obscured in favor of reporting averages. Here we have demonstrated 
that this may not be the best practice. Nevertheless, assuming the effects were reproducible, their predict-
ability may be explained by the fact that the system was highly reduced. Our work suggests that variabil-
ity is diminished when examining individual components (e.g. VD inhibition) rather than the interaction 
of multiple components (e.g., network cf). Studies on these reduced systems suggest that a given trans-
duction cascade produces a similar effect across most preparations. This is in keeping with our findings, 
which showed that a given component produced comparable effects in all preparations (e.g. increase or 
decrease), but that it varied with regard to time course and amplitude.  
If we consider only those studies that involved bath application to deafferented preparations and 
that reported on cycle frequency, we find a few reports of variable neuromodulatory effects (Beltz, Eisen 
et al. 1984; Saideman, Ma et al. 2007); however, the majority of studies suggest that a given neuroactive 
substance reproducibly alters cycle frequency (Goaillard, Schulz et al. 2004; Perez-Acevedo and Krenz 
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2005; Christie, Stemmler et al. 2006; Stemmler, Peguero et al. 2007). Again, a lack of individual variabil-
ity could not be verified, as average responses were usually reported. In many of these cases there was 
one important difference relative to our study that could account for predictability, and that was that lower 
concentrations of a neuroactive substance were often employed. Lower concentrations may activate fewer 
receptor types (i.e. components). For example, the EC50 for 5-HT1αPan is nearly an order of magnitude 
lower than that of 5-HT2βPan; thus, at one extreme the 5-HT1αPan component might act alone, whereas at 
the other extreme both components could be maximally activated.  
In sum, the paucity of reports on variable modulatory effects is intriguing. It might suggest that 
the 5-HT response system is more plastic than most neuromodulatory systems. Alternatively, it may be 
that variability in neuromodulatory response systems has been highly underestimated, perhaps due to re-
porting procedures and/or the use of techniques that examine individual components rather than their in-
teractions. 
 
Summary 
It is becoming increasingly evident that variability in neuronal modulatory systems and networks 
is often the rule rather than the exception. In the absence of all other modulatory inputs, a given modula-
tory challenge will not have consistent actions on a cellular or circuit parameter if that parameter is a tar-
get of plasticity mechanisms (reviewed in Marder and Goaillard 2006).  It is not known if this variability 
occurs in vivo, and if so, what its functional significance might be. Presumably the variability could re-
flect adaptations of the stomatogastric network to changing digestive, life cycle or environmental circum-
stances.  Future investigations on this ideal preparation should provide substantial insight into how multi-
ple modulatory, metamodulatory, and plasticity mechanisms are integrated to maintain an adaptive net-
work. 
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Table 1:  Agonist profiles of 5-HT2β and 5-HT1α from Panulirus  
      Potency            Efficacy 
(EC50, µM)           (% 5-HT activation) 
Drug 5-HT2βPan 5-HT1αPan  5-HT2βPan 5-HT1αPan 
5-HT 0.052 0.0084  100 100 
Dopamine 310 IA  54 IA 
Octopamine IA IA  IA IA 
Tyramine 283 IA  32 IA 
Histamine IA IA  IA IA 
DOI 4.5 Bkd  32 Bkd 
5-CT 6.1 2.2  79 100 
2-Me-5-HT 0.78 Bkd  96 Bkd 
MeOTryp 1.0 4.2  80 94 
N-acetyl-5-HT IA IA  IA IA 
Quipazine IA Bkd 
 
IA Bkd 
α-Me-HT 1.5 1.1  79 120 
8-OH-DPAT 0.27 7.6  77 105 
mCPP IA 139  IA 97 
Methysergide 0.11 0.089  48 81 
 
5-HT2βPan and 5-HT1αPan were expressed in cultured HEK cells and tested for second-messenger re-
sponses to various pharmacological agents. EC50 values (potencies) and relative efficacies were calculat-
ed from dose–response curves for each drug. Efficacy is presented as a given drug's ability to activate the 
receptor compared to the maximum activation obtained from 5-HT (100%). Drugs with differential ac-
tions on 5-HT2βPan and 5-HT1αPan are shown in bold. n ≥ 3 repeated experiments for each drug. IA, 
drug is inactive; Bkd, drug has background activity on the control noninduced or parental cells and was 
not tested; DOI, 2,5-dimethoxy-4-iodoamphetamine; 5-CT, 5-carboxamidotryptamine; 2-Me-5-HT, 2-
methyl-serotonin; MeOTryp, 5-methoxytryptamine; α-Me-5-HT, α-methyl-serotonin; 8-OH-DPAT, (±)-
8-hydroxy-2-(di-n-dipropylamino) tetralin; mCPP, 1-(m-chlorophenyl)-piperazine. 
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Table 2:  Antagonist profiles of 5-HT2β and 5-HT1α from Panulirus. 
 
  Potency   Efficacy 
(IC50, µM)           (%reduction) 
Drug 5-HT2βPan 5-HT1αPan  5-HT2βPan 
Clozapine 6.8 Bkd  79 
Ritanserin 0.57 IA  58 
Methiothepin 0.66 Bkd  84 
(+)Butaclamol 0.14 IA  48 
Cinanserin 1.2 IA  73 
Gramine IA IA  IA 
(-)Butaclamol IA IA  IA 
Ketanserin IA IA  IA 
Spiperone IA IA  IA 
Prazosin IA IA  IA 
Atropine IA IA  IA 
Chlorpromazine ND IA  ND 
Flupenthixol ND IA  ND 
Domperidone ND IA  ND 
Fluphenazine ND IA  ND 
Haloperidol ND IA  ND 
Metoclopride ND IA  ND 
(-)Sulpiride ND IA  ND 
WAY100635 ND IA  ND 
Yohimbine ND IA  ND 
S(-)Propanolol ND Bkd  ND 
SB269970 ND IA  ND 
Metergoline ND Bkd  ND 
Cyproheptadine ND Bkd  ND 
SB224289 ND IA  ND 
BRL15572 ND IA  ND 
TFMPP ND IA  ND 
SCH23390 ND Bkd  ND 
S(-)eticlopride ND Bkd  ND 
 
5-HT2βPan and 5-HT1αPan were expressed in cultured HEK cells and tested for second-messenger re-
sponses to various pharmacological agents. IC50 values (potencies) and relative efficacies were calculat-
ed from dose–response curves for each drug. Efficacy is presented as the percentage reduction of the total 
effect obtained from 5-HT in the absence of antagonist. Drugs with differential actions on 5-HT2βPan 
and 5-HT1αPan are shown in bold. n ≥ 3 repeated experiments for each drug. IA, inactive; Bkd, drug 
has background activity on noninduced or parental cells and was not tested; ND, not determined. 
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Table 3: Average 5-HT induced fold change relative to baseline in each phase of a given Class  
 5-HT2βPan-like component 
cf/baseline 
non-5-HT2βPan component 
(cf in 5-HT+antagonist)/baseline 
complete 5-HT response system 
(cf in 5-HT)/baseline 
Class 
(n) 
F  
(11) 
S  
(7) 
NC  
(6) 
F  
(11) 
S  
(7) 
NC  
(6) 
F  
(11) 
S  
(7) 
NC  
(6) 
 
phase 1 
 
0.86+0.07 
 
0.74+0.09 
 
0.89+0.05 
 
0.86+0.04 
 
0.67+0.08 
 
0.72+0.09 
 
0.98+0.03 
# † 
 
0.56+0.10 
* 
 
0.67+0.06 
* 
 
phase 2 
 
1.40+0.09 
 
1.15+0.16 
 
1.27+0.07 
 
0.81+0.1 
 
0.65+0.1 
 
0.7+0.014 
 
1.31+0.06 
# 
 
0.62+0.18 
* 
 
1.05+0.06 
 
phase 3 
 
1.44+0.08 
 
1.08+0.12 
 
1.4+0.10 
 
0.73+0.07 
 
0.62+0.09 
 
0.67+0.04 
 
1.22+0.04 
# † 
 
0.64+0.09 
* † 
 
0.98+0.01 
* # 
 
Values are means ± SE for the 5-HT2 β Pan–like component, the non-5-HT2β Pan component, and 
the total response. The 5-HT–induced change from baseline during each temporal phase was cal-
culated as described in METHODS for each of the 24 preparations represented in Figs. 6 and 7. 
Significant differences between classes were determined for each component or the total re-
sponse, by comparing preparations using one-way ANOVAs followed by Tukey post hoc tests. 
We compared data representing only the same temporal phase and the same component (i.e., 
three adjacent rows). Note that there were no differences in phases 1, 2, or 3 of the 5-HT2 β Pan–
like component between classes F, S, and NC. Similarly, there were no significant differences in 
the non-5-HT2 β Pan component between classes during temporal phases 1, 2, or 3. However, sig-
nificant differences between classes could be observed for the total 5-HT response during all 
three temporal phases. 
 
↵* , significantly different from Class F, P < 0.05; 
 
↵# , significantly different from Class S, P < 0.05; 
 
↵† , significantly different from Class NC, P < 0.05. 
 
 
 
Table 4: Average component ratios at steady state (Phase 3) 
 
5-HT2βPan-like component (Hz)/ non-5-HT2βPan component (Hz) 
Class F  
(11) 
Class S  
(7) 
Class NC  
(6) 
 
3.74+1.75 
# 
 
0.55+0.16 
* 
 
1.19+0.18 
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FIG. 1. The pyloric rhythm of the stomatogastric nervous system in spiny lobster is differentially modu-
lated by serotonin (5-HT). A: schematic of the pyloric circuit in P. interruptus (based on Ayali and Harris-
Warrick 1999). Large unfilled circles represent the 6 pyloric cell types. The number of cells in each cell 
type is indicated, where lack of a number indicates a unique neuron. Small filled circles represent inhibi-
tory chemical synapses. Diodes and resistors represent electrical coupling. B: sequential recordings from 
2 preparations before sucrose block (top), 1 h after sucrose block (middle), and in 10−5 M 5-HT (bottom). 
Cycle frequency was either increased (left) or decreased by 5-HT (right). For each set of traces, top extra-
cellular recordings were from the pdn, which contains only the 2 pyloric dilator (PD) axons. Thus these 
traces represent PD activity. Bottom extracellular recordings were from the mvn, which contains the ax-
ons of the single inferior cardiac (IC) and the single ventricular dilator (VD) neurons. The IC neuron was 
silent during these recordings; thus these traces represent VD spiking. C: the effect of 5-HT on pyloric 
cycle frequency varies with the preparation. The steady-state 5-HT cycle frequency (average for the last 
10 cycles during a 5-min 5-HT application) is plotted against the baseline cycle frequency (average from 
the last 10 cycles during a 1-h sucrose block, just before 5-HT application) for each of 44 preparations. x 
and y error bars represent the SE. Note that 5-HT usually makes preparations more rhythmic such that the 
y error bars are significantly smaller than the x (P < 0.002, paired t-test on the 2 sets of SEs). D: on aver-
age, 5-HT has no significant effect on pyloric cycle frequency. The bar graphs represent the average base-
line and state-state 5-HT response for all 44 preparations plotted in C. Additionally, the average cycle 
frequency after a 10-min washout of 5-HT is shown (average for the last 10 cycles during a 10-min 
wash). Error bars represent the SE. A repeated-measures ANOVA was performed followed by a Tukey 
post hoc test: *, significantly different from baseline (P < 0.05); #, significantly different from steady-
state 5-HT (P < 0.05). 
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FIG. 2. The increase in cycle frequency observed during 10 µM 5-HT washout is at least partially due to 
5-HT–independent phenomena. Preparations were classified on the basis of whether the steady-state 5-HT 
cycle frequency was slower (A), faster (B), or unchanged (C) relative to baseline as indicated in the text. 
For each Class, the average cycle frequency for baseline, steady-state 5-HT, and 10- and 60-min washes 
are plotted. D: the same measurements for experiments in which 5-HT was omitted, but that were other-
wise identical to those represented in A–C (i.e., mock experiments). Error bars, SE; a repeated-measures 
ANOVA was performed on each of the 4 data sets (A–D) followed by a Tukey post hoc test: *, signifi-
cantly different from baseline (P < 0.05); #, significantly different from steady-state 5-HT or steady-state 
mock 5-HT (P < 0.05). 
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FIG. 3. The time course of the 5-HT response. A: pyloric cycle frequency slowly increases over the 
course of 70 min in the absence of modulatory input. Plot of cycle frequency vs. time for a representative 
mock experiment (n = 6). Each point marks a single pyloric burst. These experiments are exactly like the 
experiments shown in C–H, except that 5-HT was omitted. B: sequential applications of 5-HT produce 
similar effects. Representative plot of cycle frequency vs. time for experiments in which a second 5-HT 
application followed the 1-h wash (n = 8). The gray boxes indicate the times of 5-HT application. C–H: 
the time course of the 5-HT response is variable and complex. In 37 experiments a sucrose block was 
placed on the stn for 1 h; 10 µM 5-HT was next applied for 5 min and then washed out for 1 h. Plots of 
cycle frequency vs. time for 6 representative experiments are shown before, during, and after 5-HT appli-
cation. One minute of cycles after the 1-h wash is shown after the hash marks in each plot. The vertical 
lines in C approximate the 3 temporal phases of the response described in the text. 
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FIG. 4. Signaling and pharmacology of 5-HT2βPan and 5-HT1αPan. A: dose–response curves of inositol 
phosphate (IP) activation in HEK cells. Nontransfected cells do not respond to 5-HT (crosses). Cells ex-
pressing 5-HT2βPan respond to 5-HT and an agonist, 8-OH-DPAT, with EC50 values of 52 and 270 nM, 
respectively (black squares and circles). An antagonist, cinanserin, blocks 5-HT activation of 5-HT2βPan 
with an IC50 of 140 nM (gray diamonds). B: dose–response curves of cAMP accumulation in 293-TR-5-
HT1αPan cells. In cells induced to express 5-HT1αPan, forskolin-induced accumulation of cAMP is in-
hibited in response to 5-HT and an agonist, α-Me-5-HT, with EC50 values of 8.4 nM and 1.1 µM, respec-
tively (black squares and circles). Noninduced cells did not respond significantly to 5-HT (crosses). Mean 
± SE, n ≥ 3. 
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FIG. 5. 5-HT2βPan-like receptors contribute to the 5-HT response. Time-course plots of representative 
experiments showing pyloric cycle frequency during serial application of 10 µM 5-HT alone and with 10 
µM cinanserin, n = 8 (A) or 10 µM (+)butaclamol, n = 22 (B). 
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FIG. 6. Examples of the computationally isolated 5-HT2βPan-like component of the 5-HT response sys-
tem. Cycle frequency time-course plots for 7 different preparations are shown (A–G). These experiments 
are representative of the 24 preparations analyzed. For a given experiment, the frequency plot obtained in 
10 µM 5-HT is shown in blue and the frequency plot obtained in 10 µM 5-HT + 10 µM 5-HT2βPan an-
tagonist is shown in green. Each point represents a single cycle and lines indicate the trace averages as 
described in METHODS. In many cases the trace average is such an accurate fit that it is difficult to dis-
tinguish from the row data. The gold trace on the right is the difference trace obtained by subtracting the 
response to 5-HT in the presence of antagonist (green trace average) from the 5-HT response (blue trace 
average) after arbitrarily setting both baselines to zero. 
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FIG. 7. Average 5-HT–induced changes in cycle frequency are underpinned by significant individual var-
iation in the 5-HT2βPan-like and non-5-HT2βPan components of the 5-HT response system. The same 24 
experimental preparations are represented in all panels. The left panels show the mean of the 24 trace av-
erages for preparations treated with10 µM 5-HT (A) or with 10 µM 5-HT + 10 µM antagonist (B), or the 
mean of the 24 difference traces (C). The 3 temporal phases of the response are indicated in A. The right 
panels show the distribution in 3-dimensional space of 5-HT–induced changes in cycle frequency relative 
to baseline for individual preparations in the absence (D) or presence (E) of antagonist, or for their com-
putationally isolated 5-HT2βPan-like component (F). The 3 dimensions represent the 3 temporal phases 
of the 5-HT response. The black lines emanating from each circle simply help to portray the exact loca-
tion of each individual preparation in 2-dimensional space. The colored lines in D–F indicate the number 
1 on each axis. 
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FIG. 8. 
Cycle frequency may be increased via activation of 5-HT1αPan. Serotonergic inhibition of VD does not 
occur via 5-HT1αPan. A: application of 100 µM 1-(m-chlorophenyl)-piperazine (mCPP), a 5-HT1αPan 
agonist, results in an increase of peak cycle frequency regardless of the individual preparation's response 
to 5-HT. In this example, 10 µM 5-HT application results in a significant slowing of the rhythm (left). 
When mCPP is applied, however, the cycle frequency is increased (middle). This increase is not affected 
by the 5-HT2βPan blocker (+)butaclamol (10 µM, right). B: 100 µM mCPP significantly increases peak 
cycle frequency. Bar graphs indicate the average percentage change in cycle frequency during sequential 
application of drugs [(cycle frequency/baseline) × 100]. Error bars indicate the SE. The presence (+) or 
absence (−) of a given drug is as indicated underneath each bar. Conditions in which both drugs are ab-
sent indicate the first and second washouts. The mCPP effect is not changed in the presence of the 5-
HT2βPan blocker, (+)butaclamol. C: VD spiking is not changed by mCPP applications. Bar graphs indi-
cate the average percentage change in VD spike frequency during sequential application of drugs [(spike 
frequency/baseline) × 100]. Error bars indicate the SE. The presence (+) or absence (−) of a given drug is 
as indicated underneath each bar. Washes are indicated as (−/−). In the case of the first wash, the bar rep-
resents the difference between the first and second baselines. Paired t-test, #P < 0.05 vs. baseline. 
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FIG. 9. 5-HT2βPan is not involved in elimination of VD activity by 5-HT. A: time course graph of a rep-
resentative experiment showing VD spikes per cycle during serial application of 10 µM 5-HT followed by 
10 µM antagonist alone and with 10 µM 5-HT. Serial applications are separated by 1 h of wash. Circled 
numbers correspond to time points for measurements presented in bar graphs below. Spiking in the VD 
neuron is completely inhibited in 10 µM 5-HT. This effect is not blocked by either (+)butaclamol (B) or 
cinanserin (C). Bar graphs in B and C indicate the average percentage change in VD spike frequency dur-
ing sequential application of drugs [(spike frequency/baseline) × 100]. Note that the baseline is reset be-
tween bars 2 and 3. Error bars indicate the SE. The presence (+) or absence (−) of a given drug is as indi-
cated underneath each bar. Washes are indicated as (−/−). In the case of the first wash (circle 2), the bar 
represents the difference between the first and second baselines (paired t-test, #P < 0.05 vs. baseline). 
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